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Abstract
The E2F1 transcription factor regulates the expression of key genes involved in cell
proliferation and differentiation to maintain skin homeostasis. The expression of E2F1 is
tightly regulated during cell cycle progression and when cells are committed to
differentiate, as well as in response to DNA damage. In keratinocytes, E2F1 protein and
transcript levels increase following UV-induced DNA damage, whereas, in response to
Ca2+-induced differentiation, both E2F1 protein and transcript levels decrease. In this
thesis, I examined in detail the mechanism that modulates E2F1 stability following DNA
damage and during keratinocyte differentiation. I show that E2F1 associates with hHR23
and together these proteins participate in the nucleotide excision repair (NER) pathway.
hHR23A stabilizes E2F1 by inhibiting its proteasomal degradation. Moreover, E2F1
regulates hHR23A subcellular localization and recruits hHR23A to sites of DNA
photodamage to facilitate DNA repair. These results unveil a novel mechanism involving
E2F1 and hHR23A to enhance the repair of damaged DNA, contributing to the
maintenance of genomic stability following UV-induced DNA damage in epidermal
cells. In contrast to DNA damage, proper keratinocyte differentiation occurs when E2F1
is down regulated. Although the regulation of E2F1 that leads to its nuclear export and
degradation has been reported, the exact mechanisms are poorly characterized. When
E2F1 Ser403 and/or Thr433 are substituted to an alanine (E2F1 ST/A), a significant
increase in the half-life of this mutant in differentiated keratinocytes is observed.
Furthermore, the E2F1 ST/A mutant does not form appreciable levels of K11- or K48linked polyubiquitylation, which is associated with degradation. Moreover, I show that
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Cdh1, an activator protein of the anaphase-promoting complex/cyclosome (APC/C)
complex, interacts with E2F1 in keratinocytes, and its inactivation prevents the turnover
of E2F1 following Ca2+-induced differentiation. Collectively, these results reveal a new
mechanism involving E2F1 and Cdh1 in coordinating its degradation through posttranslational modification and nuclear export in differentiated keratinocytes. By
elucidating the appropriate events required for the turnover of E2F1, we can better
understand and treat various epidermal diseases such as non-melanoma skin carcinoma.

Keywords
Keratinocytes, epidermis, E2F, phosphorylation, ubiquitylation, hHR23, DNA
photodamage, ubiquitin ligase, Cdh1, UBC13.

iii

Co-Authorship Statement
This thesis contains material from previously published and submitted manuscript coauthored by Randeep K. Singh and Lina Dagnino. All the experimental work presented in
this thesis was performed by Randeep K. Singh. All the figures and quantifications
presented in this thesis were generated by Randeep K. Singh. Part of this thesis was
written by Randeep K. Singh and Lina Dagnino. A copyright release for the manuscript is
shown in Appendix 3.

iv

Acknowledgments
Throughout my entire graduate career, there are numerous people I would like to thank.
Without anyone of them, my experience at Western would not have been as rewarding
and memorable. First and foremost, I would like to thank my supervisor, my mentor, Dr.
Lina Dagnino, without whom this thesis would have been impossible. You have taught
me how to solve many puzzles and what is required to become a real scientist. With your
guidance and advice, my presentation and writing skills have improved tremendously.
Thank you for your continuous encouragement, patience, kindness, and support over the
past eight years. You have given me a great environment to thrive at. I would also like to
thank my advisory committee members: Dr. Nathalie Bérubé, Dr. Rommel Tirona, Dr.
Sean Cregan and Dr. Patricia Watson. The wealth of your guidance has been
immeasurable.
I would also like to take this opportunity to thank all the administrative staff members in
the Department of Physiology and Pharmacology, including Susan McMillan for sending
out committee meeting reminders and making sure I have completed all course
requirements, Bruce Arppe for knowing where everything is around the department, and
Chris Webb for delivering all our lab reagents and materials, especially when it is
something I have been waiting for weeks. Thank you all for being so nice to me over the
past years. I will miss you all so very much.
I would also like to thank both past and present Dagnino lab members. They are not
merely lab members but have become part of my second family. Throughout the eight

v

years, many have left and moved on to better things but I will never forget the great
moments we shared in the lab, tea times in the office, lunch at the cafeteria or UCC
concrete beach over the summer and of course our annual summer beach day at The
Pinery. First, I would like to thank Tames Irvine who has welcomed me into the lab when
I first joined. He has been a great friend. I have learned so much from you, from new
techniques in the lab to teaching me real life experiences. I will always remember your
quote, "There's always some truth behind a joke". I would like to thank Dr. Linda Vi who
taught me to become a better scientist. Your love for research is so contagious, and
because of your enthusiasm I enjoyed research and being in the lab. I will always
remember our long talks from troubleshooting why our western blots did not work to
coming up with new and exciting experiments to do. I would like to thank Stellar Boo for
always being there for me when I needed someone to talk to the most. You are the sassy
queen, though I took your crown when you left. I would like to thank Dr. Samar
Sayedyahossein with whom I share the deepest thoughts on life. The amount of
knowledge you have never ceased to amaze me. I would also like to thank Dr. Dany
Ivanova, Dr. Kerry-Ann Nakrieko, Dr. Alena Rudkouskava Dr. Lylia Nini, Dr. Ernest Ho
and Kevin Barr - the wise and mature ones in the lab, thank you for sharing your
knowledge, experiences as a graduate student and what life entails after grad school.
Thank you Dr. David Judah for making the lab an enjoyable place to work. I will always
remember your handmade miniature sculptures, rest in peace. I would like to thank
Meera Karajgikar, the lab mom you have been so great to me. Thanks for purifying DNA
for me, feeding me, giving me amazing Indian food and a place to stay. I will never
forget your kindness. I would like to thank Michelle Im who is like my gangster sister. I

vi

thoroughly enjoyed the positivity you bring into the lab with your smile. You made the
lab livelier, especially during the days (or weeks) when none of my experiments worked.
And thank you Bradley Jackson for being the gentleman in the lab. I would also like to
thank the younglings of the lab, Maria Doubova, Shinthujah Arulanantham, Valerie
Leclerc, Melissa Crawford and Hannah Murphy-Marshman, you guys bring so much
energy in the lab and I feel young at times, though there are moments when you guys
remind me of how old I am. I would also like to thank Dr. John Di Guglielmo and his lab
members for lending me reagents and antibodies when our lab forgets to order on time.
Special thanks to Eddie Chan for tolerating my rants, especially toward the end. I will
always remember the DotBlot idea you gave me.
This thesis would not have been completed without the support and love from my family.
Thank you my brother, KoKo and my sister, Kuldeep for listening to my graduate life
stories. Thank you Mum and Dad, words cannot express my gratitude towards everything
you have done for me. I hope I have made you both very proud. And I am saving the best
for last, thank you my husband, my love, my partner in crime, Harinder Singh Dhatt.
Thank you for spending numerous hours on editing my thesis and my presentation.
Without your support, I do not think I would have been able to overcome all the
challenges. You have always reassured me that everything will work out in the end and it
always does. You have made me so happy beyond words can describe. I LOVE YOU.

vii

Table of Contents
Abstract ............................................................................................................................... ii
Co-Authorship Statement................................................................................................... iv
Acknowledgments............................................................................................................... v
Table of Contents ............................................................................................................. viii
List of Tables .................................................................................................................... xii
List of Figures .................................................................................................................. xiii
List of Appendices ........................................................................................................... xvi
List of Abbreviations ...................................................................................................... xvii
Chapter 1 ............................................................................................................................. 1
1 Introduction .................................................................................................................... 1
1.1 The Skin .................................................................................................................. 1
1.1.1

The epidermis.............................................................................................. 4

1.1.2

The dermis and hypodermis ........................................................................ 8

1.2 Regulation of keratinocyte proliferation and differentiation .................................. 9
1.2.1

Keratinocyte stem cells ............................................................................... 9

1.2.2

Regulation of keratinocyte differentiation ................................................ 11

1.3 Keratinocyte responses to UV radiation ............................................................... 13
1.3.1

Nucleotide excision repair ........................................................................ 14

1.4 The Ubiquitin-proteasome system ........................................................................ 18
1.4.1

Ubiquitylation ........................................................................................... 18

1.5 hHR23 ................................................................................................................... 19
1.6 Cell Cycle Regulation ........................................................................................... 26
1.6.1

Retinoblastoma family proteins ................................................................ 29
viii

1.6.2

The E2F family of transcription factors .................................................... 30

1.7 Other functions of E2F factors .............................................................................. 37
1.7.1

Role of E2F in apoptosis ........................................................................... 37

1.7.2

Role of E2F in DNA damage .................................................................... 38

1.8 Mechanisms of E2F1 Regulation .......................................................................... 40
1.8.1

Post-translational modifications................................................................ 40

1.8.2

E2F1 subcellular localization.................................................................... 46

1.8.3

Protein-protein interactions ....................................................................... 46

1.9 The role of E2F in the epidermis .......................................................................... 47
1.10 Rationale and Aims of this Study ......................................................................... 50
Chapter 2 ........................................................................................................................... 52
2 Materials and Methods ................................................................................................. 52
2.1 Reagents and materials ......................................................................................... 52
2.2 Antibodies, enzymes and kits ............................................................................... 57
2.3 Vectors .................................................................................................................. 61
2.4 Molecular cloning ................................................................................................. 63
2.4.1

Generation of vectors encoding E2F1 and hHR23A mutants ................... 63

2.4.2

Polymerase chain reaction (PCR) ............................................................. 69

2.4.3

Isolation and purification of DNA and PCR products .............................. 69

2.4.4

DNA ligation............................................................................................. 69

2.4.5

Preparation of competent DH5α and BL-21 (DE) cells ............................ 70

2.4.6

Bacterial transformation............................................................................ 70

2.5 Recombinant Protein Purification ......................................................................... 71
2.5.1

GST fusion protein expression.................................................................. 71

2.5.2

TRX fusion protein expression ................................................................. 72
ix

2.6 Preparation of glass coverslips for cultured cells ................................................. 73
2.7 Cell culture and transfection ................................................................................. 73
2.7.1

Isolation of primary epidermal keratinocytes ........................................... 73

2.7.2

Culture of tumour cell lines ...................................................................... 75

2.7.3

Cell transfection and drug treatments ....................................................... 75

2.8 RNA isolation and quantitative reverse-transcription PCR (qPCR) ..................... 76
2.9 Immunoblot analysis and immunoprecipitation.................................................... 77
2.10 Indirect immunofluorescence microscopy ............................................................ 78
2.11 In vitro binding assays .......................................................................................... 79
2.12 UV damage and repair assays ............................................................................... 80
2.13 Cdh1 silencing by RNA interference .................................................................... 81
2.14 Statistical analyses ................................................................................................ 82
Chapter 3 ........................................................................................................................... 83
3 Results .......................................................................................................................... 83
3.1 Interaction of hHR23A and E2F1 ......................................................................... 83
3.2 Modulation of hHR23A subcellular localization by E2F1 ................................... 89
3.3 hHR23A domains involved in binding to E2F1 ................................................... 94
3.4 Inhibition of E2F1 degradation by hHR23 proteins ........................................... 101
3.5 Modulation of DNA damage repair by hHR23A and E2F1 ............................... 109
3.6 Amino acid residues in E2F1 that contributes to its stabilization following
drug-induced DNA damage ................................................................................ 118
3.7 Identification of E2F1 amino acid residues required for nuclear export and
stabilization in differentiated keratinocytes ........................................................ 119
3.8 Nuclear export is not the only mechanism required for E2F1 ubiquitylation
and degradation following keratinocyte differentiation ...................................... 128
3.9 Role of E2F1 pseudo-phosphorylation at Ser403 and Thr433............................ 136

x

3.10 Differentiation-specific role of Ser403 and Thr433 in E2F1 degradation .......... 141
3.11 K11- and K48-linkages on E2F1 promotes its degradation in differentiated
keratinocytes ....................................................................................................... 145
3.12 Cdh1 regulates E2F1 degradation in keratinocytes ............................................ 146
3.13 E2 conjugating enzyme preferentially interacts with ST/A-E2F1 in
differentiated keratinocytes ................................................................................. 161
Chapter 4 ......................................................................................................................... 164
4 Discussion .................................................................................................................. 164
4.1 E2F1 regulation by hHR23 proteins in keratinocytes ......................................... 165
4.2 E2F1 induction following genotoxic stress in keratinocytes .............................. 171
4.3 Regulation of E2F1 turnover in differentiated keratinocytes ............................. 172
4.4 Future studies ...................................................................................................... 179
4.5 Concluding remarks ............................................................................................ 184
References ....................................................................................................................... 185
Appendices ...................................................................................................................... 208
Curriculum Vitae ............................................................................................................ 213

xi

List of Tables
Table 2.1: List of materials and catalogue numbers. ........................................................ 52
Table 2.2: Reagents, the catalogue number, and the final concentration used. ................ 53
Table 2.3: Composition of routinely used solutions and media........................................ 56
Table 2.4: Antibodies and dilutions used.......................................................................... 58
Table 2.5: Enzymes for molecular biology experiments. ................................................. 60
Table 2.6: List of kits used in this study. .......................................................................... 60
Table 2.7: Plasmids used in this study. ............................................................................. 61
Table 2.8: Forward (Fwd) and reverse (Rev) primers used to generate E2F1 point
mutants. ............................................................................................................................. 67
Table 2.9: Forward (Fwd) and reverse (Rev) primers used for deletion mutations in
hHR23A. ........................................................................................................................... 68

xii

List of Figures
Figure 1.1: The skin structure. ............................................................................................ 1
Figure 1.2: The epidermal layers. ....................................................................................... 5
Figure 1.3: Nuclear excision repair pathway. ................................................................... 16
Figure 1.4: Schematic of ubiquitin and types of ubiquitylation formed. .......................... 20
Figure 1.5: Model of HR23 regulation in proteasome degradation of proteins. ............... 24
Figure 1.6: Cell cycle regulation by CDK-cyclin complexes. .......................................... 27
Figure 1.7: The mammalian E2F family of a transcription factor. ................................... 31
Figure 1.8: Cell cycle regulation of E2F family of transcription factors. ......................... 34
Figure 1.9: Post-translational modifications on E2F1. ..................................................... 41
Figure 1.10: Regulation and signaling pathway of E2F1 in differentiated keratinocytes. 48
Figure 2.1: Schematic representation of the three-step PCR protocol used for site-directed
E2F1 mutagenesis. ............................................................................................................ 64
Figure 3.1: Expression of mHR23 and hHR23 proteins. .................................................. 84
Figure 3.2: Association of hHR23A and E2F1. ............................................................... 87
Figure 3.3: Modulation of hHR23A subcellular distribution by E2F1. ............................ 90
Figure 3.4: hHR23A domains involved in E2F1 binding. ................................................ 95
Figure 3.5: Regions in E2F1 involved in binding to hHR23A. ........................................ 99
Figure 3.6: Modulation of ubiquitylated E2F1 degradation by hHR23 proteins. ........... 102

xiii

Figure 3.7: Modulation of E2F1 t½ by hHR23 proteins. ................................................ 106
Figure 3.8: Effect of UVB radiation on E2F1 levels in keratinocytes. ........................... 110
Figure 3.9: Co-localization of E2F1 and hHR23 at DNA damage sites following UV
radiation. ......................................................................................................................... 113
Figure 3.10: Increased repair of UV-induced DNA damage by E2F1 and hHR23A. .... 115
Figure 3.11: Changes in E2F1 levels in response to etoposide....................................... 120
Figure 3.12: Ser403 and Thr433 are required for E2F1 nuclear export during keratinocyte
differentiation. ................................................................................................................. 123
Figure 3.13: Ser403 and Thr433 mediate E2F1 degradation during keratinocyte
differentiation. ................................................................................................................. 126
Figure 3.14: E2F1 is polyubiquitylated in the nucleus and in the cytoplasm when
keratinocytes are induced to differentiate with Ca2+....................................................... 129
Figure 3.15: Ubiquitylation of E2F1 is not affected by mutation of E2F1 at Ser403 and
Thr433 in keratinocytes. ................................................................................................. 132
Figure 3.16: Effect of constitutive nuclear export on E2F1 abundance in differentiating
keratinocytes. .................................................................................................................. 134
Figure 3.17: Subcellular localization of pseudophosphorylated E2F1 mutant proteins in
keratinocytes. .................................................................................................................. 137
Figure 3.18: Ser403 and Thr433 are critical contributors to E2F1 phosphorylation. ..... 139
Figure 3.19: Ser403 and Thr433 regulated E2F1 protein half-life in differentiated
keratinocytes. .................................................................................................................. 142
Figure 3.20: Ser403 and Thr433 regulate K11- and K48-linked ubiquitylation of E2F1 in
differentiated keratinocytes. ............................................................................................ 147

xiv

Figure 3.21: Cdh1 and not Skp2 reduce the abundance of E2F1 protein in keratinocytes.
......................................................................................................................................... 152
Figure 3.22: Inhibition of Cdh1 activity with hEmi1 increases E2F1 protein levels. .... 154
Figure 3.23: Cdh1 promotes E2F1 degradation in differentiating keratinocytes............ 157
Figure 3.24: E2F1 interacts with Cdh1 in keratinocytes................................................. 159
Figure 3.25: E2F1 interaction with E2 UBC13 conjugating enzyme is modulated by
Ser403 and Thr433 in differentiated keratinocytes. ........................................................ 162
Figure 4.1: Proposed model for hHR23A and E2F1 regulation of DNA repair in
undifferentiated keratinocytes ......................................................................................... 166
Figure 4.2: Proposed model of E2F1 phosphorylation-linked ubiquitylation modulated by
ubiquitin ligases and deubiquitylating enzymes. ............................................................ 176
Figure 4.3: Proposed model of E2F1 regulation and function in differentiated
keratinocytes. .................................................................................................................. 180

xv

List of Appendices
Appendix 1: Primary epidermal keratinocytes irradiated with UV. ............................... 209
Appendix 2: Ubiquitylation of E2F1 proteins in keratinocytes. ..................................... 211
Appendix 3: Copyright permission. ................................................................................ 212

xvi

List of Abbreviations
a.a

Amino acid

ANOVA

Analysis of variance

Ap1

Activator protein 1

Apaf1

Apoptotic protease-activating factor 1

APC/C

Anaphase-promoting complex/cyclosome

Aspp

Apoptosis-stimulating of p53 protein

ATM

Ataxia-telangiectasia mutated

ATR

Ataxia telangiectasia and Rad3-related

Bax

BCL2 Associated X, Apoptosis Regulator

BCL2

B-Cell CLL/Lymphoma 2

BER

Base excision repair

BMP

Bone morphogenetic proteins

bp

Base pair

BRCA1

Breast cancer type 1 susceptibility protein

BRD4

Bromodomain-containing protein 4

BRG1

Brahma-related gene 1

BRM

Brahma

BSA

Bovine Serum Albumin

C/EBP

Transcription factor CCAAT/enhancer-binding protein

Ca2+

Calcium ions

CAK

CDK-activating kinase

CBP

p300/CREB-binding protein

xvii

CBP

p300/CREB-binding protein

CD34

Hematopoietic progenitor cell antigen CD34

CD71

Transferrin receptor

Cdc

Cell division cycle

Cdh1

Cdc20 homolog 1

CDK

Cyclin dependent kinase

CETN2

Centrin-2

CHD8

Chromodomain-helicase-DNA-binding protein 8

ChIP

Chromatin immunoprecipitation

Chk

Checkpoint kinase

CHX

Cycloheximide

CIP/KIP

CDK interacting protein/Kinase inhibitory protein

CKI

Cyclin kinase inhibitor

CPD

Cyclobutane pyrimidine dimer

CRL

RING E3 ligas

CRM1

Chromosome region maintenance 1

CSB

Cockayne syndrome protein

CtBP

C-terminus-binding protein

C-terminal

Carboxyl-terminal

CtIP

CtBP interacting protein

CUL

Cullin

CUL4A-ROC1

Cullin 4A–regulator of cullins 1

DAG

Diacylglycerol

xviii

D-box

Destruction box

DDB

DNA damage-binding protein

DEME-RS

Dulbecco’s Modified Eagle Medium-Reduced Serum

Dkk1

Dickkopf-related protein 1

DMSO

Dimethyl sulfoxide

DP

Dimerization domain

DUB

Deubiquitylating enzyme

EDTA

Ethylenediaminetetraacetic acid

EMEM

Eagle’s minimum essential medium

Emil1

Early mitotic inhibitor 1

ERCC1

Excision repair cross-complementation group 1

ERK

Extracellular signal–regulated kinase

ESCRT

Endosomal sorting complex required for transport

Fas

Tumor necrosis factor receptor superfamily member 6

FBS

Fetal bovine serum

Fen1

Flag structure-specific endonuclease

FGF

Fibroblast growth factor

FZR1

Fizzy/cell division cycle 20 related 1

GADD45A

DNA-damage-inducible alpha

GAPDH

Glyceraldehyde 3-phosphodehydrogenase

GFP

Green fluorescent protein

GG-NER

Global genome NER

GST

Glutathione

xix

HA

Hemagglutinin

HCF1

Host cell factor 1

HDAC

Histone deacetylases

HEK

Human epidermal keratinocytes

Hes1

Transcription factor HES-1

His

Histidine

IB

Immunoblot

IF

Immunofluorescence

IL-1β

Interleukin-1β

IP

Immunoprecipitation

IP3

Inositol 1,4,5-trisphosphate

IPTG

Isopropyl β-D-1-thiogalactopyranoside

Jab1

c-Jun activation domain-binding protein 1

Jmy

Junction-mediating and -regulatory protein

K1-15

Keratin 1-15

KCS

Keratinocyte stem cells

kDa

Kilo Dalton

KDM1A

Lysine-specific histone demethylase 1A

LB

Luria Bertani

Lgr5

Leucine-rich repeat-containing G-protein coupled receptor 5

LMB

Leptomycin B

MAP

Mitogen-activated protein

Mdm2

Mouse double minute 2 homolog

xx

MEF

Mouse embryonic fibroblasts

MEK

Mouse epidermal keratinocytes

MEK3

MAP kinase kinase 3

MEKK

MAP kinase kinase kinase

MSH

DNA mismatch repair protein

MTPBS

Mouse tonicity phosphate-buffered saline

Myt1

Membrane-associated tyrosine- and threonine-specific cdc2inhibitory kinase

NEM

N-ethylmaleimide

NER

Nucleotide excision repair

NES

Nuclear export sequence

NLS

Nuclear localization sequence

Notch 1/2

Neurogenic locus notch homolog protein 1/2

NPDC1

Neural proliferation differentiation and control protein 1

NTA

Nitrilotriacetic acid

N-terminal

Amino-terminal

P/CAF

p300/CBP-associated factor

P/CAF

p300/CBP-associated factor

p63

Tumor protein 63

PARP1

Poly [ADP-ribose] polymerase 1

PBS

Phosphate Buffered Saline

PCNA

Proliferating cell nuclear antigen

PCR

Polymerase chain reaction

xxi

PDA4

Protein arginine deiminases 4

PEI

Polyethylenimine

PFA

Paraformaldehyde

PI3K

Phosphatidylinositol-4,5-bisphosphate 3-kinase

PIP2

Phosphatidylinositol 4,5-bisphosphate

PKC

Protein kinase C

PLC

Phospholipase C

PLL

Poly-L-lysine

PMS2

Mismatch repair endonuclease

PMSF

Phenylmethylsulfonyl- fluoride

PRMT

Protein arginine methyltransferase

PSMD14

26S proteasome non-ATPase regulatory subunit 14

PSMD4

26S proteasome non-ATPase regulatory subunit 4

PVDF

Polyvinylidene difluoride membranes

qPCR

Quantitative polymerase chain reaction

R1

Restriction point

Rb

Retinoblastoma

RBP-Jκ

Recombination signal binding protein for immunoglobulin
kappa J region

RIPA

Modified radioimmunoprecipitation assay

ROS

Reactive oxygen species

SCF

Skp1-cullin-F-box

SD

Standard deviation

SDS

Sodium dodecyl sulfate

xxii

SEM

Standard error of mean

SETD7

Histone-lysine N-methyltransferase

siRNA

Small (or short) interfering RNA

Skp2

S-phase kinase-associated protein 2

SOB

Super Optimal Broth

Sox9

Transcription factor SOX-9

Sp1

Specificity protein 1

SUMO-1

Small ubiquitin-like modifier 1

Suv39H1

Suppressor of variegation 3-9 homolog 1

SV40

Simian virus 40

SWI/SNF

SWItch/Sucrose Non-Fermentable

t½

Half-life

TAC

Transit amplifying cells

TAE

Tris-acetate-EDTA

TAp73

Transcriptional domain-containing tumor protein 73

TB

Transformation buffer

TBS

Tris-Buffered Saline

TC-NER

Transcription-coupled NER

TFIIH

Transcription initiation factor IIH

TNFα

Tumor necrosis factor–α

TopBP1

Topoisomerase IIβ-binding protein I

TPp53inp

Tumor protein p53-inducible nuclear protein

TRAF2

TNF receptor-associated factor 2

xxiii

TRIM28

Transcription intermediary factor 1-β

TRX

Thioredoxin

UBA

Ubiquitin-associated

UBC13

Ubiquitin-conjugating enzyme 13

UBD

Ubiquitin-binding domain

UbL

Ubiquitin-like

UCHL5

Ubiquitin carboxyl-terminal hydrolase isozyme L5

UNG

Uracil-DNA glycosylase

UPS

Ubiquitin-proteasome system

USP37

Ubiquitin-specific protease 37

UV

Ultraviolet

Wnt

Wingless-type MMTV integration site family member

WT

Wild type

XP

Xeroderma pigmentosum

XPC

XP complementation group C

ZBRK

Zinc finger and BRCA1-interacting protein with a KRAB
domain

xxiv

1

Chapter 1

1

Introduction

1.1 The Skin
The skin serves as the first line of defense against environmental and physical insults, and
excessive loss of water and electrolytes. A major role of the skin is to provide a barrier
protection between the organism and the external environment. Other functions of the
skin include maintenance of body temperature, synthesis of vitamin D, and tactile
sensation. Extensive damage to the skin can have substantial negative consequences,
including increased risk of infection and water-electrolyte imbalance. Therefore, proper
maintenance of skin structure and function is crucial for keeping our body healthy.
The skin is composed of three main layers: the hypodermis, the dermis and the epidermis
(Figure 1.1). The skin also contains epidermal appendages including sweat glands,
sebaceous glands, apocrine glands, and hair follicles. Signaling events can lead to the
activation of differentiation processes, giving rise to the stratified epidermis, hair follicles
and sebaceous glands (Fuchs, 2007). The epidermis is derived from the embryonic
ectoderm and the dermis and hypodermis are mesodermal in origin (Hardy, 1992). The
epidermis and the dermis are attached to each other through a basement membrane.
Epidermal morphogenesis is regulated through many signaling pathways, including the
canonical wingless-related (Wnt), bone morphogenetic proteins (BMP), and Notch
signaling pathways (Fuchs, 2007). Wnt signaling events promote the activation of BMP
signaling in early ectoderm progenitor cells to initiate the progression towards epidermal

Figure 1.1: The skin structure.
The three distinct layers of the skin are shown: epidermis (orange), dermis (pink) and
hypodermis (yellow). At the dermal-epidermal junction, a basement membrane lies
between the epidermis and dermis. Dermal papillae are finger-like projections of dermis
that project up to the epidermis, increasing the surface area. Nerve endings and blood
vessels present in the dermis are also shown. Below the dermis is the hypodermis,
composed mainly of adipose tissue. The skin also contains epithelial appendages
structures including hair follicles, sweat glands, and sebaceous glands. The hair follicle
bulge where epithelial stem cells reside is also shown.

3

4

morphogenesis. In chick embryos, expression of Wnt signaling represses fibroblast
growth factor (FGF) signals, allowing for the activation of BMP signaling, inducing
neural cell fate to switch into epidermal cell fate (Wilson et al., 2001). The Wnt signaling
pathway also plays an essential role in the initiation of epidermal appendages, such as
hair follicles (Fuchs, 2007). Constitutive expression of the Wnt inhibitor, Dickkopfrelated protein 1 (Dkk1) prevents the formation of hair follicles in the epidermis (Andl et
al., 2002). Finally, the activation of Notch signaling events promote stratification of the
epidermis (Wilson and Radtke, 2006).

1.1.1

The epidermis

The epidermis is a keratinized stratified squamous epithelium and is the outermost
protective layer of the skin. The epidermis consists of four cell types: keratinocytes,
derived from surface ectoderm, Langerhans cells derived from the bone marrow,
melanocytes and Merkel cells, both derived from the neural crest (Carlson, 1994).
Keratinocytes constitute about 80% of all epidermal cells, whereas other cell types are
scarcely found throughout the epidermis (Rook and Burns, 2004).
In humans and other mammals, the epidermis is composed of several layers (Figure 1.2).
The lowermost layer, or stratum basale, contains a heterogeneous population of
proliferating and differentiating cells that are characterized into three categories:
keratinocyte stem cells (KSC), transit amplifying cells (TAC), and postmitotic
differentiating cells (Kaur and Li, 2000; Li et al., 1998). KSC divide symmetrically or
asymmetrically (Clayton et al., 2007). During symmetric cell division (delamination),
cells expressing low levels of integrins differentiate and move out to the basal epidermal

Figure 1.2: The epidermal layers.
There are several distinct layers of the epidermis and keratinocytes are the dominant cells
aligned through the layers. Other cells found in the epidermis include melanocytes,
Merkel cells, and Langerhans cells. The stratum basale is the bottom single layer of cells
attached to the basement membrane. Epidermal stem cells are located in the basal layer
and during mitosis, it gives rise to two daughter cells. One retains the properties of a
keratinocyte stem cell (KSC), and the other differentiates into transient amplifying cells
(TAC) that migrate to the epidermal surface forming the protective layer of the skin. The
stratum spinosum begins to synthesize intermediate filaments called keratins. These
intermediate filaments are anchored to the desmosomes joining adjacent cells. In the
stratum granulosum, the cells begin to lose their nuclei and the cytoplasm looks granular.
The cells in this layer exocytose lamellar granules to generate a waterproof barrier
between the outer dead cells and the lower layer of active epidermal cells. The stratum
lucidum is a thin transparent layer present in thick skins such as palms and soles. The
outermost layer of the epidermis is called the stratum corneum. This layer is made up of
hexagonal-shaped, non-nucleated cells known as corneocytes. The corneocytes are filled
with keratin fibers and lipids. This structure provides the protective barrier function of the
skin.
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layer and high integrin expressing cells remain attached to the basement membrane (Frye
et al., 2007). These cells also expresses Numb, an inhibitor of Notch signaling, which is
required for stratification of the epidermis (Clayton et al., 2007). During asymmetric cell
division, a stem cell divides into two daughter cells, giving rise to a new cell that retains
the stem cell capability, and a TAC, which divides rapidly and initiates the process
towards differentiation to give rise to suprabasal layers (Figure 1.2). Both modes of
division contribute to the balance of epidermal self-renewal, differentiation, and
regeneration after injury. However, the mechanisms involved in one versus the other are
poorly understood (Fuchs and Chen, 2013). Over the basal layer, the stratum spinosum
and stratum granulosum are found, in body areas with thicker skin, such as the foot sole,
the stratum lucidum is found above the granular layer in human epidermis. The outermost
layer of the epidermis is the stratum corneum, which protects the inner body from foreign
invasion (Fuchs, 2009; Fuchs and Raghavan, 2002).
The cells in the stratum spinosum are metabolically and transcriptionally active. This
layer is characterized by the formation of desmosomes, which provide strong adhesion
between adjacent cells by linking the outer aspect of two cells to each other, and their
cytoplasmic domains are linked to keratin filaments providing mechanical strength. Early
markers of keratinocyte differentiation, including involucrin, and keratin-1 and -10 (K1,
K10) are expressed in this layer (Ekanayake-Mudiyanselage et al., 1998). The stratum
granulosum contains keratinocytes that are enriched in lipid-lamellar granules that
function as a water repellent, contributing to the barrier function of the skin. The
activation of transglutaminase in this layer irreversibly cross-links lysine- and glutaminerich proteins to give rise to the cornified envelope (Koster and Roop, 2007; Steinert and
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Marekov, 1999). As granular cells progress to form the stratum corneum, metabolic
activity is halted and cytoplasmic organelles are lost. The keratinocytes in this layer, also
termed corneocytes, exhibit the terminal stage of differentiation of all epidermal cells,
and are constantly shed and replaced by new differentiated cells moving outwards (Mack
et al., 2005).
Melanocytes are found in the basal layer of the interfollicular epidermis and in the hair
follicle (Figure 2.2). Melanocytes primarily function to produce the pigment melanin and
help in protecting against the harmful effects of ultraviolet (UV) radiation (Tsatmali et
al., 2002). The Merkel cells are also found in the basal layer, and are specialized in the
touch sensation (Moll et al., 2005). Langerhans cells are dendritic and are situated in the
suprabasal layer. They are involved in immunity, and function in antigen presentation.
These cells are central components of cutaneous allergic reactions (Merad et al., 2008).

1.1.2

The dermis and hypodermis

The dermis sustains and provides support to the epidermis. The dermis is composed of
two layers, papillary dermis, and reticular dermis. The elasticity and strength of the
dermis are achieved through elastin and collagen fibers, which are secreted by dermal
fibroblasts. Fibroblasts, mast cells, macrophages, and adipocytes are present within the
dermis and hypodermis. The hypodermis is beneath the dermis, and its main function is
for fat storage.
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1.2 Regulation of keratinocyte proliferation and
differentiation
A balance between epidermal proliferation and differentiation must be maintained to
ensure proper epidermal homeostasis. Defects in epidermal proliferation can lead to thin
and fragile skins (Raghavan et al., 2000). Abnormalities in epidermal differentiation and
disruption of the epidermal barrier function can lead to chronic skin inflammatory
disorders, such as atopic dermatitis, psoriasis, as well as to basal- or squamous-cell
carcinoma. In the following section, I will describe some of the main transcription factors
and mechanisms that regulate keratinocyte proliferation and differentiation.

1.2.1

Keratinocyte stem cells

The epidermis is constantly undergoing self-renewal to replace cells that have terminally
differentiated and been shed. Self-renewal and regeneration after injury are possible
through the presence of KSC. The stem cells present in the hair follicle bulge are
multipotent, as they have the ability to give rise to keratinocytes in the epidermis, hair
follicles, and sebaceous glands (Figure 1.1).
KSC express high levels of integrins. Integrins are essential for keratinocyte viability and
adhesion to the basement membrane, and non-pathologic loss of adhesion is associated
with epidermal differentiation (Carter et al., 1990). The main integrins found in basal
keratinocytes in intact epidermis are α2β1, α3β1 and α6β4 (Peltonen et al., 1989). KSC and
TAC exp erss h gh
i levels o f β1 and α6 integrins whereas suprabasal postmitotic
differentiated cells do not show detectable integrins (Kaur and Li, 2000; Li et al., 1998).
KSC population can be distinguished from TAC population through the expression of a
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cell surface marker, the transferrin receptor (CD71), where the latter expresses high
levels of CD71 (Kaur and Li, 2000; Tani et al., 2000). Therefore, KSC can be enriched in
culture by selecting cells expressing high levels of α6 integrins and low levels of CD71.
Other cell surface markers of the KSC located in the hair follicle bulge include K15
(Morris et al., 2004), CD34 (Trempus et al., 2003), Lgr5 (Jaks et al., 2008) and Sox9
(Vidal et al., 2005).
The transcription factor p63 is preferentially expressed in the basal epidermis and is
essential for normal epidermal morphogenesis (Mills et al., 1999). The p63 protein is
necessary for maintaining the epidermal proliferative capacity, commitment to KSC, and
keratinocyte differentiation (Koster et al., 2004; Senoo et al., 2007). There are two
isoforms of the p63 gene, the transactivating TAp63, and the non-transactivating ΔNp63
generated through the use of alternate promoters (Blanpain and Fuchs, 2007). Ectopic
expression of TAp63 results in hyperplasia of keratinocytes, and inactivation of ΔNp63
leads to formation of a single-layered epidermis, which indicate defects in keratinocyte
differentiation (Koster et al., 2004; Romano et al., 2012). In the current proposed model,
the function of TAp63 is to maintain high proliferative potential during embryogenesis
while limiting the differentiation process, and ΔNp63 functions as a dominant-negative
protein to inhibit TAp63 to promote differentiation (McKeon, 2004). p63 also functions
to prevent the activation of p16INK4A, an inhibitor of the G1-S phase transition of the cell
cycle (Su et al., 2009). Inhibition of p16INK4A allows for CDK4/6-Cyclin D activation,
consequently regulating the E2F/Rb pathway to promote cell proliferation. Thus, p63 is
necessary for epidermal proliferation. In addition to p63 transcriptional repression on
p16IK4A, p63 prevents the activation of Notch-targeted genes including p21Cip1/Waf1,
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involucrin and Hes1. Reciprocally, Notch activation leads to suppression of p63
expression in differentiated keratinocytes. Hence, the cross-talk between p63 and Notch
signaling is one of the mechanisms that maintain the balance between epidermal cell
proliferation and differentiation (Nguyen et al., 2006).

1.2.2

Regulation of keratinocyte differentiation

The Notch signaling pathway is a key regulator of keratinocyte differentiation and is
activated in the suprabasal layer, where it induces p21Cip1/Waf1 expression in an RBP-Jκdependent manner (Rangarajan et al., 2001; Watt et al., 2008). Activation of p21Cip1/Waf1
expression leads to keratinocyte growth arrest and initiation of terminal differentiation.
Moreover, Neurogenic locus notch homolog protein 1 (Notch1) and Notch2 induce the
expression of the early differentiation markers involucrin and K1 through an RBP-Jκindependent pathway (Rangarajan et al., 2001). Notch activity is stimulated when
cultured keratinocytes are induced to differentiate by increasing the extracellular calcium
ion (Ca2+) concentration (Kolly et al., 2005).
A Ca2+ gradient is observed throughout the epidermal layers, with lower Ca2+ levels in
the basal layer and higher concentration in the granular compartment (Mascia et al.,
2012). This Ca2+ gradient plays a crucial role in epidermal homeostasis and
differentiation. Any disruption to the gradient leads to abnormal keratinocyte
differentiation and loss of epidermal barrier function (Elias et al., 2002). Cultured
keratinocytes can be induced to differentiate by modulating the extracellular Ca2+
concentration (Hennings et al., 1980; Yuspa et al., 1989). When keratinocytes are
cultured in low Ca2+ medium (0.02 to 0.09 mM), they are undifferentiated and maintain
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their proliferative capacity. These cells model basal keratinocytes. An increase in the
extracellular Ca2+ concentration to >0.1 mM leads to cell cycle arrest and up regulation of
differentiation markers, such as involucrin (Xie et al., 2005). Ca2+ activates a variety of
signaling pathways, including Notch, phospholipase C (PLC), protein kinase C (PKC)
and Phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) (Denning et al., 1995;
Rangarajan et al., 2001; Xie and Bikle, 1999; Xie et al., 2005).
Ca2+-induced keratinocyte differentiation occurs through the PLC/PKC signaling
pathway. PLCγ activation hydrolyses phosphatidylinositol 4,5-bisphosphate (PIP2) to
diacylglycerol (DAG) and inositol 1,4,5-trisphosphate (IP3). IP3 binds its receptor and
activates the release of intracellular Ca2+. Both Ca2+ and DAG subsequently activate PKC
to initiate differentiation (Mascia et al., 2012). There are nine PKC family members, of
those, the classical PKCα (activated by both Ca2+ and DAG), the novel PKCδ, PKCη, and
PKCε (stimulated by DAG and not Ca2+) and the atypical PKCζ (not activated by Ca2+ or
DAG) are present in keratinocytes (Denning et al., 1995).
PKCδ and PKCη are key for keratinocyte differentiation. The expression levels of PKCδ
and PKCη increase following Ca2+-induced keratinocyte differentiation (Denning et al.,
1995; Deucher et al., 2002; Kashiwagi et al., 2002). The increase in PKCη leads to
transcriptional activation of proteins involved in the formation of the cornified envelope
at the suprabasal layer of the epidermis including transglutaminase I and involucrin
(Efimova and Eckert, 2000; Ueda et al., 1996). The transcriptional activation of
involucrin occurs through the nPKC/Ras/MEKK/MEK3/p38δ-ERK1-2 signaling
pathway, resulting in an increase in transcription factor CCAAT/enhancer-binding
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protein (C/EBP), activator protein 1 (AP1) and specificity protein 1 (Sp1) levels and
binding to the involucrin promoter sequence, thereby increasing involucrin gene
transcription (Agarwal et al., 1999; Crish et al., 2006; Efimova et al., 2002; Efimova et
al., 1998). PKCη activates Fyn and p21Cip1/Waf1, which lead to cell cycle arrest followed
by keratinocyte differentiation (Cabodi et al., 2000; Kashiwagi et al., 2000). PKCη
phosphorylates p21Cip1/Waf1 at serine 146 and inhibits CDK2 kinase activity, which leads
to G1 arrest through dephosphorylation of the retinoblastoma protein (pRb) (Kashiwagi
et al., 2000).

1.3 Keratinocyte responses to UV radiation
The epidermis of the skin is constantly exposed to environmental insults and therefore
has established endogenous processes to prevent, protect, and repair damage. There are a
number of signals that sense the presence of damaged DNA, which lead to cell cycle
arrest, allowing time for the repair to occur, or force cells to undergo apoptosis if the
damage is beyond repair. If the damage is not repaired properly, it will result in loss of
DNA integrity and accumulation of mutations that can lead to cancer.
Solar UV radiation is a major environmental factor that influences and affects the
survival of epidermal keratinocytes, which can lead to the development of premature skin
aging and skin cancer (Diffey, 1991). Nonmelanoma skin carcinomas are the most
frequent cancers in humans, accounting for about 40% of all diagnosed cancers in North
America (Christenson et al., 2005). UV radiation is composed of UVA (320-420nm),
UVB (280-320 nm), and UVC (200-280 nm). UVC radiation is highly bioactive,
however, most of the rays are absorbed by the atmospheric ozone layer, and therefore, we
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are not exposed to significant levels of UVC (unless you live in Antarctica). UVB
radiation causes direct DNA damage and reaches the epidermis. UVA radiation
penetrates the dermis and increases levels of reactive oxygen species (ROS) that can
induce DNA mutations.

1.3.1

Nucleotide excision repair

UV radiation causes specific mutations in epidermal keratinocytes. This occurs through
the reaction between UV photons and cellular DNA (Grossman and Leffell, 1997). In the
presence of UV light, two pyrimidines on the same DNA strand can undergo dimerization
and become covalently bound to each other, forming cyclobutane pyrimidine dimers
(CPD) and (6-4) pyrimidine pyrimidone ((6-4)PP) photoproducts (Sancar et al., 2004).
Approximately 85% of primary lesions caused by UV radiation give rise to CPD
photoproducts and (6-4)PP accounts for 10 to 20% (Grossman and Leffell, 1997). In
mammals, DNA repair of these lesions relies on nucleotide excision repair (NER)
pathways (Thiagarajan et al., 2011).
The importance of the NER pathway is demonstrated by the hereditary disorder
xeroderma pigmentosum (XP), an autosomal recessive genetic disorder that arises from
an impaired ability of epidermal cells to repair damaged DNA. Individuals with XP have
a mutation in one of the several genes involved in the NER pathway, and are
hypersensitive to UV radiation, exhibiting an increased risk of developing nonmelanoma
skin carcinoma (Rezvani et al., 2011). The NER pathway can occur through either global
genome NER (GG-NER), which repairs damage from the entire genome or through
transcription-coupled NER (TC-NER), which generally repairs lesions when RNA
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polymerase II is stalled on actively transcribed DNA strands (Figure 1.3) (Marteijn et al.,
2014).
The first step in the NER pathway is recognition of damaged DNA. The damage sensor
protein, XP complementation group C (XPC) forms a complex with UV excision repair
protein Rad23 homolog (hHR23) and centrin 2 (Sugasawa et al., 1997; van der Spek et
al., 1996a). When the XPC complex is recruited at the sites of DNA damage, hHR23
dissociates from the complex. In the NER pathway, the hHR23 protein functions to
recruit XPC to sites of DNA damage and promote nuclear accumulation of XPC by
preventing its proteasomal degradation (Ng et al., 2003). At the damaged site, complex
formation also occurs between DNA damage-binding protein-1 (DDB1, also known as
the XPE-binding factor) and DDB2, the UV-DDB complex, which further facilitates
subsequent binding of XPC (Reardon and Sancar, 2003). Lesion recognition is followed
by verification of DNA damage by recruitment of transcription initiation factor IIH
(TFIIH), composed of 10 protein subunits including XPA, XPB and XPD helicases. This
complex verifies the presence of the lesion and unwinds approximately 20 base pairs (bp)
around the damaged DNA site (Evans et al., 1997). This is followed by recruitment of
XPG, XPF and excision repair cross-complementation group 1 (ERCC1) endonucleases
by the XPA subunit to make a′ and
3 5′ incisions, respectively and

excise 25-26 bp

nucleotide strand surrounding the lesion site (Staresincic et al., 2009). In the final step,
DNA gap-filling is completed by the proliferating cell nuclear antigen (PCNA), which
recruits DNA polymerases and the repaired DNA is ligated by DNA ligases (Figure 1.3)
(Moser et al., 2007; Ogi et al., 2010).

Figure 1.3: Nuclear excision repair pathway.
The two pathways, global genomic NER, and transcriptional coupled NER differ in the
recognition of DNA damage but converge to a common mechanism from verification to
DNA synthesis and ligation. In global genomic NER (left), the UV-DDB complex and
the cullin 4A-regulator of cullins 1 (CUL4-ROC1) complex mediates XPC ubiquitylation
to increase its binding affinity to damaged DNA and recruitment to lesion sites together
with HR23 protein. Once XPC and centrin 2 (CETN2) is on lesion site, the UV-DDB
complex is ubiquitylated and dissociates together with HR23, which is essential for the
recruitment of TFIIH to verify the damaged site. In transcriptional couple NER (right),
the stalled RNA polymerase II facilitates the recruitment of Cockayne syndrome protein
(CSB) to sites of DNA damage. The recognition is followed by verification of DNA
damage by TFIIH in both pathways. The XPC-CETN2 complex is ubiquitylated and
targeted for degradation to enable binding of XPF-ERCC1 and XPG endonuclease to
excise 20-25 nucleotide of the damaged DNA. In the final step, the gap is filled by DNA
polymerase (DNA pol) to synthesize new DNA and the nick is sealed by DNA ligase.
Ub, ubiquitylation.
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1.4 The Ubiquitin-proteasome system
The ubiquitin-proteasome system (UPS) is a complex biological system that targets
proteins for degradation in the cytosol, the nucleus, or within the endoplasmic reticulum
of eukaryotic cells (Peters et al., 1994). The main function of the UPS is to degrade
misfolded, denatured, or improperly translated proteins, as well as participating in normal
protein turnover. Target proteins are first marked by ubiquitylation and the ubiquitylated
protein is then recognized, unfolded and hydrolyzed by the proteasome.

1.4.1

Ubiquitylation

Ubiquitin is a small 8.5-kDa protein with 76 amino acid (a.a.) residues that functions as a
protein degradation signal (Ciechanover et al., 1980). Ubiquitylation is also an inducible
event activated by extracellular stimuli, phosphorylation or during DNA damage
response (Hershko and Ciechanover, 1998). When a substrate protein is covalently linked
to polyubiquitin chains, it is frequently targeted for degradation through the 26S
proteasome. When the substrate protein in delivered to the proteasome, the ubiquitin is
recycled by deubiquitylating enzymes (DUB).
Ubiquitin is conjugated to a substrate in a three-step process catalyzed by specific E1, E2
and E3 enzymes (Scheffner et al., 1995). The carboxyl-terminal (C-terminal) end of
ubiquitin contains two glycine residues (Gly75-Gly76) that are activated by the E1
enzyme in an ATP-dependent manner. This forms a covalent thioester linkage between
ubiquitin and a cysteine residue of the E1 ubiquitin-activating enzyme. The activated
ubiquitin is subsequently transferred to an E2 ubiquitin-conjugating enzyme, which acts
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as a ubiquitin carrier protein. The E2 enzyme then transfers the ubiquitin to an active
cysteine residue on the E3 ubiquitin-ligase bound to the substrate protein. Ubiquitin is
subsequently transferred to the substrate protein through an amide isopeptide linkage
between Gly76 of ubiquitin and the ε-amino group of a lysine residue on the substrate
protein (Scheffner et al., 1995). A single ubiquitin molecule can be transferred to a lysine
residue on the substrate protein, leading to monoubiquitylation or it can be attached to
multiple lysine residues, which leads to multi-monoubiquitylation (Chan et al., 2006;
Hoege et al., 2002). Additional ubiquitins can be added to a lysine residue of ubiquitin,
resulting in the formation of polyubiquitin chains (Pickart, 2000). Ubiquitin has seven
lysine residues, all capable of forming polyubiquitin chains (Figure 1.4). There are
proteins with ubiquitin-binding domains (UBD) that interact with different types of
ubiquitin linkages, leading to numerous biological effects (Ravid and Hochstrasser,
2008). For example, K63-linked polyubiquitylation binds UBD-containing endosomal
sorting complex required for transport (ESCRT) proteins, and targets a substrate for
endosomal trafficking to lysosomes (Erpapazoglou et al., 2012; Nathan et al., 2013). On
the other hand, K11- and K48-linked polyubiquitin chains preferentially interact with
ubiquitin-binding receptors, such as hHR23, and target a substrate for degradation
(Bremm and Komander, 2011; Elsasser et al., 2004).

1.5 hHR23
The yeast Saccharomyces cerevisiae, Rad23 and its mammalian orthologue, hHR23 are
evolutionary conserved scaffold proteins essential for NER and are also involved in

Figure 1.4: Schematic of ubiquitin and types of ubiquitylation formed.
The seven lysine residues on ubiquitin are shown. The K0 ubiquitin has all lysine
residues substituted for an arginine, and therefore can only form mono-ubiquitin on one
or more sites on proteins (multi-ubiquitylation). The K0 ubiquitin prevents the generation
of polyubiquitin chains. The K11, K48, and K63 ubiquitins have all lysine substituted to
an arginine expect for the indicated lysine residue. Therefore, K11, K48, or K63 ubiquitin
can only form K11-, K48- or K63- linked polyubiquitin chains, respectively. Different
ubiquitin linkages lead to different biological consequences, multi-ubiquitylation of
substrate leads to endocytosis, K11- or K48-linked polyubiquitylation leads to substrate
degradation through the proteasomal pathway, and K63-linked polyubiquitylation leads
to DNA repair, endocytosis, or activation of kinase function. K, lysine; R, arginine; Ub,
ubiquitylation.
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modulating proteasomal degradation of variety of proteins (Dantuma et al., 2009;
Masutani et al., 1994). Depending on the cellular context, hHR23 can bind to and escort
polyubiquitylated proteins to the proteasome, increasing their degradation, or,
paradoxically, protect XPC and other proteins from proteasomal degradation (Blount et
al., 2014; Fang et al., 2013; Ng et al., 2003; Zhu et al., 2001).
There are two homologs of the mammalian HR23: HR23A, and HR23B (Renaud et al.,
2011). XPC associates with hHR23B and hHR23A in vivo (Sugasawa et al., 1997; van
der Spek et al., 1996a). mHR23A knockout mice are viable, develop normally and show
no defects in NER, whereas inactivation of the gene that encodes mHR23B severely
impairs the development of mice (Ng et al., 2003; Ng et al., 2002). This indicates
mHR23A can only partially compensate for the loss of mHR23B, and mHR23B has
additional important functions. Moreover, inactivation of both genes leads to embryonic
lethality, suggesting a role in pathways other than NER, most likely linked to the UPS.
Indeed, mHR23B associates with proteins involved in the UPS and knockout of mHR23B
affects the proteasome function resulting in decreased cell proliferation (Bergink et al.,
2013). HR23 proteins are composed of an amino-terminal (N-terminal) ubiquitin-like
(UbL) domain, two ubiquitin-associated domains (UBA1 and UBA2), and linking the
UBA1 and UBA2 regions is the XPC domain (Jung et al., 2014). These four domains are
connected through flexible linker regions ranging in length from 25 to 80 a.a. (Walters et
al., 2003).
The UbL domain of hHR23 consists of 80 a.a. and shares ~23% sequence similarity with
ubiquitin (van der Spek et al., 1996b). The UbL domain interacts with the 26S
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proteasome non-ATPase regulatory subunit 4 (PSMD4) (Chen and Madura, 2006;
Hiyama et al., 1999). Deletion of the UbL domain of Rad23 leads to increased sensitivity
to UV radiation, which indicates the importance of the interaction between UbL and the
proteasome and its function to efficiently repair damaged DNA (Lambertson et al.,
2003). Indeed, the NER recognition protein, XPC is stabilized by hHR23 (Ng et al.,
2003). The interaction between the UbL domain of hHR23 and the proteasome inhibits
the formation of multi-ubiquitin chains leading to increased protein stability (Ortolan et
al., 2000).
The UBA1 and UBA2 domains in hHR23 contain 48 a.a. and 44 a.a., respectively. Both
UBA domains can interact with ubiquitin and multi-ubiquitin chains (Bertolaet et al.,
2001; Kang et al., 2006). The interaction between UBA and ubiquitin prevents the
assembly and disassembly of multi-ubiquitin chains, and therefore can either inhibit or
favor degradation, respectively (Chen et al., 2001; Raasi and Pickart, 2003). UBA1 and
UBA2 domains mediate inhibition of proteolysis and the UbL domain is dispensable for
inhibiting substrate proteasomal degradation. The UbL domain can interact with both
UBA domains and PSMD4 (Kang et al., 2007; Lambertson et al., 1999). The interaction
between PSMD4 and UbL changes the conformation of hHR23A, so that it prevents UbL
from interacting with the UBA domain. The UBA domain can then interact with
polyubiquitylated substrates. This tertiary structure mediates the delivery of ubiquitylated
substrates to the proteasome for degradation where hHR23 act as an adaptor protein
linking the proteasome with the substrate (Figure 1.5A). Through biochemical and
structural analysis, many studies have proposed a working model for hHR23 proteins,
where high levels of hHR23 leads to protein stability and lower levels of hHR23 promote

Figure 1.5: Model of HR23 regulation in proteasome degradation of proteins.
A. In the first model, HR23 interacts with ubiquitylated substrates through its UBA
domain and the UbL domain mediates its interaction with PSMD4 of the proteasome.
This tertiary complex delivers ubiquitylated proteins to the proteasome for degradation.
In this model, HR23 functions as a bridging factor to facilitate protein turnover. B. In a
second proposed model, HR23 functions as a negative regulator of proteasome
degradation. HR23 prevents the assembly of more than four ubiquitins on a substrate,
which is crucial for the degradation of ubiquitylated proteins through the proteasome.
Secondly, an excess amount of HR23 proteins binds to ubiquitylated proteins and the
proteasome separately preventing the formation of a tertiary structure. Ub, ubiquitylation.
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degradation of ubiquitylated substrates (Figure 1.5B) (Brignone et al., 2004; Chen and
Madura, 2002; Fang et al., 2013; Glockzin et al., 2003; Kim et al., 2004; Ng et al., 2003).
Following UV-induced DNA damage, hHR23 stabilizes XPC and recruits it to DNA
damage site in the presence of DNA lesions (Baron et al., 2012; Kumar et al., 1999; Ng
et al., 2003). In humans, cells lacking either of these proteins are sensitive to UV
radiation and are at an increased risk of transformation to nonmelanoma skin carcinoma.
Thus, hHR23 and XPC are necessary to prevent loss of DNA integrity and inhibit
accumulation of mutations leading to cancer. The signals that sense the damaged DNA
will initiate cell cycle checkpoint signaling pathways to allow repair to occur, and
constitute cellular surveillance strategies to coordinate DNA repair and cell cycle
transitions.

1.6 Cell Cycle Regulation
A somatic cell can move through two phases, the mitosis phase (M) and interphase,
which includes three sub-phases: Gap phase 1, (G1), DNA synthesis (S), Gap phase 2,
(G2) (Figure 1.6A). Both intrinsic and extrinsic factors control cell division (van den
Heuvel, 2005). However, when G1 cells pass a restriction point (R1), they are committed
to go through the cell cycle. Cells can exit the cell cycle and enter the G0 quiescent phase.
Exposure to growth factors promotes entry into the G1 phase where cells prepare for
DNA replication in S phase. During S phase, the DNA is duplicated before cell division
and in G2 phase, the cell ensures proper intracellular signals prior to entering into M
phase where cells are divided into two daughter cells (van den Heuvel, 2005). Each of
these cycles is tightly regulated by cyclins and cyclin-dependent kinases (CDK) (Figure

Figure 1.6: Cell cycle regulation by CDK-cyclin complexes.
A. The cell cycle is divided into four phases: G1, S, G2, and M phase. Different CDKcyclin complexes regulate each of these phases. When cells are not prepared to progress
through the cell cycle, cells enters the G0 quiescent phase. The CDK interacting
protein/Kinase inhibitory protein (CIP/KIP) family of CDK inhibitors involved in
suppressing the activity of CDK are shown. B. CDK-cyclin is regulated through
phosphorylation and dephosphorylation by membrane-associated tyrosine- and threoninespecific cdc2-inhibitory kinase (Myt1) and cell division cycle 25 (Cdc25) to form an
inactive and active complex, respectively. The CDK-activating kinase (CAK) also
phosphorylates CDK to form an active CDK-cyclin complex. P, phosphorylation.
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1.6). CDK are serine/threonine protein kinases activated by association with cyclins. The
CDK-cyclin complex is inactivated through association with cyclin kinase inhibitors
(CKI) and phosphorylation of CDK by membrane-associated tyrosine- and threoninespecific cdc2-inhibitory kinase (Myt1). The inhibitor effect is lifted off when CKI are
ubiquitylated and targeted for degradation and dephosphorylation of CDK by cell
division cycle (Cdc25) phosphatase (Figure 1.6B). In order to ensure proper cell cycle
progression, there are multiple cyclins and CDK governing each phase of the cell cycle.
During early G1 phase the CDK4 and CDK6 form a complex with cyclins D1, D2, and
D3. During transition and progression through S phase, CDK2-cyclin E/A are activated
and in G2/M phase, the CDK2/CDK1 and cyclins A/B are involved (Figure 1.6A). One of
the main functions of the CDK-cyclin complex is to phosphorylate the retinoblastoma
(Rb) proteins to activate transcription of E2F-dependent genes required for S phase
transition.

1.6.1

Retinoblastoma family proteins

There are three family members of the Rb proteins: pRb, p107, and p130 (DeCaprio et
al., 1988; Dyson et al., 1989; Hannon et al., 1993; Mayol et al., 1993). Mutations in the
RB gene lead to retinoblastoma (Knudson et al., 1975) and other cancers, including
osteosarcomas, breast cancer, and lung cancer (Ceccarelli et al., 1998; Kelley et al.,
1995; Toguchida et al., 1988). pRb is phosphorylated during late G1 phase of the cell
cycle and regulates G1 to S phase transition (DeCaprio et al., 1988). All three Rb family
members interact with E2F to inhibit its transcriptional activity.
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The Rb family of proteins are often referred to as "pocket proteins" owing to their highly
conserved carboxyl-domain that interacts with E2F called the pocket domain. The pocket
domain is subdivided into the A and B domains separated by a spacer region. The p107
and p130 have two B domains. Many mutations on Rb proteins are found on the pocket
domain (Giacinti and Giordano, 2006). The Rb family of proteins also contain an Nterminal and C-terminal domain, sixteen phosphorylation sites, and a highly conserved
LXCXE binding cleft to interact with proteins containing an LXCXE motif, such as
histone deacetylases (HDAC) (Dahiya et al., 2000; Rubin, 2013). Mutations on the
LXCXE binding cleft do not prevent Rb proteins to bind E2F family proteins but inhibit
Rb proteins from recruiting repressor complexes to promoters of E2F target genes
(Dahiya et al., 2000). In addition to binding of E2F1 to the pocket domain of pRb, E2F1
binds pRb on a second site located at the end of the C-terminus of pRb (Dick and Dyson,
2003). This interaction is unique to E2F1 and prevents E2F1-induced apoptotic events
(Julian et al., 2008). Following DNA damage, the interaction of E2F1 to the pRb unique
site is lost but the interaction with the pocket domain is enhanced (Dick and Dyson, 2003;
Inoue et al., 2007). This complex formation not only represses transcription of genes
required for cell cycle progression, but also transcriptionally activates proapoptotic genes
(Inoue et al., 2007).

1.6.2

The E2F family of transcription factors

The E2F family of transcription factors regulates many functions including: proliferation,
apoptosis, differentiation, metabolism and DNA repair. In mammals, the E2F family is
composed of E2F 1-8 and three dimerization partners (DP), DP1, -2 and -4 (Figure 1.7).
E2F1 through -6 have a DNA binding domain, a leucine zipper, a marked box domain,

Figure 1.7: The mammalian E2F family of a transcription factor.
E2F family of transcription factors are comprised of ten members and three polypeptide
DP1, -2, and -4 to form a heterodimer. E2F family members share several homologous
regions including the DNA binding domain and a dimerization domain. E2F1 through -3
have a nuclear localization sequence and a CDK-cyclin binding domain in the Nterminus; and a transcriptional activation domain and Rb proteins binding site
(specifically interacts with pRb, p107 or p130) at the C-terminus. E2F4 and -5 lack a
CDK-cyclin binding sequence but still contain a pocket protein binding domain
(preferentially interact with the other Rb family proteins, p107 and p130). E2F4 and -5
are exported out of the nucleus via their nuclear export signal. E2F6 shares only the DNA
binding domain and the dimerization domain with the other E2F family members. Both
E2F7 and -8 contain two conserved DNA binding domains allowing it to form
heterodimer without DP proteins. E2F6 through -8 lack pRb-binding and a transcriptional
activation domain. DP1, -2, and -4 proteins lack transcriptional activation domains and
pRb-binding regions.
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and a dimerization domain which associates with DP proteins to form a functional
heterodimer complex. In E2F1, the marked box domain interacts with c-Jun activation
domain-binding protein 1 (Jab1) to enhance E2F1-induced apoptosis and not proliferation
(Hallstrom and Nevins, 2006). E2F1 through -5 have a transactivation domain and an Rb
protein-binding region. Rb family proteins can modulate the transcriptional activity of
E2F proteins. E2F1 through -3 associate specifically with pRb, E2F4 preferentially
interacts with p107 or p130 and E2F5 binds p130 (Beijersbergen et al., 1994; Hijmans et
al., 1995; Ivey-Hoyle et al., 1993; Lees et al., 1993; Shan et al., 1992). The interaction
between E2F and Rb family proteins represses the transcriptional activity of E2F1
through -5 (Figure 1.8). E2F6 does not have a transactivation domain or an Rb-binding
region. E2F1 through -3 are structurally similar and have a cyclin A-binding domain,
which is not present on E2F4 and -5. E2F7 and -8 have two DNA binding domains but
lack a dimerization domain. Thus, they are not dependent on DP proteins for functional
activity. E2F7 and -8 can interact with each other to form homodimer complexes (Li et
al., 2008).
Binding of E2F family of proteins to hypophosphorylated Rb family proteins recruits
histone deacetylases and DNA methyltransferases, such as HDAC1, suppressor of
variegation 3-9 homolog 1 (Suv39H1) and SWItch/Sucrose Non-Fermentable (SWI/SNF)
(Figure 1.8). This complex functions to inhibit transcription of E2F-responsive genes
(Magnaghi-Jaulin et al., 1998; Nagl et al., 2007; Vandel et al., 2001). In an actively
proliferating cell, Rb family proteins are sequentially phosphorylated by CDK4/6-cyclin
D and CDK2-cyclin E complexes resulting in dissociation from E2F, rendering E2F
activators transcriptionally active to target genes required for G1/S phase progression

Figure 1.8: Cell cycle regulation of E2F family of transcription factors.
The activity of different E2F-DP-Rb protein complexes during each phase of the cell
cycle are shown. E2F1 through -3 function as activators during late G1 to initiation S
phase progression and G2 phase to promote activation of genes required for mitosis. E2F6
through -8 are involved in repressing E2F-target genes during S phase. E2F1 through -5
are involved in repressing E2F-dependent transcription during cell cycle arrest (G0
phase). pRb is preferentially phosphorylated by CDK4/6-cyclin D during late G1 phase
which leads to subsequent phosphorylation at multiple sites on pRb by CDK2-Cyclin E
causing full inactivation of pRb and dissociation with E2F1 through -3 to promote G1 to
S phase transition. P, phosphorylation.
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(Ezhevsky et al., 1997; Lundberg and Weinberg, 1998). The E2F family members
function as both transcriptional repressors and activators, depending on cellular context.
E2F1 through -3 can switch from being transcriptional activators in proliferating cells to
repressors in cells committed to differentiate and in response to DNA damage (Chong et
al., 2009a; Ianari et al., 2009).
The best-characterized function of E2F1 through -3 is the activation of gene transcription
to promote G1/S phase transition leading to proper cellular proliferation (Wu et al., 2001).
Constitutive expression of E2F1 through -3 induce S phase entry of quiescent cells and
triple knockout lead to defects in proliferation and increased cell death (Chong et al.,
2009a; Johnson et al., 1993; Wu et al., 2001). During G2 phase, E2F1 through -3 activate
transcription of genes required for G2/M progression (Zhu et al., 2004). The E2F3 locus
encodes two gene products, E2f3a and E2f3b, through the use of alternate promoters.
While E2F3a expression is highest during S phase, E2F3b is expressed constitutively
throughout the cell cycle (Leone et al., 2000). Both E2F3 isoforms can function as
activators or repressors of E2F target genes (Chong et al., 2009b).
E2F4 and -5 function as transcriptional repressors by forming a complex with p107 or
p130, which recruits chromatin remodeling proteins to repress E2F target genes and
prevent G1/S phase transition (Takahashi et al., 2000). E2F6 acts as a transcriptional
repressor to inactivate E2F-responsive genes and inhibit S phase entry by forming a
repressor complex with enhancer of polycomb (Attwooll et al., 2005; Cartwright et al.,
1998; Trimarchi et al., 1998). E2F7 and -8 delay cell cycle progression during S phase
functioning as transcriptional repressors (Logan et al., 2005). E2F7 and -8 repress the
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expression of E2F1 and their expression is dependent on E2F1 (Moon and Dyson, 2008).
This negative feedback loop serves to maintain E2F1 balance during cell cycle
progression.

1.7 Other functions of E2F factors
Inactivation of E2f genes in mice has demonstrated the existence of multiple roles for
these proteins. They include tumour formation in mice lacking the E2f1, E2f2 or E2f3
gene (Olson et al., 2007; Paulson et al., 2006; Scheijen et al., 2004), fetal erythrocyte
maturation defects in mice lacking the E2f4 gene (Kinross et al., 2006), prenatally lethal
hydrocephalus upon inactivation of the E2f5 gene (Lindeman et al., 1998), and
embryonic lethality with widespread apoptosis, vascular dilation and hemorrhage upon
joint inactivation of the E2f7 and E2f8 genes (Li et al., 2008).

1.7.1

Role of E2F in apoptosis

E2F1 through -6 play a role in activating apoptotic events in cultured cells and transgenic
mouse models (Chang et al., 2000; Chen et al., 2013; Johnson and Degregori, 2006;
Martinez et al., 2010; Yang et al., 2007). The involvement of E2F1 in activating
apoptosis has been extensively studied. Expression of E2F1 induces p53-dependent and independent apoptosis. E2F1 increases p53 expression levels by transcriptionally
activating the p14ARF gene. The p14ARF protein negatively regulates mouse double
minute 2 homolog (Mdm2), an E3 ubiquitin ligase, essential for ubiquitylating p53 and
targeting it for degradation. Deregulated Mdm2 stabilizes p53 protein levels followed by
activation of genes required for apoptosis, such as TAp73, Fas, Bax, and Noxa (Haupt et
al., 2003). E2F1 also stimulates expression of ataxia-telangiectasia mutated (ATM),
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checkpoint kinase 1 (Chk1), and Chk2, which leads to p53 phosphorylation and
stabilization. Moreover, E2F1 up regulates transcription of several p53 co-factors,
including Aspp1, Aspp2, Jmy, and TP53inp, which are essential for induction of the proapoptotic p53 target gene, Bax.
E2F1 can also stimulate apoptosis by inducing TAp73 expression (Wu et al., 2008).
Similarly, E2F1 is found on the promoter of genes important for the apoptotic pathway,
such as the Bcl-2 family of proteins, apoptotic protease-activating factor 1 (Apaf1),
caspase 3, and caspase 7 (Moroni et al., 2001; Wu et al., 2009). E2F1 is also involved in
transcriptionally inactivating genes important for cell survival, by disrupting the NF-κB
signaling pathway through down regulation of TNF receptor-associated factor 2 (TRAF2)
(Ginsberg, 2002).

1.7.2

Role of E2F in DNA damage

E2F1 up regulates expression of genes required for the initiation of the DNA damage
response (Polager et al., 2002). Some of these genes function in the mismatch repair
pathway, such as DNA mismatch repair protein 2 (MSH2), MSH6, mismatch repair
endonuclease (PMS2). Others include uracil-DNA glycosylase (UNG), flag structurespecific endonuclease (Fen1), and PCNA, which participate in the base excision repair
(BER) pathway. E2F1 also induces the expression of genes involved in the NER
pathway, such as DDB2/XPE (Prost et al., 2007), and XPC (Lin et al., 2009). By acting
as a transcriptional repressor, E2F1 forms a complex with pRb, C-terminus-binding
protein (CtBP), and CtBP interacting protein (CtIP) corepressor to mediate transcriptional
inactivation of zinc finger and BRCA1-interacting protein with a KRAB domain 1
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(ZBRK1) (Liao et al., 2010). ZBRK1 negatively regulates growth arrest and DNAdamage-inducible alpha (GADD45A), an important DNA repair response protein that
functions to stimulate cell cycle arrest following DNA damage (Zheng et al., 2000).
Treatment with DNA damaging agents including UV or ionizing radiation, actinomycin
D, adriamycin, neocarzinostatin or etoposide increases E2F1 through -3 transcript and
protein levels (Castillo et al., 2015; Hofferer et al., 1999; Martinez et al., 2010; Meng et
al., 1999). Both transcriptional and post-translational modifications are required for the
induction of E2F1 through -3 in response to DNA damage. E2F1 and E2F3 are
phosphorylated at Ser364 and Ser124, respectively by Chk1/2 to activate transcription of
pro-apoptotic genes, such as TAp73 and Apaf1 (Martinez et al., 2010; Pediconi et al.,
2003; Stevens et al., 2003). E2F1 is also phosphorylated at Ser31 by ATM and/or ataxia
telangiectasia and Rad3-related (ATR) proteins following drug-induced DNA damage
(Lin et al., 2001). This leads to E2F1 stabilization and transcriptional activation of TAp73
and Apaf1. This residue is also necessary for E2F1's interaction with DNA topoisomerase
IIβ-binding protein I (TopBP1) to repress transcriptional activity of E2F1 by recruiting
Brahma (BRM) and Brahma-related gene 1 (BRG1), subunits of the SWI/SNF
chromatin-remodeling complex and to activate replication checkpoint surveillance
following DNA damage (Liu et al., 2003; Liu et al., 2004). UV-induced DNA damage
also phosphorylates E2F1, however under these circumstances, phosphorylation at Ser31
facilitates E2F1 recruitment to sites of UV-induced DNA damage or DNA double strand
breaks (DSB). Ser31 of E2F1 is also required for the recruitment of XPA, XPC, GCN5,
and accumulation of H3K9 acetylation at sites of UV-induced DNA damage but is
dispensable for E2F-dependent transcriptional activity and induction of apoptosis
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(Biswas et al., 2014; Guo et al., 2011; Guo et al., 2010). Therefore, the stabilization of
E2F1 through phosphorylation at Ser31 could either increase its transcriptional activity or
promote non-transcriptional functions of E2F1 (Biswas and Johnson, 2012).

1.8 Mechanisms of E2F1 Regulation
1.8.1

Post-translational modifications

E2F1 can be modified by acetylation, citrullination, methylation, neddylation,
ubiquitylation, and phosphorylation (Figure 1.9). E2F1 can be acetylated at Lys117,
Lys120, and Lys125 by the p300/CREB-binding protein (CBP) or by p300/CBPassociated factor (P/CAF) acetyltransferase (Martinez-Balbas et al., 2000; Marzio et al.,
2000). Acetylation of E2F1 allows for stabilization and increase in transcriptional
activation of E2F1 target genes (Farhana et al., 2002; Martinez-Balbas et al., 2000).
Ectopic expression of P/CAF or p300/CBP increases E2F1 ubiquitylation and it is
dependent on Lys117, Lys120, and Lys125 following DNA damage (Galbiati et al.,
2005). This could indicate that DNA damaging signals may prevent ubiquitylated E2F1
to be targeted for degradation through the proteasomal pathway (Galbiati et al., 2005).
Acetylation of E2F1 also promotes its interaction with bromodomain-containing protein 4
(BRD4). This interaction is dependent on E2F1 citrullination at Arg109, Arg111,
Arg113, and Arg127 by protein arginine deiminases 4 (PDA4) and enhances E2F1
binding to the promoter region of inflammatory genes tumor necrosis factor–α (TNFα)
and interleukin-1β (IL-1β) (Ghari et al., 2016).
Methylation of E2F1 can occur at Lys185 by histone-lysine N-methyltransferase
(SETD7), and demethylated by lysine-specific histone demethylase 1A (KDM1A) in

Figure 1.9: Post-translational modifications on E2F1.
The protein kinases involved in modifying the residues on E2F1 is shown. Ac,
acetylation; Ci, citrullination; Me, methylation; NE, NEDDylation; P, phosphorylation.
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vitro and in cultured cells (Kontaki and Talianidis, 2010; Xie et al., 2011a).
Demethylation stabilizes E2F1 and up regulates the transcription of TAp73 in response to
DNA damage. Importantly, methylation of E2F1 impairs its acetylation and
phosphorylation at Ser364, targeting E2F1 for ubiquitylation and degradation (Kontaki
and Talianidis, 2010). Methylation of E2F1 at Lys185 promotes E2F1 neddylation (also
at Lys185) and subsequent down regulation of E2F1 transcriptional activity and increases
turnover of E2F1 (Loftus et al., 2012). E2F1 can also be methylated at arginine residues.
Asymmetric

arginine

methylation

of

E2F1

at

Arg109

by

protein

arginine

methyltransferase 1 (PRMT1) stabilizes E2F1 and symmetric arginine methylation at
Arg111 and Arg113 by PRMT5 promotes E2F1 ubiquitylation and degradation (Cho et
al., 2012; Zheng et al., 2013). In response to DNA damage, the interaction between E2F1
and PRMT1 is enhanced with concomitant increase in asymmetric arginine methylation
and this prevents PRMT5 binding and symmetric arginine methylation of E2F1.
Together, the E2F1-PRMT1 complex favors E2F1-induced apoptosis. On the other hand,
when E2F1 is methylated by PRMT5, the binding of E2F1 with PRMT1 is inhibited and
cell proliferation is stimulated (Zheng et al., 2013).
E2F1 regulation can also be controlled through ubiquitylation. Targeting of E2F1 for
ubiquitylation can occur through the C-terminal activation domain. The physical
association between pRb and E2F1 stabilizes E2F1 by protecting it from ubiquitylation
(Campanero and Flemington, 1997; Hateboer et al., 1996; Hofmann et al., 1996). At the
S/G2 boundary, E2F1 is regulated through ubiquitylation by S-phase kinase-associated
protein-2 (Skp2), the F-box protein of the Skp1–Cullin–F-box protein (SCF) E3 ubiquitin
ligase complex (Marti et al., 1999). Skp2 functions as a substrate recognition component
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to specifically recognize phosphorylated substrates resulting in subsequent ubiquitylation
and proteasomal degradation of the targeted protein (Tsvetkov et al., 1999). E2F1
interaction with 14-3-3τ (Wang et al., 2004) or Mdm2 (Zhang et al., 2005) displace Skp2
from E2F1 thereby inhibiting E2F1 ubiquitylation and degradation. Both 14-3-3τ and
Mdm2 enhance E2F1 transcriptional activity (Martin et al., 1995; Wang et al., 2004).
During mitosis, the interaction between E2F1 and activator cell division cycle20 (Cdc20)
of the anaphase-promoting complex/cyclosome (APC/C) complex regulates E2F1
stability (Budhavarapu et al., 2012). Cdc20 homolog 1 (Cdh1), another activator subunit
of the APC/C complex that preferentially interacts with destruction box (D-box) of
substrates (Qin et al., 2016), specifically forms K11-linked polyubiquitin chains on E2F1
to target it for degradation during late S phase (Budhavarapu et al., 2012) However, DNA
damage does not prevent Cdh1 from ubiquitylating E2F1, but rather inhibits its
degradation. E2F1 can also be ubiquitylated in vitro by the multi-subunit Cullin (CUL)RING E3 ligase (CRL) independent of Skp2 and phosphorylation of E2F1 (Ohta and
Xiong, 2001). The presence of multiple E3 ligases that interact with and mediate
degradation of E2F1 enables orderly control of E2F1 expression under different
circumstances.
E2F1 can also be de-ubiquitylated by deubiquitylase 26S proteasome non-ATPase
regulatory subunit 14 (PSMD14) and Ubiquitin carboxyl-terminal hydrolase isozyme L5
(UCHL5). PSMD14 stabilizes E2F1 by cleaving K11- and K63- linked polyubiquitin
chains, which lead to increased expression of E2F1-induced pro-survival genes (Wang et
al., 2015). UCHL5 is not involved in the stability of E2F1 but the cleavage of K63-linked
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polyubiquitin chains lead to enhanced E2F1 transcriptional activity following DNA
damage (Mahanic et al., 2015).
E2F1 is phosphorylated at multiple sites at the N- and C-terminus in vitro and in vivo by
a number of kinases, and most of these phosphorylation sites are conserved between
human and mouse orthologues. E2F1 phosphorylation at Ser332 and Ser337 residues by
CDK4-cyclin D attenuates E2F1-pRb association and phosphorylation of these residues
indirectly regulates E2F1 ubiquitylation (Fagan et al., 1994). E2F1 is also phosphorylated
by CDK2-cyclin A on Ser375 and reduces DNA binding (Dynlacht et al., 1994; Krek et
al., 1995; Xu et al., 1994). During S phase, E2F1 is also phosphorylated at Ser403 and
Thr433 by TFIIH-CDK7, which targets E2F1 for degradation (Vandel and Kouzarides,
1999). Disruption of the cyclin A binding domain or the TFIIH-CDK7 binding domain of
E2F1 increases its stability and can lead to apoptosis, emphasizing the importance of tight
regulation of E2F1 by both CDK2-cyclin A and TFIIH kinases (Krek et al., 1995; Vandel
and Kouzarides, 1999). The Ser403 and Thr433 of E2F1 are also phosphorylated in vitro
by p38β-MAPK. Activation of p38β-MAPK triggers E2F1 nuclear export and
degradation allowing for proper keratinocyte differentiation (Ivanova et al., 2009).
As mentioned earlier, E2F1 is phosphorylated at Ser31 and Ser364 residues by ATM and
Chk1/2, respectively, in response to DNA damage, and phosphorylation mediates E2F1
stabilization (Lin et al., 2001; Stevens et al., 2003). The Ser31 of E2F1 resides within the
Skp2 binding domain and has been suggested to modulate E2F1 degradation by inhibiting
Skp2 binding. It also mediates interactions with 14-3-3τ, which interfere with
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ubiquitylation (Wang et al., 2004). Phosphorylation of E2F1 at Ser364 increases E2F1
transcriptional activity (Stevens et al., 2003).

1.8.2

E2F1 subcellular localization

E2F regulation can also be modulated by its subcellular localization (Verona et al., 1997).
The N-terminal domain of E2F1 through -3 has a nuclear localization signal (NLS)
(Muller et al., 1997). Differentiation leads to E2F1 nuclear export and degradation in
keratinocytes (Ivanova and Dagnino, 2007). E2F1 has a nuclear export sequence (NES),
which allows chromosomal maintenance-1 (CRM1)-dependent export and is involved in
nucleocytoplasmic shuttling in a variety of cells (Ivanova et al., 2007). Conversely, E2F4
and -5 are expressed predominantly in the cytoplasm owing to the presence of NES
(Magae et al., 1996). Both E2F4 and -5 are localized to the nucleus through their
interactions with DP or p107/p130. However, the N-terminus of E2F5 has an intrinsic
nuclear localization signal, which is required for its nuclear import independent of
interactions with DP or p130 (Apostolova et al., 2002).

1.8.3

Protein-protein interactions

In addition to pRb and DP factors, E2F1 associates with other proteins. E2F1 interactions
with transcription intermediary factor 1-β (TRIM28) (Wang et al., 2007), MDM4
(Strachan et al., 2003), and neural proliferation differentiation and control protein 1
(NPDC1) (Sansal et al., 2000) reduces DNA binding and hence E2F1 transcriptional
activity. On the other hand, E2F1 binding with poly [ADP-ribose] polymerase 1 (PARP1)
(Simbulan-Rosenthal et al., 2003), host cell factor 1 (HCF1) (Tyagi et al., 2007), and
chromodomain-helicase-DNA-binding protein 8 (CHD8) (Subtil-Rodriguez et al., 2014)
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promotes cell cycle progression by recruiting chromatin remodeling proteins to E2F1
target promoter regions.

1.9 The role of E2F in the epidermis
The E2F family of transcription factors modulate many cellular processes involved in
epidermal homeostasis, including cell proliferation, apoptosis, differentiation, DNA
replication, DNA damage response and DNA repair (Dicker et al., 2000; Hong et al.,
2008; Ivanova et al., 2009; Stevens and La Thangue, 2004; Wang et al., 2004).

One of

the events that contribute to the abnormal regulation of proliferation and differentiation is
the disruption of the pRb/E2F pathway, which is common in most cancers, including
NMSC (Ebihara et al., 2004; Yamazaki et al., 2005).
The members of the E2F family of transcription factors are differentially expressed in the
epidermis. The E2f1 through -4 transcripts are expressed in the basal layer, whereas E2f5
transcripts are abundant in the suprabasal layers (Dagnino et al., 1997). Moreover, the
expression levels of E2F1 through -3 decrease following keratinocyte differentiation,
with an increase in E2F5 protein levels (D'Souza et al., 2001; Wong et al., 2003).
E2F1 maintain normal proliferation in undifferentiated keratinocytes and modulates
keratinocyte differentiation (Ivanova et al., 2009; Wong et al., 2003). In undifferentiated
keratinocytes E2F1 localizes to the nucleus, but differentiation induces E2F1 export to
the cytoplasm, where it is degraded through the proteasomal pathway. The signaling
pathways involved in E2F1 turnover during Ca2+-induced keratinocyte differentiation
involve the activation of PKCη and PKCδ. PKCη and PKCδ subsequently activate p38β,
which appears to phosphorylate E2F1 at Ser403 and Thr433 (Figure 1.10). E2F1 nuclear

Figure 1.10: Regulation and signaling pathway of E2F1 in differentiated
keratinocytes.
In keratinocytes, E2F1 shuttles between the nucleus and cytoplasm. Upon keratinocyte
differentiation through external stimuli, such as Ca2+, it triggers signaling events that lead
to activation of protein kinase C eta and delta which phosphorylates p38β. p38β appears
to phosphorylate E2F1 at Ser403 and Thr433. This leads to E2F1 nuclear export through
the chromosome region maintenance 1 (CRM1)-nuclear protein export pathway with
concurrent ubiquitylation of E2F1 and degradation through the proteasomal pathway. The
sequence of events involving E2F1 phosphorylation, ubiquitylation, nuclear export, and
subsequent degradation are required for proper keratinocyte differentiation. Ub,
ubiquitylation; P, phosphorylation.
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export is dependent on chromosome region maintenance 1 (CRM1) and requires E2F1
Ser403 and Thr433. When differentiated keratinocytes are exposed to a specific inhibitor
of CRM1-nuclear export,leptomycin B (LMB), E2F1 accumulates in the nucleus and is
stable. Further, forced nuclear retention by engineering an additional NLS protects E2F1
from degradation. This indicates that E2F1 nuclear export is required for its proteasomal
degradation during keratinocyte differentiation. The sequence of events involving E2F1
phosphorylation, ubiquitylation, nuclear export, and subsequent degradation are therefore
required for proper keratinocyte differentiation. In cultured keratinocytes, substitution of
Ser403 and Thr433 to Ala (hereafter termed ST/A) generated a mutant protein defective
in nuclear export, and more stable than wild-type E2F1 following Ca2+-induced
keratinocyte differentiation. Exogenous expression of the ST/A in cultured keratinocytes
caused defects in differentiation (Ivanova et al., 2009). Abnormal increases in E2F1
expression and activity can lead to epidermal tumor formation by inducing proliferationspecific genes and suppressing squamous differentiation-specific genes (Dicker et al.,
2000). Constitutive expression of E2F1 in basal keratinocytes results in hyperkeratosis
and contributes to tumor development (Pierce et al., 1998b). Inactivation of the E2f1 gene
results in impaired keratinocyte migration, proliferation and significant delay in wound
healing (D'Souza et al., 2002).

1.10 Rationale and Aims of this Study
The E2F1 transcription factor regulates expression of key genes involved in cell cycle
progression and cell survival. The levels of E2F1 are tightly regulated during the cell
cycle, when keratinocytes and other cells differentiate, as well as in response to DNA
damage. Despite the fact that the regulation of E2F1 has been extensively studied, major

51

questions remain to be addressed. First, E2F1 is necessary for recruitment of XPC to
damaged sites, however the recognition of DNA damage by XPC is dependent on
hHR23. This begs the question: does E2F1 co-operate with hHR23 to recruit XPC and
subsequent recruitment of XPA to DNA damage sites? Second, E2F1 degradation is
necessary for proper keratinocyte differentiation. E2F1 Ser403 and Thr433 are required
for its degradation, but whether other sites on E2F1 are necessary for proper keratinocyte
differentiation is not known. Third, it is currently unclear whether mechanisms that
regulate E2F1 stability during cell cycle progression also regulate E2F1 stability
following DNA damage or differentiation. The objective of this study is to further
understand the regulation of E2F1 in epidermal keratinocytes. I hypothesize that the
regulation of E2F1 protein turnover plays a critical role during epidermal keratinocyte
DNA repair and differentiation. To test the hypothesis, I addressed the following aims:
Specific Aims:
1) Characterize the role of E2F1 and hHR23 following UV-induced DNA damage in
keratinocytes.
2) Identify residues essential for E2F1 stability following drug-induced DNA damage in
keratinocytes.
3) Investigate the mechanisms of E2F1 degradation following keratinocyte
differentiation.
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Chapter 2

2

Materials and Methods

2.1 Reagents and materials
The materials used in this study are listed in Table 2.1. The reagents and, where
applicable, the concentrations used in this study are listed in Table 2.2. The composition
of routinely used solutions and the final concentrations of each reagent are presented in
Table 2.3.
Table 2.1: List of materials and catalogue numbers.
Materials

Source

Catalogue number

3-µm pore polycarbonate
membrane

EMD Millipore, Billerica, MA

TSTP02500

8×10 inch Blue Ray Film

Endoch Inc. Concord, ON, CA

810UPB

Amicon Ultra-15 columns

EMD Millipore, Billerica, MA

UFC903024

Amersham Hybond-N+ Nylon
membrane

GE Healthcare, Mississauga,
ON

RPN203B

Falcon® 70 µm cell strainers

Corning Incorporated, Corning,
352350
NY

Grade 703 Blotting paper

VWR International, Radnor,
PA

28298-020

PD10 desalting column

GE Healthcare, Mississauga,
ON

17-0851-01

Poly-L-lysine-coated glass
coverslips 12 mm

Neuvitro Corporation,
Vancouver, WA

NEU-GG-12-PLL

Immu-mount mounting media

Thermo Scientific, Waltham,
MA

9990402

Polyvinylidene difluoride
membranes (PVDF)

EMD Millipore, Billerica, MA

IPVH00010

Ultra Cruz autoradiography film

Santa Cruz Biotechnology,
Santa Cruz, CA

SC-201697

53

Table 2.2: Reagents, the catalogue number, and the final concentration used.
Reagents

Source

Catalogue Number

Concentration

0.25% trypsin with
ethylenediaminetetraacetic
acid (EDTA)

Gibco, Burlington,
ON

25200-056

0.25%

2.5% Trypsin

Gibco, Burlington,
ON

15090-046

0.25%

Agar

BioShop,
Burlington, ON

AGR001

1.5%

Albumin, Bovine Serum
(BSA)

BioShop,
Burlington, ON

ALB001

2%

Amersham ECL Prime
Western Blotting detection
reagent

GE Healthcare,
Mississauga, ON

RPN2232

N/A

Aprotinin

BioShop,
Burlington, ON

APR200

1 µg/ml

Betaine

Sigma, St Louis,
MO

B2629

1M

Bradford protein
quantification solution

Bio-Rad,
Mississauga, ON

500-0006

20%

Ca2+-free Eagle’s
minimum essential
medium (EMEM)

Lonza,
Walkersville, MD

06-174G

N/A

Chelex 100 resin (100-200
dry mesh size, 150–300
µm wet bead size)

Bio-Rad,
Mississauga, ON

1422832

80 mg/ml

Cholera toxin

Sigma, St. Louis,
MO

C8052

9.5 ng/ml

Cycloheximide (CHX)

Sigma, St Louis,
MO

C7698

100 µg/ml

Dimethyl sulfoxide
(DMSO)

Caledon Labs Ltd.
Georgetown, ON

4100-1

N/A

Dispase II

Roche Diagnostics,
Indianapolis, IN

4942078001

8 mg/ml

Epidermal growth factor
(EGF)

Sigma, St Louis,
MO

E4127

5 ng/ml
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FBS for keratinocytes

Thermo Scientific,
Waltham, MA

12483-020

8%

Fetal bovine serum (FBS)

Gibco, Burlington,
ON

12483

4%

Etoposide

Sigma, St Louis,
MO

E1383

150 µM

Glutathione Sepharose™
4B

GE Healthcare,
Mississauga, ON

17-0756-01

50%

Hoechst 33342

Thermo Scientific,
Waltham, MA

H1399

1 µg/ml

Hydrocortisone

Sigma, St. Louis,
MO

H4001

74 ng/ml

HyQ-Dulbecco’s Modified
Eagle Medium-Reduced
Serum (HyQ-DMEM-RS)

Thermo Scientific,
Waltham, MA

SH3056501

N/A

Imidazole

Thermo Scientific,
Waltham, MA

03196-500

Varies

Insulin

Sigma, St. Louis,
MO

H4001

5 µg/ml, pH
3.0

Isopropyl β-D-1thiogalactopyranoside
(IPTG)

BioShop,
Burlington, ON

Leptomycin B (LMB)

Enzo life sciences,
Plymouth, PA

ALX-380-100

5 ng/ml

Leupeptin

BioShop,
Burlington, ON

LEU001

1 µg/ml

L-Glutathione reduced

Sigma, St. Louis,
MO

G4251

10 mM

Lipofectamine 2000
Transfection Reagent

Thermo Scientific,
Waltham, MA

11668029

15 µg

N-ethylmaleimide (NEM)

Sigma, St. Louis,
MO

E3876

10 mM

Ni-NTA agarose slurry

Qiagen, Louisville,
KY

30210

50%

IPT001.5

0.5 mM
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Paraformaldehyde (PFA)

Thermo Scientific,
Waltham, MA

AC416780030

4%

Penicillin-Streptomycin,
100× liquid

Gibco, Burlington,
ON

15140-122

100 U/ml,
(Pen) 100
µg/ml (Strep)

Pepstatin A

BioShop,
Burlington, ON

PEP605

1 µg/ml

Phenylmethylsulfonylfluoride (PMSF)

BioShop,
Burlington, ON

PMS123

1 mM

Pierce protein A/G
magnetic beads

Thermo Scientific,
Waltham, MA

88803

400 µg or
250 µg

Polyethylenimine (PEI, 25
kDa linear)

Polysciences,
Warrington, PA

23966

1 mg/ml,
pH 5.0 (Stock)

Poly-L-lysine
hydrobromide

Sigma, St. Louis,
MO

A00013

1 mg/ml

Rat tail collagen type I

BD Biosciences,
Bedford, MA

354236

20 µg/cm2

SimpleBlue™ Safe Stain

Thermo Scientific,
Waltham, MA

LC6060

100%

Sodium Pyrophosphate
tetrabasic decahydrate
(Na₄P₂O₇·10H2O)

Sigma, St. Louis,
MO

S9515

10 mM

Sodium Azide (NaN3)

BDH Inc. Dubai,
UAE

B30111

10 mM

Sodium Deoxycholate

Sigma, St. Louis,
MO

D6750

0.5%

Sodium Fluoride (NaF)

Sigma, St. Louis,
MO

S-6521

10 mM

Sodium Orthovanadate
(Na₃VO₄)

BioShop,
Burlington, ON

SOV664-10

1.2 mM

Triiodothyronine (T3)

Sigma, St. Louis,
MO

T6397

6.7 ng/ml

Z-Leu-Leu-Leu-al (MG132)

Sigma, St. Louis,
MO

C2211

10 µM
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Table 2.3: Composition of routinely used solutions and media.
Name

Composition

1× Sodium dodecyl sulfate
(SDS)

25 mM Tris, 192 mM glycine, 0.1% (w/v) SDS

1× Laemmli loading buffer

50 mM Tris-HCl pH 6.8, 2% (w/v) SDS, 0.1% (w/v)
bromophenol blue, 10% (v/v) glycerol, 100 mM DTT

1× Phosphate Buffered
Saline (PBS)

137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 1.8 mM
KaH2PO4, pH 7.4

1× Tris-acetate-EDTA (TAE) 40 mM Tris, 5 mM NaAc, 1 mM EDTA, 20 mM HAc
1× Tris-Buffered Saline
(TBS)

25 mM Tris-HCl, 137 mM NaCl, 5 mM KCl, pH 7.4

1× Tris-Glycine Transfer
Buffer

39.2 mM glycine, 48.1 mM Tris, 20% (v/v) methanol

2× Yeast extract and
Tryptone (2× YT) broth

2% (w/v) bacto-tryptone, 1% (w/v) yeast extract, 85
mM NaCl2, 17 mM MgSO4

Guanidine hydrochloridebased (GnHCl) stripping
solution

6 M GnHCl, 0.2% (v/v) Nonidet P-40 (NP-40), 20 mM
Tris-HCl pH 7.5

Luria Bertani (LB) Broth

1% (w/v) bacto-tryptone, 0.5% (w/v) yeast extract, 0.5%
(w/v) NaCl2

Low pH stripping buffer

25 mM glycine pH 2.0, 1% (w/v) SDS

LB Agar

LB + 1.5% (w/v) Agar

Modified
radioimmunoprecipitation
assay (RIPA) Buffer

50 mM Tris-HCl pH 7.4, 150 mM NaCl, 0.1% (v/v)
NP-40, 0.5% (w/v) sodium deoxycholate, 0.1% (w/v)
SDS, 1 µg/ml aprotinin, leupeptin, pepstatin A, 1 mM
PMSF, 10 mM sodium pyrophosphate, 10 mM sodium
fluoride, 1.2 mM sodium orthovanadate

Mouse tonicity phosphatebuffered saline (MTPBS)

150 mM NaCl, 4 mM NaH2PO4, 16 mM Na2HPO4

Super Optimal Broth (SOB)
medium

2% (w/v) bacto-tryptone, 0.5% (w/v) yeast extract, 10
mM NaCl, 2.5 mM KCl, 10 mM MgCl2, 10 mM MgSO4

TBST

TBS, 0.1% (v/v) Tween-20

Transformation buffer (TB)
solution

10 mM PIPES, 15 mM CaCl2, 250 mM KCl, adjust to
pH 6.7 with KOH, then add MnCl2 (final concentration,
55mM)
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2.2 Antibodies, enzymes and kits
The antibodies used in the study are listed in Table 2.4. Table 2.5 shows the list of
restriction endonucleases, DNA polymerases, and other modifying enzymes. Table 2.6
shows the list of commercially available kits used in this study. For immunoblotting,
primary antibodies were diluted in TBST unless stated otherwise, and secondary
antibodies were diluted in TBST containing 5% (w/v) non-fat milk. For
immunofluorescence microscopy, primary antibodies were diluted in PBS containing 5%
(v/v) goat serum, and secondary antibodies were diluted in PBS containing 1% (w/v)
non-fat milk and 5% (v/v) goat serum.
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Table 2.4: Antibodies and dilutions used.
Antibodies

Source

Catalogue Number

Dilution*

Anti-FZR1 [DH01 (DCS266)]

Abcam, Cambridge,
UK

ab3242

IB: 1:2500

Anti-c-Myc (9E10)

Santa Cruz
Biotechnology,
Santa Cruz, CA

SC-40

IB:1:1000

Anti-CPD (Clone TMD-2)

CosmoBio Co.
Tokyo, Japan

NMDND001

IB: 1:5000
IF: 1:1000

Anti-dsDNA

Abcam, Cambridge,
UK

Ab27156

IB: 1:1000

Anti-E2F1

OriGene
Technologies,
Rockville, MD

TA308764

IB: 1:1000
IP: 3 µg

Anti-E2F1 (C-20)

Santa Cruz
Biotechnology,
Santa Cruz, CA

SC-193

IB: 1:500

Anti-FLAG (Rabbit)

Sigma, St. Louis,
MO

F7425

IP: 3 µg

Anti-FLAG M2

Sigma, St. Louis,
MO

F1804

IB: 1:5000

Anti-GAPDH

Assay Designs, Ann
Arbor, MI

CSA-335

IB: 1:10 000

Anti-HA (Y-11)

Santa Cruz
Biotechnology,
Santa Cruz, CA

SC-805

IB: 1:5000
IP: 3 µg
IF: 1:1000

Anti-Lamin A/C

Cell Signaling,
Danvers, MA

2032S

IB: 1:2500

Anti-Rad23A (D-6)

Santa Cruz
Biotechnology,
Santa Cruz, CA

SC-365669

IB: 1:1000

Anti-V5 (Chicken)

Abcam, Cambridge,
UK

Ab9113

IF: 1:1000

Anti-V5 (Mouse)

Thermo Scientific,
Waltham, MA

R960-25

IB: 1:5000
IP: 3 µg
IF: 1:1000

Primary antibodies
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Anti-β-Tubulin

Hybridoma Bank,
University of Iowa

E7
RRID:AB_2315513

IB: 1:50

Anti-γ-Tubulin

Sigma, St. Louis,
MO

T6557

IB: 1:50 000

AlexaFluor™ 488Phalloidin

Thermo Scientific,
Waltham, MA

A12379

IF: 1:100

AlexaFluor™ 564Phalloidin

Thermo Scientific,
Waltham, MA

A12381

IF: 1:100

AlexaFluor™ 647Phalloidin

Thermo Scientific,
Waltham, MA

A22287

IF: 1:100

ChromPure Mouse IgG
Whole molecule

Jackson
ImmunoResearch,
West Grove, PA

015-000-003

IP: 3 µg

AffiniPure Goat antiRabbit IgG [H+L]

Jackson
ImmunoResearch,
West Grove, PA

111-005-045

IP: 3 µg

AlexaFluor™ 488conjugated Goat antiRabbit IgG

Thermo Scientific,
Waltham, MA

A11008

IF: 1:1000

AlexaFluor™ 594conjugated Goat antiChicken IgG

Thermo Scientific,
Waltham, MA

A11042

IF: 1:1000

AlexaFluor™ 594conjugated Goat antiMouse IgG

Thermo Scientific,
Waltham, MA

A11005

IF: 1:1000

AlexaFluor™ 647conjugated Goat antiMouse IgG

Thermo Scientific,
Waltham, MA

A21235

IF: 1:1000

AlexaFluor™ 647conjugated Goat antiRabbit IgG

Thermo Scientific,
Waltham, MA

A21244

IF: 1:1000

115-035-146

IB: 1:5000

Secondary antibodies

Jackson
HRP-conjugated Goat antiImmunoResearch,
Mouse IgG
West Grove, PA

Jackson
HRP-conjugated Goat antiImmunoResearch,
111-035-003
Rabbit IgG
West Grove, PA
*IB: immunoblot, IP: immunoprecipitation; IF: immunofluorescence.

IB: 1:5000
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Table 2.5: Enzymes for molecular biology experiments.
Enzymes

Source

Catalogue number

ApaI

New England BioLabs Inc,
Whitby, ON

R0114

HindIII-HF

New England BioLabs Inc,
Whitby, ON

R3104

λ Protein Phosphatase

New England BioLabs Inc,
Whitby, ON

P0753S

NotI-HF

New England BioLabs Inc,
Whitby, ON

R3189

PerfeCTa® qPCR SuperMix

Quanta Biosciences,
Gaithersburg, MD

95064-100

Platinum™ Taq DNA
polymerase

Thermo Scientific, Waltham,
MA

10966-018

SuperScript™ II Reverse
Transcriptase

Thermo Scientific, Waltham,
MA

18064-014

T4 DNA ligase

New England BioLabs Inc,
Whitby, ON

M0202

XhoI

New England BioLabs Inc,
Whitby, ON

R0146

Table 2.6: List of kits used in this study.
Kits

Source

Catalogue Number

RNeasy Mini Kit

Qiagen, Louisville, KY

74104

DNeasy® Blood & Tissue Kit

Qiagen, Louisville, KY

69506

QIAprep Spin Miniprep Kit

Qiagen, Louisville, KY

27106

EndoFree Plasmid Maxi Kit

Qiagen, Louisville, KY

12362

QIAquick Gel Extraction Kit

Qiagen, Louisville, KY

28704

NE-PER™ Nuclear and
Cytoplasmic Extraction Kit

Thermo Scientific, Waltham,
MA

78833

NucleoBond® Xtra Maxi Kit

Macherey-Nagel, Düren,
Germany

740414

QIAquick PCR Purification
Kit

Qiagen, Louisville, KY

28104
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2.3 Vectors
Table 2.7: Plasmids used in this study.
Plasmid

References or source

pCDNA 3.1

Thermo Scientific, Waltham, MA
catalogue number V790-20

pCDNA 3.1 hHR23A-FLAG
pCDNA 3.1 hHR23A-HA
pCDNA 3.1 hHR23A-HA UBA2
pCDNA 3.1 hHR23A-HA ΔUBA2

Dr. Christine Blattner, Institute of Toxicology
and Genetics, Karlsruher Institut für Technologie,
Germany (Glockzin et al., 2003)

pCDNA 3.1 hHR23A-HA ΔUbL
pCDNA 3.1 hHR23B-FLAG
pCDNA 3.1 V5-E2F1
K117R/K120R/K125R (KTR)
pCDNA 3.1 V5-E2F1 K185R
pCDNA 3.1 V5-E2F1
R111K/R113K (RDK)
pCDNA 3.1 V5-E2F1 S31A
pCDNA 3.1 V5-E2F1 S332A
pCDNA 3.1 V5-E2F1 S337A
pCDNA 3.1 V5-E2F1 S364A
pCDNA 3.1 V5-E2F1 S375A
pCDNA 3.1 V5-E2F1 S403D
pCDNA 3.1 V5-E2F1 T433D
pCDNA 3.1 V5-E2F1
S403D/T433D (ST/D)
pCDNA 3.1 V5-E2F1 WT-NES
pCDNA 3.1 V5-E2F1 ST/A-NES

This study
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pEGFP-C1 hHR23A-HA WT
pEGFP-C1 hHR23A-HA UBA1
pEGFP-C1 hHR23A-HA UBA2
pEGFP-C1 hHR23A-HA XPCUBA2
pEGFP-C1 hHR23A-HA ΔUBA1

This study

pEGFP-C1 hHR23A-HA ΔUBA2
pEGFP-C1 hHR23A-HA ΔUbL
pEGFP-C1 hHR23A-HA ΔXPC
pET32b-TRX-hHR23A-FLAG
pCDNA 3.1 V5-E2F1 WT
pCDNA 3.1 V5-E2F1 T433A
pCDNA 3.1 V5-E2F1 S403A

Dr. Iordanka A. Ivanova, Western University,
London, Ontario (Ivanova et al., 2007)

pCDNA 3.1 V5-E2F1
S403A/T433A (ST/A)
pCDNA 3.1 FLAG-Cdh1
pCDNA 3.1 FLAG-Cdc20

Dr. Daniele Guardavaccaro, Hubrecht Institute,
Utrecht, Netherlands (Ping et al., 2012)

pCMV2 FLAG-Skp2

Dr. Wenyi Wei, Harvard Medical School
Boston, MA (Wei et al., 2004)

pCMV2 FLAG-Ubc13

Addgene, Cambridge, MA, deposited by Dr.
Dong-Er Zhang, plasmid #12460 (Zou et al.,
2005)

pCS2-Myc-hEmi1

Dr. Peter K. Jackson, Stanford University School
of Medicine, Stanford, CA (Hsu et al., 2002)

pEGFP-C1

Clontech Laboratories, Inc, Mountain View, CA,
catalogue number 6084-1

pET32b-TRX

Novagene®, EMD Millipore, Billerica, MA
catalogue number 69016
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pGEX-4T-1

Amersham Pharmacia Biotech, Piscataway, NJ
catalogue number 28-9545-49

pGEX-GST-E2F1

Dr. Paul Hamel, University of Toronto, Toronto,
Ontario

pBluescriptSK--HA-Ubiquitin-WT

Dr. David Litchfield, Western University,
London, Ontario (Treier et al., 1994)

pRK-HA-Ubiquitin-K11

Addgene, Cambridge, MA, deposited by Sandra
Weller, plasmid #22901 (Livingston et al., 2009)

pRK-HA-Ubiquitin-K0

Plasmid #17603

pRK-HA-Ubiquitin-K48

Plasmid #17605

pRK-HA-Ubiquitin-K63

Plasmid #17606

pRK-HA-Ubiquitin-WT

Plasmid #17608

Addgene, Cambridge,
MA, deposited by Dr.
Ted Dawson (Lim et al.,
2005)

2.4 Molecular cloning
2.4.1

Generation of vectors encoding E2F1 and hHR23A mutants

All E2F1 mutants were generated using a three-step site-directed mutagenesis strategy, as
summarized in Figure 2.1. This approach allowed for introduction of mutations in the
central regions of the E2F1 cDNA while simultaneously maintaining good amplicon
yields, which proved challenging because the E2F1 cDNA has several GC-rich regions
that interfered with optimal polymerase-chain reaction (PCR) amplification. The plasmid
encoding V5-tagged wild type E2F1 was used as a template (Table 2.7). For each V5tagged E2F1 mutant, the N- and the C-terminal halves were amplified separately. For the
N-terminal half, a forward primer containing a HindIII site for subsequent cloning,
together with sequence encoding the V5 tag. In these reactions, the reverse primer
contained the mutated nucleotide(s). For the C-terminal half, a forward primer containing

Figure 2.1: Schematic representation of the three-step PCR protocol used for sitedirected E2F1 mutagenesis.
A three-step PCR amplification procedure was used to generate fragments F’, R’ and FL.
Two complementary primers to the E2F1 cDNA, as indicated by a and d (primers E2F1
V5 WT Fwd and Rev, see Table 2.8) including, respectively HindIII and NotI sequences,
together with primers containing the desired point mutations (red circle) were designed to
generate the vectors encoding E2F1 mutants used in this thesis. For each mutant
construct, fragment F’ was amplified using primers a and c (PCR 1), and fragment R’
was amplified using primers b and d (PCR 2). Amplicons F’ and R’ contain overlapping
sequences, which allowed them to be used as templates for the third, and final PCR
reaction to synthesize full-length FL fragments , using primes a and d (PCR 3). All FL
fragments were digested with HindIII and NotI and cloned into pCDNA3.1.
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the same mutated nucleotide(s) paired with a reverse primer containing the STOP codon
(TGA) and a NotI site for subsequent cloning (Figure 2.1). The N- and C- terminal
amplicons were then combined and served as templates in a third PCR reaction, which
generated full-length V5-tagged E2F1 cDNAs, using the HindIII-V5-tag forward and
STOP-NotI reverse primer (primers a and d, Figure 2.1). Full-length E2F1 mutant
cDNAs thus obtained (1500 bp) were cloned into the expression plasmid pCDNA3.1
(4500bp) at the HindIII and NotI sites. The sequences of all the primers used to generate
mutant E2F1 cDNAs are shown in Table 2.8.
To add a NES to the E2F ST/A mutant, the simian virus 40 (SV40) large T antigen NES
(LPPLERLTL) was inserted at the C-terminus of E2F1 ST/A by PCR. The sequences of
all mutant constructs generated were verified by dideoxy sequencing at the Robarts
Research Institute sequencing facility.
To generate vectors encoding GFP-tagged hHR23A forms, cDNAs corresponding to wild
type hHR23A and the deletion mutants ∆UbL, ∆UBA1, ∆UBA2, ∆XPC, XPC-UBA2,
UBA1 and UBA2 were amplified by PCR using reverse primers that included sequences
corresponding to the HA tag (AGCATAATCAGGAACATCATA) at the C-terminus
(Table 2.9). The templates used for these reactions were vectors encoding the
corresponding HA-tagged hHR23A proteins, which were generous gifts from Dr.
Christine Blattner (Glockzin et al., 2003). Amplicons thus generated were cloned into the
XhoI and ApaI sites of pEGFP-C1. The sequences of all mutant constructs generated
were verified by dideoxy sequencing at the Robarts Research Institute sequencing
facility.
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Table 2.8: Forward (Fwd) and reverse (Rev) primers used to generate E2F1 point
mutants.
Primers
Sequence*

E2F1 V5 WT

Fwd: 5'-CTTaagcttCCATGGGTAAGCCTATCCCTAACCCTCTCC
TCGGTCTCGATTCTACGGCCTTGGCCGGGGCCCCTGCGGGC
GGCCCA-3'
Rev: 5'-AATAATgcggccgcTCAGAAATCCAGGGGGGTGAGGT
CCCCAAAGTCACAGTCG-3'

E2F1 S31A

Fwd: 5'-CGGCTGCTCGACTCCGCGCAGATCGTCATCATC-3'
Rev: 5'-GATGATGACGATCTGCGCGGAGTCGAGCAGCCG-3'

E2F1 S332A

Fwd:5'-CTGCCACCATAGTGGCACCACCACCATCATC-3'
Rev: 5'-GATGATGGTGGTGGTGCCACTATGGTGGCAG-3'

E2F1 S337A

Fwd: 5'-CACCACCACCATCAGCTCCCCCCTCATCCC-3'
Rev: 5'-GGGATGAGGGGGGAGCTGATGGTGGTGGTG-3'

E2F1 S364A

Fwd:5'-GTTGTCCCGGATGGGCGCCCTGCGGGCTCCCGTG-3'
Rev: 5'-CACGGGAGCCCGCAGGGCGCCCATCCGGGACAAC3'

E2F1 S375A

Fwd: 5'-GACGAGGACCGCCTGGCCCCGCTGGTGGCGG-3'
Rev: 5'-CCGCCACCAGCGGGGCCAGGCGGTCCTCGTC-3'

E2F1 K185R

Fwd: 5'-GCCAAGAAGTCCAGGAACCACATCCAGTGG -3'
Rev: 5'- CCACTGGATGTGGTTCCTGGACTTCTTGGC -3'

E2F1
K117R/K120R/K
125R

Fwd:5'- CCATCCAGGAAGAGGTGTGAGATCCCCGGGGGAG
AGGTCACGCTATG -3'
Rev: 5'- CATAGCGTGACCTCTCCCCCGGGGATCTCACACCT
CTTCCTGGATGG -3'

E2F1
R111K/R113K

Fwd: 5'-CCAGCTCGGGGCAAAGGCAAGCATCCAGGAAAAG
GTGTG-3'
Rev: 5'- CACACCTTTTCCTGGATGCTTGCCTTTGCCCCGAG
CTGGC-3'

E2F1 S403D

Fwd: 5'-CCTGAGGAGTTCATCAGCCTTGACCCACCCCACGA
GGCCC-3'
Rev: 5'-GGCCTCGTGGGGTGGGTCAAGGCTGATGAACTCCT
CAGG-3'

E2F1 T433D

Rev: 5'- CGAgcggccgcTCAGAAATCCAGGGGGTCGAGGTCC
CCAAAGTCACAGTCG-3'

Rev: 5'-gcggccgcTCAAAGAGTAAGTCTCTCAAGCGGTGGTA
GG AAATCCAGGGGGGCGAGGTCCCC 3'
*Mutated nucleotides are underlined and shown in bold characters; the nucleotide
sequence for the V5 tag is italicized. The HindIII and NotI sequences are written in lower
case characters.
E2F1 ST/A NES
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Table 2.9: Forward (Fwd) and reverse (Rev) primers used for deletion mutations in
hHR23A.
Primers
Sequence*

hHR23A WT

Fwd: 5'-CCATACGACGTCCCAGActcgagAGGGATCCATGGCC
GTCACC-3'
Rev: 5'-GgggcccTTAAGCATAATCAGGAACATCATACTCGT
CATCAAAGTTCTG-3'

hHR23A UbL

Fwd: 5'-CCATACGACGTCCCAGActcgagAGGGATCCATGCAG
GG TACC-3'
Rev: 5'-GgggcccTTAAGCATAATCAGGAACATCATAGGCAG
GTGGGGGATGGG-3'

hHR23A UBA2

Fwd: 5'-CATACGACGTCCCAGActcgagAGGGATCCATGGCGT
ACCCATAC-3'
Rev: 5'-GgggcccTTAAGCATAATCAGGAACATCATACTCGT
CATCAAAGTTCTG-3'

hHR23A UBA1

Fwd: 5'-CCCAGActcgagAGGGATCCATGGCCAGAGAGGACA
AG-3'
Rev: 5'-GgggcccTTAAGCATAATCAGGAACATCATACGGCT
GCTCCGATACCTGG-3'

hHR23A ∆UBA1

Fwd:5'-GCCAGAGAGGACAAGAGCGCCACGGAAGCAGCAG
G-3'
Rev: 5'-GCTCTTGTCCTCTCTGGCGGCAGGTGGGGGATGGG3'

Fwd: 5'-GAGCAGCCGGCCACGCAGGTGACGCCGCAG-3'
Rev: 5'-CGTGGCCGGCTGCTCCGATACCTGGCTCTC-3'
*The HA-tag is bolded and underlined; The XhoI and ApaI nucleotides are written in
lower case characters.
hHR23A ∆XPC

To generate the construct encoding the thioredoxin (TRX) fusion protein of hHR23A for
bacterial expression, a cDNA containing the FLAG tag sequence at the C-terminus was
amplified by PCR using the following primers: Forward 5’-CCCAGAAAGCTTGCCGT
CACCATCACGCTC-3’ and reverse 5’-CCGTCTGGCGGCCG CTCATATGTCGTAA3’. The amplicon was digested with HindIII and NotI and cloned into the corresponding
sites of the bacterial expression vector pET32b-TRX.
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2.4.2

Polymerase chain reaction (PCR)

All PCR reactions were carried out using Platinum™ Taq DNA polymerase (Qiagen) in a
50-µl reaction containing 150 ng of DNA, 300 nM each forward and reverse primers, 200
µM dNTP mix, 1× PCR buffer (20 mM Tris-HCl pH 8.4 and 50 mM KCl), 1 M Betaine,
2 mM MgCl2, and 5 U Platinum™ Taq DNA polymerase. The reactions were conducted
in a PCR thermal cycler (Eppendorf Mastercycler EP Gradient S, Hauppauge, NY) under
the following cycling parameters: one cycle at 95ºC for 2 min, followed by 30 cycles of
denaturation at 94ºC for 30 sec, annealing at 58ºC for 30 sec, and elongation at 72ºC for
50 sec. The final step involved a post-elongation cycle at 72ºC for 7 min, followed by
cooling to 4ºC until sample retrieval from the thermal cycler. All PCR products were
analyzed on 1× TAE agarose gels.

2.4.3

Isolation and purification of DNA and PCR products

The PCR products were purified from agarose gels using gel purification kits (Qiagen),
following the manufacturers’ instructions. After gel purification, amplicons were digested
with the appropriate restriction enzymes and purified with PCR cleanup kits (Qiagen),
followed by ligation into appropriate vectors previously digested with the appropriate
restriction enzymes and gel purified.

2.4.4

DNA ligation

All ligation reactions were performed in 10-µl reaction volumes containing 1:3 molar
reactions of vector to insert, and using T4 DNA ligase. Ligation reactions were incubated
at 22ºC for 1 h before transformation into Escherichia coli (E. coli).

70

2.4.5

Preparation of competent DH5α and BL-21 (DE) cells

E. coli DH5α or BL-21(DE) cells were streaked on an LB agar plate and cultured for 16 h
at 37ºC. Immediately afterwards, a single colony from the streak was used to inoculate 5
ml of LB medium and cultured for 16 h at 37ºC with shaking (250 rpm). The following
day, bacteria were subcultured into 250 ml of SOB medium at a ratio of 1:3. The culture
was incubated at 18ºC with shaking at 250 rpm. When the culture reached an optical
density at 600 nm (OD600) of 0.6, it was cooled on ice for 10 min and centrifuged at
2500×g for 10 min at 4ºC. After removing the supernatant, cell bacterial pellets were
resuspended in 80 ml ice-cold TB and incubated on ice for 10 min. The bacteria were
then collected by centrifugation (2500×g, 10 min, 4ºC). The bacterial pellets were gently
resuspended in 20 ml ice-cold TB and DMSO was added to a final concentration of 7%
(w/v). Two hundred-µl aliquots of competent cells were freeze using liquid nitrogen, and
stored at -80ºC. The competence of the bacteria was determined by transforming 100 pg
of DNA, and calculated using the following equation:
Number of colonies obtained × 106pg × 1000 µl total transformation volume × DF
100 pg transformed DNA
µg
100 µl plated
= Number of colony-forming-units (cfu) per µg plasmid DNA
The transformation efficiency following this protocol was routinely > 1 × 106 cfu/µg
supercoiled plasmid DNA.

2.4.6

Bacterial transformation

Plasmids were transformed into E. coli DH5α, to prepare vectors used for mammalian
cell transfection. For bacterial expression of recombinant proteins, E. coli BL-21(DE)
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was used because this strain generally attains higher yields of recombinant proteins. For
transformation, a 250-µl aliquot of competent bacteria was thawed on ice and mixed with
10 ng of purified plasmid DNA or 2 µl from a 10-µl ligation reaction. The bacterial
suspension was incubated on ice for 30 min with intermittent mixing, followed by heat
shock at 42ºC for 45 sec. Seven-hundred and fifty ml of LB medium were quickly added
and the bacteria were incubated at 37ºC for 1 h with shaking at 250 rpm. The
transformation mixture was centrifuged (3000×g, 3 min, 22ºC). The bacterial pellet was
resuspended in 100 µl LB and plated on LB agar plates containing 100 μg/ml ampicillin
or 50 µg/ml kanamycin, according to the antibiotic resistance associated with the plasmid
transformed, and the plates were incubated at 37ºC for 16ºC to allow for colony
formation.

2.5 Recombinant Protein Purification
2.5.1

GST fusion protein expression

Glutathione S-transferase (GST) fusion proteins were purified as described (Apostolova
et al., 2002; Ivanova et al., 2007) with slight modifications. GST and GST-E2F1
expression plasmids were transformed into E. coli BL-21(DE). A single colony was used
to inoculate 5 ml of 2× YT medium containing 200 µg/ml ampicillin, and cultured for 16
h at 37ºC with shaking at 250 rpm. One ml of this overnight culture was used to inoculate
200 ml of fresh 2× YZ with 200 µg/ml ampicillin, and was cultured at 37ºC until the
OD600 was 0.6 (approximately 4 h). To induce protein expression, isopropyl β-D-1thiogalactopyranoside (IPTG) was added to the bacterial culture to a final concentration
of 0.5 mM, and incubation continued at 18ºC for 18 h. Bacteria were harvested by
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centrifugation (6000×g, 15 min, 4ºC) and resuspended in MTPBS buffer (Section 2.1,
Table 2.3) containing 1% (v/v) Triton X-100, 1 mM PMSF, 1 µg/ml each aprotinin,
leupeptin, and pepstatin A. The cells were lysed through a French-pressure cell press
(American instrument Co In, Silver Spring MD) twice at a pressure of 10,000-11,000 psi.
The lysate was then centrifuged (14000×g, 15 min, 4ºC) to remove cell debris. The
supernatant was incubated in 50% (v/v) slurry of GST sepharose beads rinsed with lysis
buffer prior to use. Incubation proceeded for 30 min at 4ºC with gentle mixing. The
sepharose beads were washed three times with MTPBS, and bound GST or GST fusion
proteins were eluted with 50 mM Tris-HCl pH 8.0 containing 10 mM reduced Lglutathione. The purified GST fusion proteins were desalted using PD10 columns, and
concentrated to a final volume of about 500 µl, using Amicon Ultra-15 columns. The
protein concentrations in the eluates were determined using Bradford assays, and
recombinant proteins were stored in single-use 20-µl aliquots at -80ºC.

2.5.2

TRX fusion protein expression

His-TRX and His-TRX-hHR23A-FLAG proteins were induced as described in Section
2.5.1 and purified as described (Ho et al., 2009), with the following exceptions.
Harvested bacterial pellets were resuspended in lysis buffer containing imidazole (10 mM
imidazole, 300 mM NaCl, 50 mM NaH2PO4 (pH 8.0), 1% (v/v) Triton X-100, 1 mM
PMSF, 1 µg/ml each aprotinin, leupeptin, and pepstatin A), homogenized using a Frenchpress, and cleared by centrifugation as above. Supernatants were mixed with 50% (v/v)
slurry of Ni-NTA agarose previously rinsed with lysis buffer. Agarose slurry mixtures
incubated for 30 min at 4ºC with gentle rocking, washed three times with wash buffer (40
mM imidazole, 300 mM NaCl, 50 mM NaH2PO4 (pH 8.0)), and eluted with wash buffer
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containing 250 mM imidazole. The purified TRX fusion proteins were desalted using
PD10 columns, and concentrated to a final volume of about 500 µl, using Amicon Ultra15 columns. The protein concentrations in the eluates were determined using Bradford
assays, and recombinant proteins were stored in single-use 20-µl aliquots at -80ºC.

2.6 Preparation of glass coverslips for cultured cells
Glass coverslips were washed in 1 N HCl at 60ºC for 4 h, and subjected to 2-3 washes in
double distilled H2O (ddH2O) at 50-60°C. The glass coverslips were allowed to cool to
room temperature, and were then rinsed with 95% (v/v) ethanol and allowed to air dry.
Dry coverslips were incubated in a sterile poly-L-lysine (PLL) solution (1 mg/ml) for 1 h
at 22°C, with gentle rocking. PLL-coated coverslips were washed with sterile ddH2O and
allowed to air dry under sterile conditions in a tissue culture biosafety cabinet. Sterile
PPL-coated coverslips were then stored at 22ºC until needed. Prior to use to culture
mammalian cells, PPL-coated coverslips were further coated with collagen type I as
described (Nakrieko et al., 2008). Briefly, the coverslips were rinsed with 70% (v/v)
ethanol, washed with PBS, and incubated in a solution of rat tail collagen type I (20
µg/cm2) dissolved in 0.02 N acetic acid for 4 h at 37°C. These coverslips were then
washed three times with sterile PBS, and placed in tissue culture plates.

2.7 Cell culture and transfection
2.7.1

Isolation of primary epidermal keratinocytes

All experiments that involved the use of mice were approved by the University of
Western Ontario Animal Care Committee (Protocol No. 2015-021), in accordance with
regulations and guidelines from the Canadian Council on Animal Care. Primary mouse
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keratinocytes were isolated from 2d-old CD-1 mice and cultured in keratinocyte growth
medium (Ca2+-free EMEM supplemented with 100U/ml penicillin, 100μg/ml
streptomycin, 74 ng/ml hydrocortisone, 5 μg/ml insulin, 9.5 ng/ml cholera toxin, 5 ng/ml
EGF, 6.7 ng/ml T3 and 8% (v/v) FBS pre-treated with chelex resin) (Dagnino et al.,
2010; Ivanova et al., 2006; Ivanova et al., 2009). Mice were euthanized by CO2/O2
inhalation and placed in 70% (v/v) isopropyl alcohol for sterilization. The limbs, tail and
head were removed, and a longitudinal incision was made along the back, starting at the
base of the skull. The skins were harvested using two forceps, washed with PBS, spread
epidermis side up on 10-cm bacterial culture plates containing freshly diluted 0.25% (v/v)
trypsin, and incubated for 16 h at 4°C. The trypsin was then removed by aspiration, and
replaced with fresh 0.25% (v/v) trypsin, and the tissues were incubated at 37ºC for 15
min. The epidermis was mechanically separated from the dermis, and placed in 5 ml of
keratinocyte growth medium. The epidermis was minced very finely with scissors, and 30
ml of keratinocyte growth medium was added. The minced epidermis was incubated with
gentle rocking at 37ºC for 30-40 min. The cell suspension was filtered through a 70-μm
nylon mesh to remove the cornfield envelope, and the cell density in the suspension was
determined using a haemocytometer. Keratinocytes were plated at a density 1.6 × 105
cells/cm2. For microscopy experiments, cells were seeded on PPL- and collagen-coated
sterile glass coverslips (Section 2.5). The day after plating, keratinocytes were washed
once with PBS and cultured in fresh growth medium, which was subsequently replaced
every other day. Keratinocyte differentiation was induced by in culture by adding growth
medium containing 1 mM CaCl2 (“High-Ca2+ medium”) for at least 24 h. Keratinocytes
were transfected 3 days after plating.
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2.7.2

Culture of tumour cell lines

HeLa cervical carcinoma and RPMI-7951 human melanoma cells were purchased from
the American Type Culture Collection. These cells were cultured in HyQ Reduced Serum
DMEM, supplemented with 4% (v/v) FBS at 37ºC in a humidified 5% (v/v) CO2
atmosphere. When cells reached a confluence of ~ 90%, they were subcultured at a ratio
of 1:4, and the growth medium was replaced 2-3 times per week. All experiments were
conducted with cells that had reached less than 80% confluence, and had been passaged
for 10 generations or less.

2.7.3

Cell transfection and drug treatments

Cells were transfected with PEI solution (Section 2.1, Table 2.2), as previously described
(Dagnino et al., 2010). Cells were transfected at a ratio of 1 µg of DNA per 3 µl PEI,
adjusted to 100 µl (24-well plates), 200 µl (6-well plates), 300 µl (6-cm plates), or 500 µl
(10-cm plates) with sterile 150 mM NaCl. The DNA/PEI mixture was vortexed, followed
by a pulse centrifugation, incubated at 22ºC for 10 min, and added dropwise onto the
culture medium, swirling gently to ensure thorough mixing. The cells were cultured in
the presence of DNA/PEI mix for 4 h, at which time they were washed twice with Ca2+free PBS and cultured with fresh growth medium. Where indicated, transfected
keratinocytes were induced to differentiate by culturing in growth medium containing 1
mM CaCl2 for a total of 24 h, which was initiated 4 h after transfection. For experiments
with proteasome inhibitors, cells were treated with MG132 (10 µM) for 6 h prior to
harvesting. Where indicated, LMB (5 ng/ml) was added 24 h after transfection and cells
were harvested 6 h later. To induce single strand DNA damage, etoposide (150 µM) was
added 24 h after transfection and cells were harvested 8 h later. For steady-state E2F1
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protein levels, CHX was added to keratinocyte cultures 24 h after transfection for 30 min
prior to replacing the culture medium with growth medium containing either low Ca2+ or
high Ca2+ in the presence of CHX, and cell lysates were prepared 2.5 h later. For E2F1 t½
experiments, CHX (100 µg/ml) was added 24 h after transfection to keratinocytes
cultured in low Ca2+ or high Ca2+ for 4 h. Cell lysates were prepared at timed intervals
following CHX addition and protein abundances were measured by immunoblot analysis
(Section 2.9).

2.8 RNA isolation and quantitative reverse-transcription
PCR (qPCR)
Total RNA was isolated from cultured cells or from tissues harvested from 2d-old CD-1
mice, using RNeasy mini-kits (Qiagen), and following the manufacturer’s instructions.
Epidermis and dermis samples were obtained from skin treated with 8 mg/ml dispase for
15 minutes at 37°C, as described (Judah et al., 2012). RNA concentration and quality
were determined with an Agilent 2100 Bioanalyzer (Agilent, Santa Clara, CA). Only
samples with RNA integrity numbers ≥8.5 were used. RNA (200 ng/sample) was reversetranscribed using SuperScriptTM II RT, as per manufacturer’s protocol. qPCR reactions
were conducted on a CFX384™ Real-Time PCR system (Bio-Rad) operated by CFX
Manager™ software (version 1.6). cDNA samples corresponding to 20 ng of RNA were
amplified using PerfeCTa® qPCR SuperMix and the following primers (400 nM, final):
mHR23A forward 5’-AAGATCCGCATGGAACCTGA-3’ and reverse 5’-TGGTC
ACCATGACAACCACAA-3’; mHR23B forward 5’-CTTAGGCACCATGCAGGTCA3’ and reverse 5’-CGGAAAGGCATCTTTCCCCT-3’. The results were normalized to
the expression of the housekeeping genes Rpl6 and Rps29, which encode ribosomal
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protein L6 and S29, respectively (de Jonge et al., 2007). Replicate cDNA samples were
amplified for 40 cycles (98°C for 10 sec, and 58°C for 30 seconds per cycle). Primer
specificity and amplicon sizes were confirmed, respectively, by analysis of melt curves
conducted between 65°C and 95°C, in 0.5°C increments, and agarose gel electrophoresis.
Relative mHR23A and mHR23B mRNA levels were calculated using the ΔΔCt method.

2.9 Immunoblot analysis and immunoprecipitation
Whole-cell lysates were prepared using a modified RIPA-lysis buffer (Section 2.1, Table
2.3). To prepare nuclear and cytoplasmic fractions, primary keratinocytes were lysed
using a NE-PER nuclear and cytoplasmic extraction kit, following the manufacturers’
protocol. For phosphatase treatments (Ivanova et al., 2009), cell lysates were prepared in
duplicate. One of the samples was prepared in modified RIPA-lysis buffer, and the other
in the same buffer, but without phosphatase inhibitors (Na3VO4, NaF and Na4P2O7). The
lysates prepared in the absence of phosphatase inhibitors were further incubated with λ
phosphatase (4 U/µg of lysate protein) at 30ºC for 30 min. In experiments assessing E2F1
ubiquitylation, the lysis buffer also contained 25 mM NEM. The protein concentration of
lysates were measured using the Bio-Rad protein assay reagent (Table 2.2) on a DU®640
spectrophotometer (Beckman Coulter Inc. CA, USA). Proteins in lysates (30 µg/sample)
were resolved by denaturing polyacrylamide gel electrophoresis and transferred to PVDF
membranes, which were probed with antibodies indicated in individual experiments.
After antibody probing, protein signals were visualized using Amersham ECL Prime
Western Blotting Detection Reagent. Keratinocytes exhibits contact inhibition and
therefore to obtain 1.5 mg of protein, five 10-cm tissue culture dishes (9.6 × 106 cells,
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~2.5 skins from 3-day-old mice per plate) per sample were used for immunoprecipitation
assays. Cell lysates prepared as described above (1.5 mg protein/sample, for Figures 3.2,
3.6, 3.14, 3.15, and 3.20 and 1 mg/protein/sample for Figures 3.4, 3.5, 3.21, and 3.23)
were incubated

with

antibodies

indicated

in

individual

experiments

(3

µg

antibody/sample for Figures 3.2, 3.6, 3.14, 3.15, and 3.20 and 2 µg antibody/sample for
Figures 3.4, 3.5, 3.21, and 3.23) for 16 h at 4°C, with rotation. The immune complexes
were captured by incubation with 400 µg of A/G magnetic beads previously rinsed with
PBS containing 0.05% (v/v) Tween-20 for 1 h at 22°C with rotation, followed by 5
washes with PBS containing 0.05% (v/v) Tween-20, and elution in 1× Laemmli sample
buffer (Table 2.3) for 10 min at 25°C. Immune complexes were resolved and analyzed by
immunoblot, as described above. Protein signals were visualized with either a 8×10 inch
Blue Ray Film and quantified using ImageJ (Schneider et al., 2012) or with a VersaDoc3000 imager (Bio-Rad Laboratories) and quantified with Quantity One software (Bio-Rad
Laboratories). In all experiments, E2F1 and hHR23A band intensities were normalized to
γ-Tubulin or GAPDH. For E2F1 turnover experiments, E2F1 to γ-Tubulin band intensity
ratio for each time point was normalized to t=0. The apparent t½ of E2F1 protein was
calculated by plotting the percentage of band intensity setting T=0 at 100% against time
(min) following CHX treatment and determined using GraphPad Prism software (version
5.00 for Windows, San Diego, CA) setting Y=0 at 100.0 and plateau at 0.0.

2.10 Indirect immunofluorescence microscopy
Twenty-four hours after transfection, cells were fixed and processed for microscopy, as
previously described (Ivanova and Dagnino, 2007). Cells were fixed with 4% (w/v) PFA
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on ice for 15 min and permeabilized with PBS containing 0.1% (v/v) Triton X-100 at
22ºC for 10 min. After washing with PBS buffer, cells were incubated with 1% (w/v)
non-fat milk and 5% (v/v) goat serum diluted in TBST for 1 h at 22ºC, and then
incubated with primary antibodies for 16 h at 4ºC (Table 2.4). Cells were washed three
times with 1× PBS and incubated with the appropriate AlexaFluor-conjugated secondary
antibody (Table 2.4) for 1 h at 22ºC. DNA was visualized using Hoechst 33342 (1 µg/ml,
final; Table 2.2). The fraction of cells with nuclear or cytoplasmic E2F1 or hHR23A was
determined from the analysis of at least 100 cells per experiment in replicates. To
visualize CPD, cells were fixed in freshly diluted 4% (w/v) PFA in 1× PBS, followed by
incubation in 0.2N HCl for 30 min at 22°C, to denature nuclear DNA. The cells were
washed 5 times with PBS and incubated with primary antibodies, as described (Ivanova
and Dagnino, 2007). All photomicrographs shown are representative of experiments
conducted on duplicate samples, and scoring > 100 transfected cells per experiment.
Images were obtained with a Leica DMIRBE fluorescence microscope equipped with an
Orca-ER digital camera (Hamamatsu Photonics, Hamamatsu City, Japan), using Volocity
6.1.1 software (Improvision-PerkinElmer, Waltham, MA).

2.11 In vitro binding assays
For in vitro protein binding assays, 2 µg of each recombinant protein indicated were
mixed in a final volume of 250-µl of PBS containing 1 mM PMSF, and 1 µg/ml each
aprotinin, leupeptin, and pepstatin A. Protein mixtures were incubated at 4ºC for 16 h,
followed by incubation in 50% (v/v) slurry of pre-equilibrated Ni-NTA agarose or GST
sepharose beads at 4ºC for 30 min. Protein complexes captured by the resins were washed
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5 times with PBS containing 0.05% (v/v) Tween-20 and eluted in 1× Laemmli sample
buffer for 10 min at 70°C. The samples were resolved by electrophoresis, using
polyacrylamide gels as described in Section 2.9.

2.12 UV damage and repair assays
The co-localization of proteins to sites of UVC radiation-induced DNA damage was
conducted as described (Guo et al., 2011; Guo et al., 2010), with minor modifications.
Keratinocyte monolayers were rinsed once with PBS, leaving a thin PBS layer. A sterile
3-µm pore polycarbonate membrane was gently placed onto the cells, followed by
irradiation with 254 nm UVC light (200 J/m2), using a Bio-Rad GS Gene Linked UV
Chamber. The membrane was removed and normal growth medium was added to the
cells, which were processed for immunofluorescence microscopy 2 h later, as described
in Section 2.10.
Repair of UV-induced DNA damage was assessed as described (Guo et al., 2011), with
some modifications. HeLa or RPMI-7951 cells seeded in 10-cm culture dishes were
transfected with vectors encoding E2F1 and/or hHR23A. Sixteen hours after transfection,
the cells were trypsinized, re-seeded in quadruplicate 35-mm culture dishes, and cultured
for an additional 16-h interval to allow attachment. Duplicate samples were then mockirradiated or subjected to UVB treatment (302 nm, 100 J/m2), using a UVM-28 EL
series8-watt lamp (UVP, Upland, CA). At timed intervals following UVB irradiation,
genomic DNA was purified with DNeasy® Blood & Tissue kits (Qiagen) and denatured
by boiling at 95ºC for 5 min. Replicate 200 ng samples were spotted onto Hybond N+
membranes (Amersham, NJ), which were baked at 80ºC for 1 h, and placed onto filter
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paper pre-wetted with 0.4 N NaOH for 20 min. The membranes were blocked for 16 h at
4°C in 5% (w/v) non-fat milk diluted in TBST. After two TBST washes, membranes
were incubated for 2 h at 22°C with anti-CPD antibodies. To normalize for DNA content,
the membrane was blocked for 1 h at 22ºC in 2% (w/v) BSA diluted in TBST and probed
with anti-dsDNA antibodies diluted in TBST containing 2% (w/v) BSA. CPD and
dsDNA signals were visualized with a VersaDoc-3000 imager (Bio-Rad Laboratories)
and quantified with Quantity One software (Bio-Rad Laboratories).

2.13 Cdh1 silencing by RNA interference
Primary keratinocytes were transfected 2 d after plating onto 60-mm culture dishes with a
non-targeting Silencer Negative Control siRNA #1 (AM4611, Ambion® ThermoFisher
Scientific, Waltham, MA) or Cdh1-targeting siFZR1 siGENOME SMARTpool (M065289-00, Dharmaco™ GE Healthcare, Lafayette, CO) using Lipofectamine 2000
transfection reagent according to manufacturer's instruction. Specifically, 15 µl of
Lipofectamine 2000 (1 µg/µl stock) mixed with 1 ml of serum-free (SF) and Ca2+-free
EMEM were combined with 200 pmoles of siRNA that had been mixed with 1 ml SF and
Ca2+-free EMEM. The samples were vortexed and incubated at 22ºC for 5 min. This
solution was then used to replace the culture medium of the keratinocytes, which had
been previously rinsed once with Ca2+-free PBS. The cells were incubated at 37ºC for 4 h
prior to the addition of 3 ml of keratinocyte growth medium (Ca2+-free EMEM
supplemented with growth additives and 8% (v/v) FBS pre-treated with chelex resin).
The cells were cultured for 24 h, at which time they were washed twice with Ca2+-free
PBS and cultured with fresh growth medium for 72 h. The cells were transfected with
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vectors encoding V5-tagged E2F1, as described in section 1.7.3, and cultured for 21
additional hours. Keratinocytes were then treated with CHX as described in section 1.7.3
prior to lysis and protein analysis (Section 1.9).

2.14 Statistical analyses
Data are expressed as mean ± SEM or mean ± SD, as indicated in individual experiments.
Student’s t-tests were used for comparisons between two groups. One-way analysis of
variance (ANOVA) with Newman-Keuls post-hoc test was used for comparisons among
multiple groups and one variable. Two-way ANOVA with Bonferroni post-hoc test was
used for comparisons among multiple groups and two variables. Statistical analyses were
conducted with GraphPad Prism software (version 5.00 for Windows, San Diego, CA),
and significance was set at P<0.05. The results shown in all figures are representative of
3-8 experiments, each conducted with independent cell isolates.
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Chapter 3

3

Results

3.1 Interaction of hHR23A and E2F1
The mammalian orthologues of yeast Rad23 (HR23) proteins play dual roles in DNA
NER and modulation of ubiquitin-mediated protein degradation (Dantuma et al., 2009).
To begin to address the role of these proteins in the epidermis, their expression levels in
mouse tissues were first assessed. Quantitative polymerase chain reaction (qPCR)
analysis revealed the presence of transcripts encoding mHR23A and mHR23B in the
epidermis and the dermis, at levels comparable to those found in a variety of other tissues
(Figure 3.1A). Further, mHR23A and mHR23B mRNA species were also detected in
primary cultured epidermal keratinocytes, irrespective of whether they were
undifferentiated or had been induced to differentiate (Figure 3.1A). mHR23A protein was
detected at low levels in mouse epidermis and in cultured keratinocytes, whereas it was
substantially more abundant in various human epithelial cell types and mouse tissues,
including the dermis (Figure 3.1B, 3.1C).
hHR23A and mHR23A proteins participate in NER processes through the formation of
multiprotein complexes that recognize sites of DNA damage (Dantuma et al., 2009). The
ability of the E2F1 transcription factor to recognize sites of DNA damage induced by UV
radiation and to promote NER (Guo et al., 2010) prompted me to investigate the
possibility that E2F1 and hHR23A might associate. To this end, exogenous V5-tagged
E2F1 together with FLAG-tagged hHR23A were expressed in primary mouse

Figure 3.1: Expression of mHR23 and hHR23 proteins.
A. mRNA was isolated from primary undifferentiated (Undiff. KT) or differentiated
(Diff. KT) 3-day keratinocyte cultures, or from the indicated tissues harvested from 2-dold CD-1 mice. mHR23A and mHR23B mRNA levels were assessed by qPCR, and
normalized to the abundance of Rpl16 and Rps29 transcripts. The results are expressed as
the mean + SEM (n=3), relative to mRNA abundance in undifferentiated keratinocytes,
which is set to 1.0. The asterisks indicate P<0.05, relative to abundance in
undifferentiated keratinocytes (ANOVA). B, C. The abundance of mHR23A or hHR23A
was determined in protein lysates from the tissues harvested in (A) or from the indicated
cultured cells. Glyceraldehyde-3-phosphatase (GAPDH) was used to normalize for
protein loading. MEK and HEK indicate, respectively, primary cultures of
undifferentiated mouse and human epidermal keratinocytes. Blot exposure times and the
amount of protein on the blots (in μg) are indicated, to better illustrate differences in
protein abundance (n=3).
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keratinocytes that had been maintained undifferentiated, or had been induced to
differentiate by 24 h of culture in medium containing 1 mM Ca2+ (High-Ca2+ medium).
When hHR23A immune complexes were isolated, V5-tagged E2F1 was detected,
irrespective of the differentiation status of the keratinocytes (Figure 3.2A). Reciprocally,
hHR23A fused to green fluorescent protein (GFP) and hemagglutinin (HA) tags was
readily detected in V5-E2F1 immune complexes (Figure 3.2B). The larger molecular
mass of the GFP-tagged hHR23A species avoided the interference of IgG heavy chains in
this analysis. It was also found that endogenous E2F1 could associate with hHR23A
proteins (Figure 3.2C), but I was unable to detect mHR23A in E2F1 immune complexes,
likely due to its very low abundance in primary keratinocytes.
hHR23 proteins can function as scaffolds between ubiquitylated substrates and the
proteasome. To determine if hHR23A interactions with E2F1 required ubiquitylation of
the latter, I examined if bacterially produced hHR23A and glutathione (GST)-tagged
E2F1 were able to interact. I readily detected hHR23A in GST-E2F1 immune complexes,
indicating that interactions between these two proteins do not require the presence of
post-translational modifications (Figure 3.2D). These observations do not exclude the
possibility that binding of hHR23A to E2F1 also occurs through ubiquitylated residues on
the latter. Bacterially produced hHR23A or GST-E2F1 could also interact with
exogenously expressed V5-tagged E2F1 or HA-tagged hHR23A from mammalian cell
lysates respectively (Figure 3.2E, 3.2F).

Figure 3.2: Association of hHR23A and E2F1.
A, B. Primary keratinocytes were transfected with vectors encoding V5-tagged E2F1
with or without FLAG-tagged hHR23A or HA- and GFP-tagged hHR23A and cultured
for 24 h after transfection in Low Ca2+ or in High Ca2+ medium, to induce differentiation.
Cell lysates were prepared and immunoprecipitated with anti-FLAG or anti-V5
antibodies, as indicated, or an irrelevant IgG. Immune complexes were resolved by
denaturing gel electrophoresis, transferred to membranes, and the blots were probed with
the indicated antibodies. Samples of lysates used for immunoprecipitation show
expression levels of exogenous proteins. γ-Tubulin was used to normalize for protein
loading, and the asterisks indicate a non-specific band. n=3. C. Lysates prepared from
transfected keratinocytes as in (A, B), were immunoprecipitated with anti-E2F1
antibodies, to isolate endogenous and/or exogenous E2F1 immune complexes. Replicate
lysate samples were also analyzed to show expression levels of endogenous and
exogenous proteins. n=3. D. Bacterially produced GST, GST-E2F1, as well as His- and
FLAG-tagged hHR23A (2 μg each) were used in immunoprecipitation experiments with
anti-GST or anti-His antibodies, as indicated. The immune complexes were further
analyzed by immunoblot, using anti-FLAG or anti-E2F1 antibodies. The lanes labelled
“Input” contain 100 ng each of the indicated recombinant proteins. n=3. E. GST fusion
E2F1 from bacterial extracts were incubated with cell lysates prepared from
undifferentiated keratinocytes transfected with HA-tagged hHR23A for 16 h at 4ºC. The
protein mixtures were subjected for GST pull down and immunecomplexes were
analyzed by immunoblot with anti-HA antibodies, to detect hHR23A. n=3. F. His fusion
FLAG-tagged hHR23A from bacterial extracts were incubated with cell lysates prepared
from keratinocytes transfected with V5-tagged E2F1. The protein complexes were
subjected for His pull down and analyzed by immunoblot using anti-V5 antibodies, to
detect E2F1. Samples of the lysates were also analyzed by immunoblot with the indicated
antibodies. n=3.
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3.2 Modulation of hHR23A subcellular localization by E2F1
Given that hHR23 proteins and their orthologues are involved in both proteasomal
degradation and DNA repair, the subcellular localization of exogenously expressed
hHR23A in undifferentiated keratinocytes was investigated. I observed that hHR23A
exhibited cytoplasmic distribution in about 90% of the cells (Figure 3.3A). This pattern
markedly differs from that observed in transformed HeLa cells, which show nuclear
concentration of hHR23A (Figure 3.3B).
In many cell types, including undifferentiated keratinocytes, E2F1 is predominantly
found in the nucleus, although it exhibits nucleocytoplasmic shuttling (Ivanova et al.,
2007) (Figure 3.3A). Significantly, the joint expression of hHR23A and E2F1 resulted in
the co-localization of both proteins in the nucleus of almost all keratinocytes (Figure
3.3A). Induction of differentiation in keratinocytes promotes E2F1 nuclear export and
degradation (Ivanova and Dagnino, 2007). Thus, it was of interest to investigate if the
presence of cytoplasmic E2F1 in these cells was associated with loss of nuclear pools of
hHR23A. Keratinocytes were cultured in medium containing either 0.12 mM or 1.0 mM
Ca2+, and found that in both culture conditions, when E2F1 was cytoplasmic, hHR23A
was also excluded from the nucleus (Figure 3.3C). These observations are consistent with
the concept that E2F1 is capable of modulating hHR23A subcellular localization and
recruitment into the nucleus, possibly mediated via complex formation between these two
proteins.

Figure 3.3: Modulation of hHR23A subcellular distribution by E2F1.
A. Primary keratinocytes or B. HeLa cells were transfected with vectors encoding the
indicated proteins, and 24 h later were processed for immunofluorescence microscopy
using the indicated antibodies. The histograms represent the average fraction of cells with
nuclear (N) or cytoplasmic (C) protein distribution + SEM (n=4). At least 100 transfected
cells per condition were scored in each experiment. The asterisks indicate P<0.05,
relative to cells transfected with single vectors (ANOVA). F-actin and DNA were
visualized, respectively, with phalloidin and Hoechst 33342. Bar, 25 μm. C. Subcellular
distribution of hHR23A and E2F1 in differentiated keratinocytes. Keratinocytes were
transfected with vectors encoding the indicated proteins, and 4 h after transfection cells
were induced to differentiate by culture in growth medium with the indicated Ca2+
concentration. The cells were processed for immunofluorescence microscopy using antiV5 and anti-HA antibodies to detect, respectively, E2F1 and hHR23A. DNA was
visualized with Hoechst 33342. Bar, 25 μm.
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3.3 hHR23A domains involved in binding to E2F1
To begin to understand the biological significance of E2F1 binding to hHR23A, I next
undertook an analysis of the protein domains involved in these interactions. As a scaffold
protein, hHR23A has several functionally important domains that mediate interactions
with ubiquitin and/or various ubiquitin-unrelated proteins (Dantuma et al., 2009). To
identify which of those regions are important for E2F1 binding, I exogenously expressed
several GFP- and HA-tagged hHR23A deletion mutants (Figure 3.4A). The use of GFPtagged hHR23A allowed for the confirmation that the GFP moiety did not affect the
ability of hHR23A to bind E2F1 (Figure 3.4B, 3.4C), and allowed for efficient expression
of small hHR23A domains for analysis. The N-terminal ubiquitin-like domain (UbL) in
hHR23A mediates binding to the proteasome, and is important for protein-protein
interactions. The deletion of this domain (∆UbL hHR23A) did not affect the ability of
hHR23A to interact with E2F1 (Figure 3.4B, 3.4C). hHR23A has two ubiquitinassociated domains, UBA1 and UBA2, which mediate interactions with ubiquitin
moieties conjugated to various proteins. When I exogenously expressed two hHR23A
fragments corresponding to UBA1 or UBA2, I observed that only the former was able to
associate with E2F1 (Figure 3.4B). Thus, the contribution of UBA2 to hHR23A binding
to E2F1 is likely negligible, if any. In a complementary approach, I also investigated the
consequences of deleting UBA1 or UBA2 in the context of the entire hHR23A protein
(hHR23A ∆UBA1 or ∆UBA2), and observed efficient binding of these mutants to E2F1
(Figure 3.4B). This suggests that, in addition to UBA1, other hHR23A regions likely
contribute to its association with E2F1. hHR23 proteins bind the XPC via their XPC

Figure 3.4: hHR23A domains involved in E2F1 binding.
A. Schematic of GFP- and HA- doubly tagged hHR23A proteins analyzed for their ability
to bind E2F1. B. and C. Primary keratinocytes were transfected with vectors encoding
V5-tagged E2F1 and the indicated hHR23A proteins. Twenty-four hours after
transfection, cell lysates were prepared and hHR23A immune complexes were isolated
and analyzed by immunoblot with the indicated antibodies, and γ-Tubulin was used to
normalize for protein loading. A portion of the lysates from cells co-expressing wild type
(WT) hHR23A and V5-tagged E2F1 were also used for immunoprecipitation with an
unrelated IgG control. n=4.
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domain (Dantuma et al., 2009). To determine if the XPC region contributes to E2F1
binding, an hHR23A mutant composed of only the XPC and UBA2 domains was
expressed (hHR23A XPC-UBA2). I reasoned that this mutant would provide information
on the role of the XPC domain in this process, given our previous observation that UBA2
does not bind E2F1. I found that this hHR23A form was still able to bind E2F1 fairly
efficiently (Figure 3.4B, 3.4C). However, the XPC region appears to be sufficient, but not
indispensable for E2F1 binding, given that an hHR23A mutant lacking these sequences
(∆XPC) also associates with E2F1 (Figure 3.4C). Together, my observations implicate
the UBA1 and XPC domains in the association of hHR23A with E2F1.
I undertook a similar analysis to determine the regions in E2F1 involved in binding to
hHR23A. The N-terminal domain in E2F1 mediates protein-protein interactions, such as
binding to cyclin A, and contains the nuclear localization and export domains responsible
for nucleocytoplasmic shuttling (Ivanova et al., 2007). A mutant, constitutively
cytoplasmic E2F1 protein lacking these sequences (E2F1 126-437) associated with
hHR23A (Figure 3.5A, 3.5B), indicates that nuclear localization of E2F1 is not required
for this interaction. The C-terminus in E2F1 contains the transcriptional activation
domain, and mediates protein-protein interactions with other proteins, including those in
the retinoblastoma family (reviewed in (Meng and Ghosh, 2014)), but it was also
dispensable for hHR23A binding (Figure 3.5B). Similarly, E2F1 proteins incapable of
both cyclin A and retinoblastoma binding also formed complexes with hHR23A (Figure
3.5B). Of note, E2F1 contains 14 lysine residues that can potentially be modified by

Figure 3.5: Regions in E2F1 involved in binding to hHR23A.
A. Schematic of V5-tagged E2F1 proteins analyzed. B. Primary keratinocytes were
transfected with vectors encoding wild type hHR23A and the indicated V5-tagged E2F1
proteins. Twenty-four hours after transfection, cell lysates were prepared and hHR23A
immune complexes were isolated using anti-HA antibodies. The immune complexes were
resolved by denaturing gel electrophoresis, and analyzed with the indicated antibodies. γTubulin was used to normalize for protein loading. Lysates from cells co-expressing
E2F1 and wild type (WT) hHR23A were used for immunoprecipitations using anti-HA
antibodies, or an unrelated, control IgG. n=3.

100

101

ubiquitylation and, given that the ubiquitin-binding UBA1 domain in hHR23A
participates in the interaction between these two proteins, it is conceivable that no single
region in E2F1 is indispensable.

3.4 Inhibition of E2F1 degradation by hHR23 proteins
E2F1 ubiquitylation includes K11-, K48- and K63-linked polyubiquitin chains, which can
promote its proteasomal degradation (Wang et al., 2015). To begin to characterize the
functional significance of the interactions between hHR23 proteins and E2F1,
keratinocytes were exogenously expressed with V5-tagged E2F1 and HA-tagged wild
type ubiquitin, in the presence or absence of hHR23 proteins. Next, HA-containing
immune complexes were isolated and investigated therein the presence of E2F1. This
approach examined the effects of hHR23 on the abundance of ubiquitylated E2F1. In the
absence of exogenous hHR23 proteins, and consistent with previous reports (Ivanova et
al., 2006), low levels of ubiquitylated E2F1 in both undifferentiated and differentiated
keratinocytes were detected, likely because it efficiently undergoes proteasomal
degradation (Figure 3.6A, 3.6B). The presence of either hHR23A or hHR23B
substantially increased the abundance of ubiquitylated E2F1, irrespective of the
differentiation status of the keratinocytes. Thus, hHR23 proteins appear to protect E2F1
from degradation, although this effect does not appear to involve interference with E2F1
ubiquitylation per se (Figure 3.6A, 3.6B). Next, the effect of proteasomal inhibition on
modulation by hHR23A of polyubiquitylated E2F1 was determined. To this end, I
exogenously expressed V5-tagged E2F1 together with HA-tagged wild type ubiquitin and
FLAG-tagged hHR23A as before, and assessed the effect of proteasomal inhibition by

Figure 3.6: Modulation of ubiquitylated E2F1 degradation by hHR23 proteins.
A. Primary undifferentiated keratinocytes were transfected with vectors encoding V5tagged E2F1 and HA-tagged ubiquitin, in the presence or absence of hHR23-encoding
vectors, as indicated. The cells were cultured for 24 h in Low Ca2+ (undifferentiated
keratinocytes) or High Ca2+ medium (differentiated keratinocytes) in the absence of
MG132. Cell lysates were prepared and ubiquitylated proteins were immunoprecipitated
with anti-HA antibodies. HA immune complexes were analyzed with anti-V5 antibodies,
to detect ubiquitylated E2F1 in the immune complexes. The asterisk indicates a lower
mobility non-specific band. n=3. B. Primary undifferentiated keratinocytes were
transfected with a vector encoding V5-tagged E2F1 and either wild type (WT) ubiquitin,
or a ubiquitin mutant lacking all Lys residues (K0), in the presence or absence of FLAGtagged hHR23A. Keratinocytes were treated with vehicle (dimethylsulfoxide) or MG132
(10 μM) for 6 h, and cell lysates were prepared, immunoprecipitated with anti-HA
antibodies and analyzed for the presence of ubiquitylated V5-E2F1, as in (A). n=3.
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MG132 on the abundance of E2F1. A robust increase in polyubiquitylated E2F1 in the
presence of hHR23A was slightly enhanced in MG132-treated cells (Figure 3.6B),
indicating that exogenous expression of hHR23A does not impair proteasomal activity
but interferes with the ability of the proteasome to target E2F1 for degradation.
The UBA domains of hHR23A exhibit maximum affinity for chains composed of 4-6
ubiquitin residues (Raasi et al., 2004). Cellular proteins can be modified by polyubiquitin
chains linked through isopeptide bonds between the terminal glycine (G76) in ubiquitin
and one of the seven Lys residues on another ubiquitin moiety. To determine whether the
stabilizing effect of hHR32A required the presence of polyubiquitin chains on E2F1, I coexpressed V5-tagged E2F1, FLAG-tagged hHR23A and an HA-tagged mutant ubiquitin
form lacking all lysine residues (K0). This mutant is presumably incapable of forming
polyubiquitin chains, although it can still contribute to monoubiquitylation (Lim et al.,
2005). In the absence of MG132, I found negligible E2F1 immunoreactivity in ubiquitinK0 immunoprecipitates (Figure 3.6B). Significantly, proteasomal inhibition was
associated with the presence of abundant poly-ubiquitylated E2F1 species (Figure 3.6B).
These observations suggest that hHR23A preferentially modulates the degradation of
poly-ubiquitylated E2F1, although monoubiquitin modification of the latter on one or
more Lys residues likely also takes place in keratinocytes, without precluding its
proteasomal degradation.
The outcomes of hHR23 modulation of proteasome-mediated proteolysis are complex. In
some cases, they deliver polyubiquitylated substrates to the proteasome for destruction
(Verma et al., 2004). In others, they impede the interaction of bound proteins with the
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proteasome, thus suppressing their degradation (Blount et al., 2014). First, I assessed the
effect of increasing amount of hHR23A on the stability of E2F1 and showed that E2F1
levels gradually increased with increasing amount of hHR23A (Figure 3.7A). To further
confirm that hHR23 negatively modulates E2F1 turnover, I used cycloheximide chase
assays to determine E2F1 apparent half-life (t½) in undifferentiated keratinocytes
expressing wild type or mutant hHR23A proteins (Figure 3.7B). The apparent t½ of V5E2F1 was 77±8 min, which was increased 3- and 2-fold, respectively, in the presence of
similar levels of wild type hHR23A and hHR23B. Thus, although both hHR23 forms are
able to stabilize E2F1, the effect of hHR23A would appear to be more pronounced.
Similar to full-length hHR23A, ∆UbL GFP-hHR23A, which can efficiently bind E2F1,
increased its apparent t½ 3-fold to 185±5 min. In contrast, expression of UBA2 GFPhHR23A did not significantly alter E2F1 t½, consistent with the notion that the
stabilizing effect of hHR23A requires its association with E2F1, and that UBA2 does not
associate with this transcription factor. Although the UBA2 domain does not participate
in binding to or stabilizing E2F1, it is critical for the ability to hHR23A to escape
proteasomal degradation itself, and its deletion markedly increases hHR23A turnover
(Heinen et al., 2011). Consistent with these characteristics, I observed that, whereas the
apparent t½ of wild type hHR23A was > 6 h, the apparent t½ of ∆UBA2 GFP-hHR23A
was only about 4 h (Figure 3.7B). Further, ∆UBA2 GFP-hHR23A was without effect on
E2F1 apparent t½, suggesting that insufficient pools of the former protein may have been
available to protect exogenous E2F1 from degradation.

Figure 3.7: Modulation of E2F1 t½ by hHR23 proteins.
A. Undifferentiated keratinocytes were transfected with vectors encoding V5-tagged
E2F1 with the indicated DNA concentration of FLAG-tagged hHR23A. Cell lysates were
prepared 24 h later and analyzed by immunoblot with the indicated antibodies. The
histograms represent quantification of E2F1 proteins (mean + SEM, n=3), relative to
E2F1 abundance in the absence of exogenous hHR23A, which is set at 100%. The
asterisks indicate P<0.05 relative to E2F1 levels in cells cultured in Low Ca2+ medium in
the absence of exogenous hHR23A proteins (ANOVA). B. Primary undifferentiated
keratinocytes were cotransfected with vectors encoding V5-tagged E2F1 and the
indicated FLAG- or HA-tagged hHR23 proteins. Twenty-four hours after transfection,
cycloheximide (CHX, 100 μg/ml, final) was added to the culture medium, and cell lysates
were prepared at the indicated time intervals thereafter. The lysates were analyzed by
immunoblot with the indicated antibodies, and γ-Tubulin was used to normalize for
protein loading. The graphs represent the mean ± SD of E2F1 levels quantified in
replicate immunoblots generated from lysates prepared from three independent cell
isolates, and were used to calculate E2F1 apparent t½ (mean ± SD, n=3) in the presence
of each hHR23 protein, as summarized in the chart. The asterisks indicate P<0.05 relative
to E2F1 t½ in the absence of any exogenous hHR23 protein (ANOVA).

107

108

109

3.5 Modulation of DNA damage repair by hHR23A and
E2F1
Following DNA damage, hHR23A participates in NER processes, whereas E2F1 is
stabilized, either promoting apoptosis or stimulating DNA repair (Biswas et al., 2014).
Given that a major source of DNA damage in keratinocytes is UV radiation, I examined
the responses of these two proteins to UV-induced DNA damage.

I observed that

endogenous E2F1 levels are increased by UVB radiation or by expression of hHR23A,
and the presence of exogenous hHR23A further increased E2F1 levels in UVB-treated
keratinocytes (Figure 3.8A). The kinetics of exogenous E2F1 and hHR23A proteins were
also examined following UVB radiation. A time course of post- irradiation was carried
out at 0, 3 and 6 h. The protein levels of hHR23A did not change 6 h post-irradiation,
whereas E2F1 showed increased protein levels at 6 h (Figure 3.8B). Interestingly, when
E2F1 and hHR23 were co-expressed, the expression levels of both proteins peaked at 3 hr
and returned to control levels by 6 hr (Figure 3.8B). Next, I determined if hHR23A
subcellular localization was regulated by DNA damage in primary keratinocytes, using
filtered UV radiation coupled with immunofluorescence microscopy (Guo et al., 2010;
Mone et al., 2001). Cells were irradiated with UV light through a filter (3-µm pore size),
and nuclear regions containing UV-induced photoproducts were identified with an
antibody specific for CPD. UVB radiation penetrated through the entire filter, giving rise
to CPD-positive nuclei, rather than discrete CPD-positive areas with DNA damage
(Appendix 1A). UVC radiation did not penetrate through the entire filter, and was
transmitted down the nuclear DNA only through the pores (Appendix 1B). This allowed

Figure 3.8: Effect of UVB radiation on E2F1 levels in keratinocytes.
Primary keratinocytes expressing HA-tagged hHR23A and/or V5-tagged E2F1 was
exposed to A. 250 J/m2 of UVB, and whole cell lysates were prepared 24 h after
irradiation, n=3 or B. 100 J/m2 of UVB, and cell lysates were prepared at indicated time
point post-irradiation to analyze levels of the indicated proteins. GAPDH levels were
used to normalize for protein loading. The graphs in (B) represent the mean ± SD (n=3)
of hHR23A (left) and E2F1 (right) levels quantified in replicate immunoblots generated
from lysates prepared from three independent cell isolates.
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detection of discrete CPD-positive DNA damaged foci. Therefore, I used light in the
UVC spectrum for these experiments. Although, UVC light does not reach the earth
surface because it is absorbed by the ozone layer, both UVB and UVC radiation induce
the same type of DNA damage and activate the same DNA repair pathways, making the
use of UVC irradiation physiologically relevant. It was observed that UV treatment of
keratinocytes induced cytoplasm-to-nucleus translocation of hHR23A (Figure 3.9). In the
majority of cells expressing exogenous E2F1, E2F1 was substantially enriched in nuclear
areas that exhibited CPD immunoreactivity (Figure 3.9). Significantly, when E2F1 and
hHR23A were co-expressed, both proteins concentrated in CPD-positive regions,
indicating that E2F1 promotes enrichment of hHR23A at sites of UV-induced DNA
damage in primary keratinocytes (Figure 3.9).
Next, I investigated if the increased localization of hHR23A to DNA photolesions in the
presence of E2F1 was associated with changes in DNA repair. To this end, I transfected
cells with vectors encoding hHR23A and/or E2F1, subjected the cells to 100 J/m2 UVB
radiation, and measured CPD abundance in genomic DNA (indicative of NER) as a
function of time. Because UVB treatment of transfected primary keratinocytes resulted in
variable proportions of transfected cell death among different cell isolates, I conducted
this experiment on HeLa cervical carcinoma cells, in which no such variability was
observed. CPD levels in control cells transfected with empty vector decreased by about
30%-40% of initial values 3 h after UVB treatment, and did not decrease substantially
further 6 h after UVB treatment (Figure 3.10A). CPD levels in cells expressing E2F1 or
hHR23A had decreased by about 20%-25% 6 h after UVB treatment. In contrast, in cells

Figure 3.9: Co-localization of E2F1 and hHR23 at DNA damage sites following UV
radiation.
Keratinocytes were transfected with vectors encoding the indicated proteins, and 24 h
later were subjected to UVC irradiation through 3-μm polycarbonate isopore filters, and
cultured for 2 h. The cells were processed for immunofluorescence microscopy to detect
cyclobutane pyrimidine dimers (CPD), V5-tagged E2F1 and HA-tagged hHR23A.
Nuclear DNA was visualized with Hoechst 33342. Bar, 25 μm. n=3
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Figure 3.10: Increased repair of UV-induced DNA damage by E2F1 and hHR23A.
A. HeLa or B. RPMI 7951 human melanoma cells transfected with plasmids encoding the
indicated proteins were subjected to UVB irradiation (100 J/m2). Genomic DNA was
isolated at the indicated times after UVB treatment, and analyzed for the presence of
CPD as described in “Materials and Methods”. CPD levels were normalized to the
amount of dsDNA. The histograms show the fraction of normalized CPD signal
remaining after 3 or 6 h, relative to CPD 0.1 h after irradiation (set to 100%), for each
transfection group. The results are expressed as the mean + SD (n=3), and the asterisks
indicate P<0.05 (ANOVA).
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co-expressing E2F1 and hHR23A, CPD levels steadily decreased by about 40% and 60%,
respectively, 3 h and 6 h following UVB exposure. Similar results were observed in
RPMI 7951 human melanoma cells (Figure 3.10B). Thus, the joint expression of E2F1
and hHR23A accelerates CPD removal and DNA repair following UVB damage.

3.6 Amino acid residues in E2F1 that contributes to its
stabilization following drug-induced DNA damage
E2F1 accumulates in mouse embryonic fibroblasts (MEF) and cancer cell lines when
treated with various chemotherapeutic drugs (Lin et al., 2001). Several residues on E2F1
are essential for its stabilization following DNA damage. They include Ser31, Arg111,
Arg113, Lys117, Lys120, Lys125, Lys185, Ser403, and Thr433 (Cho et al., 2012;
Kontaki and Talianidis, 2010; Lin et al., 2001; Pediconi et al., 2003; Real et al., 2010;
Xie et al., 2011b). The importance of these residues has been established by site-directed
mutagenesis studies in transformed cell lines. However, their importance in primary cells
treated with DNA damaging agents has not been studied. Therefore, to better understand
the role of each residue on E2F1 in response to DNA damage, the following constructs
were made: a single mutant with Ser to Ala substitution on a.a. site 31 (S31A); a single
mutant with Lys to Arg substitution on a.a. site 185 (K185R); a triple mutant with Lys to
Arg substitution on a.a. sites 117, 120, and 125 (KTR); a double mutant with Arg to Lys
substitution on a.a. sites 111 and 113 (RDK); and a double mutant with Ser to Ala
substitution on a.a. sites 403 and 433 (ST/A). The various E2F1 mutants were
exogenously expressed in primary mouse keratinocytes and subsequently DNA double
strand breaks was induced by treating the cells with 150 µM etoposide.
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Consistent with previous studies on transformed cell lines and MEFs, the protein levels of
wild-type E2F1 increased and the E2F1-S31A mutant failed to accumulate following
etoposide treatment in undifferentiated and differentiated keratinocytes (Figure 3.11).
The KTR triple E2F1 mutant also showed impaired induction following treatment with
etoposide in differentiated keratinocytes (Figure 3.11). These results indicate that
modifications at Ser31, Lys117, Lys120, and Lys125 play an essential role in stabilizing
E2F1 in response to DNA damage not only in transformed cell lines but also in primary
mouse keratinocytes. However, in undifferentiated keratinocytes, the KTR triple E2F1
mutant protein levels increased following etoposide treatment (Figure 3.11). This
indicates that multiple mechanisms contribute to E2F1 induction in response to DNA
damage. On the other hand, the K185R, RDK, or ST/A E2F1 mutant increased following
etoposide treatment in undifferentiated and differentiated keratinocytes (Figure 3.11).
This indicates that these residues are not essential for E2F1 accumulation and
stabilization following DNA damage.

3.7 Identification of E2F1 amino acid residues required for
nuclear export and stabilization in differentiated
keratinocytes
Following Ca2+-induced keratinocyte differentiation, E2F1 is exported to the cytoplasm
and substitutions of Ser403 and Thr433 to Ala (ST/A) generated a mutant protein that is
defective in nuclear export and is more stable than WT-E2F1 (Ivanova and Dagnino,
2007; Ivanova et al., 2009). Whether other amino acid residues on E2F1 are required for
its nuclear export and stabilization is yet to be elucidated. First, residues shown to be
required for the interaction between E2F1 and pRb were examined. During the cell cycle,

Figure 3.11: Changes in E2F1 levels in response to etoposide.
Vectors encoding V5-tagged wild type (WT) E2F1 or the indicated mutants were
transfected in undifferentiated keratinocytes. Fours after transfection, the cells were
cultured in Low (-) or High (+) Ca2+ medium, and 24 h later, they were incubated in the
absence or presence of etoposide (150 µM). Cell lysates were prepared 8 h later and
analyzed by immunoblot, using anti-V5 antibodies or GAPDH as loading control. The
histograms represent normalized densitometric quantification of each E2F1 protein (mean
+ SEM, n=3), and are expressed as percentage of a given E2F1 form relative to its
abundance in Low Ca2+ medium, which is set at 100%. The asterisks indicate P<0.05, and
# indicate P<0.05 relative to the corresponding E2F1 mutant protein levels in cells
cultured in Low Ca2+ medium in the absence of etoposide (ANOVA).
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E2F1 is specifically regulated by associating with pRb. The interaction between pRb and
E2F1 protects E2F1 from ubiquitylation; therefore, events that affect the association
between pRb and E2F1 could regulate E2F1 stability. Phosphorylation at Ser332 and
Ser337 is required for the dissociation of E2F1 from pRb (Fagan et al., 1994), whereas
phosphorylation at Ser375 favors pRb binding to E2F1 (Peeper et al., 1995). To test
whether the association with pRb plays a role in E2F1 nuclear export and degradation,
three E2F1 single mutants with serine to alanine substitutions at sites 332 (S332A), 337
(S337A), or 375 (S375A) were generated and expressed in keratinocytes. These three
mutant E2F1 showed no apparent defect in nuclear export and were efficiently degraded
in differentiated keratinocytes in a similar manner as wild-type E2F1 (WT-E2F1), which
is significantly different from the ST/A mutant E2F1 protein (Figure 3.12, 3.13). These
findings indicated that the residues known to promote the association or dissociation
between E2F1 and pRb may not be essential for the Ca2+-induced nuclear export and
degradation of E2F1 in keratinocytes.
As mentioned earlier, during DNA damage, E2F1 is post-translationally modified, which
contributes to its increased stability. Thus, residues involved in the stabilization of E2F1
were examined. The triple KTR E2F1 mutant showed increased cytoplasmic localization
(Figure 3.12) and decreased E2F1 abundance following Ca2+-induced keratinocyte
differentiation (Figure 3.11, 3.13), similar to that observed with WT-E2F1. This indicates
that these three lysine residues are dispensable for regulation of E2F1 abundance upon
keratinocyte differentiation. Similarly, S31A, K185R, RDK and S364A E2F1 mutants
also showed increased nuclear export (Figure 3.12) and decreased E2F1 protein levels

Figure 3.12: Ser403 and Thr433 are required for E2F1 nuclear export during
keratinocyte differentiation.
Undifferentiated keratinocytes were transfected with vectors encoding V5-tagged wild
type (WT) or the indicated E2F1 mutant proteins. Four hours after transfection, the
culture medium was replaced with Low or High Ca2+ medium, and the cells were
processed for immunofluorescence microscopy 24 h later, using anti-V5 antibodies. DNA
was visualized with Hoechst 33342. The photomicrographs represent three replicas, and
100 cells per experiment were analyzed. The values in the histograms represent the
percentage of cells (mean + SEM, n=5) that exhibited nuclear (N, green bar) or
cytoplasmic (C, yellow bar) E2F1 distribution. The asterisks indicate P<0.05 relative to
values in the corresponding subcellular compartments in Low Ca2+ medium (ANOVA).
Bar, 16 μm. KTR: K117R/K120R/K125R; RDK: R109K/R113K; ST/A: S403A/T433A.
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Figure 3.13: Ser403 and Thr433 mediate E2F1 degradation during keratinocyte
differentiation.
Vectors encoding V5-tagged wild type (WT) or the indicated E2F1 mutants were
transfected in undifferentiated keratinocytes. Twenty-four hours after transfection, cells
were treated with cycloheximide (CHX, 100 μg/ml) and 30 min later the culture medium
was replaced with Low or high Ca2+ medium supplemented with CHX. Cell lysates were
prepared 2.5 h later and analyzed by immunoblot for the indicated proteins, using anti-V5
antibodies, or γ-Tubulin as loading control. The histograms represent normalized
densitometric quantification of each E2F1 protein (mean + SEM, n=3), and are expressed
as percentage of a given E2F1 form relative to its abundance in Low Ca2+ medium, which
is set at 100%. The asterisks indicate P<0.05 (ANVOA). KTR: K117R/K120R/K125R;
RDK: R109K/R113K; ST/A: S403A/T433A.
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following Ca2+ induction, as seen with WT-E2F1 (Figure 3.11, 3.13). Therefore, these
data indicate that residues involved in the regulation of E2F1 levels following DNA
damage are not major contributors to E2F1 stability, whereas Ser403 and Thr433 are
involved in E2F1 nuclear export and degradation following Ca2+-induced differentiation.

3.8 Nuclear export is not the only mechanism required for
E2F1 ubiquitylation and degradation following keratinocyte
differentiation
E2F1 nuclear export and ubiquitylation are both required for the degradation of E2F1
following Ca2+-induced keratinocyte differentiation. When differentiated keratinocytes
are exposed to a specific inhibitor of CRM1-mediated nuclear export, LMB, E2F1
accumulates in the nucleus and its stability increases (Ivanova and Dagnino, 2007). This
indicates that E2F1 nuclear export is required for E2F1 degradation following
keratinocyte differentiation. However, whether nuclear export could inhibit E2F1
ubiquitylation has yet to be elucidated. First, the subcellular compartment of E2F1
ubiquitylation was assessed by exogenously expressing V5-tagged E2F1 and HA-tagged
wild type ubiquitin in keratinocytes. Subsequently, cells were treated with ethanol or
LMB to prevent nuclear export and lysates were harvested from whole cell, nuclear, and
cytoplasmic fractions. HA-containing immune complexes were isolated and the presence
of E2F1 was investigated. In differentiated keratinocytes, the abundance of ubiquitylated
E2F1 was indistinguishable in the presence or absence of LMB (Figure 3.14). Further, the
presence of polyubiquitylated E2F1 species was detected in both nuclear and cytoplasmic
fractions (Figure 3.14). These results indicate that nuclear export is not required for E2F1
ubiquitylation, and the ubiquitin enzymes that promote E2F1 ubiquitylation are present in

Figure 3.14: E2F1 is polyubiquitylated in the nucleus and in the cytoplasm when
keratinocytes are induced to differentiate with Ca2+.
Undifferentiated keratinocytes were transfect with vectors encoding V5-tagged wild type
(WT) E2F1 and HA-tagged ubiquitin. Twenty-four hours later, MG132 (10 µM) was
added to the culture medium, followed 3 h later by leptomycin B (LMB, 10 ng/ml) or
ethanol (vehicle). Cultures were incubated in the presence of both drugs for 30 min, at
which time the Ca2+ concentration was adjusted to 1.0 mM. Lysates containing wholecell (T), nuclear (N), and cytoplasmic (C) fractions were prepared 2.5 h later, HAubiquitin immunecomplexes were isolated, resolved by denaturing gel electrophoresis,
and analyzed with anti-V5 antibodies to detect ubiquitylated V5-tagged E2F1. Antibodies
against β-Tubulin and Lamin A/C were used to verify the purity of the fractionated
extracts and as loading controls. n=3.
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the nucleus and in the cytoplasm. The increase in stability of the ST/A mutant E2F1
protein could be due to alterations in E2F1 ubiquitylation. Therefore, the importance of
these residues for E2F1 ubiquitylation was examined. Consistent with previous accounts
(Ivanova and Dagnino, 2007), the abundance of polyubiquitylated WT- E2F1 species was
increased following Ca2+ induction (Figure 3.15). Interestingly, the ST/A E2F1 mutant
was polyubiquitylated in undifferentiated keratinocytes and differentiation increased the
abundance of the polyubiquitylated ST/A E2F1 mutant species (Figure 3.15). This
indicates that ST/A is still ubiquitylated but not degraded as seen with the WT-E2F1.
The increase in stability of the ST/A mutant suggested that nuclear export is essential for
degradation in differentiated keratinocytes (Ivanova et al., 2009). If nuclear export is the
only mechanism involved in E2F1 degradation, it is predicted that sequestrating the ST/A
mutant E2F1 to the cytoplasm should induce its degradation in differentiated
keratinocytes. To test this, an ST/A mutant containing a.a. encoding for the NES present
in Simian Virus 40 (SV40) large T antigen, which directs CRM1-mediated nuclear
export, was generated. The addition of NES to wild-type E2F1 (WT-E2F1-NES)
produced a protein that is 100% cytoplasmic in both undifferentiated and differentiated
keratinocytes (Figure 3.16A), and its protein levels decreased upon Ca2+-induced
differentiation (Figure 3.16B). Similarly, the addition of NES sequences to E2F1 ST/A
(ST/A-NES) also produced a protein that is 100% cytoplasmic in both undifferentiated
and differentiated keratinocytes (Figure 3.16A). However, the protein levels of ST/ANES remained the same in differentiated keratinocytes (Figure 3.16B). This indicates
nuclear export is not the only mechanism involved in the turnover of E2F1 in
differentiated keratinocytes.

Figure 3.15: Ubiquitylation of E2F1 is not affected by mutation of E2F1 at Ser403
and Thr433 in keratinocytes.
Undifferentiated keratinocytes were transfected with vectors encoding HA-tagged
ubiquitin and V5-tagged wild type (WT) or ST/A E2F1. Four hours after transfection, the
cultured medium was replaced with Low (-) or High (+) Ca2+ medium, and 24 h later,
they were incubated in the presence of MG132 (10 µM). Cell lysates were prepared 6 h
later, HA or unrelated IgG immunecomplexes were isolated and analyzed by immunoblot
with anti-V5 antibodies. The abundance of exogenous E2F1 protein in lysates was
analyzed by immunoblot, using γ-Tubulin as loading control. The asterisk indicates IgG
heavy chain. n=5.
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Figure 3.16: Effect of constitutive nuclear export on E2F1 abundance in
differentiating keratinocytes.
A. Undifferentiated keratinocytes were transfected with vectors encoding V5-tagged wild
type (WT) or the indicated E2F1 mutant proteins. Four hours after transfection, the
culture medium was replaced with Low or High Ca2+ medium, and the cells were
processed for immunofluorescence microscopy 24 h later, using anti-V5 antibodies. DNA
was visualized with Hoechst 33342. The photomicrographs are representative of three
indepenent cell isolates, and 100 cells per experiment were analyzed. Bar, 16 μm. n=3. B.
Cells transfected as described in (A) were cultured for 24 h in Low Ca2+ medium.
Cycloheximide (100 μg/ml) was added, and 30 min later the cells were cultured for 2.5 h
in Low or High Ca2+ medium supplemented with cycloheximide. Cell lysates prepared
and analyzed by immunoblot with antibodies against V5 or γ-Tubulin used as loading
control. The histograms represent normalized densitometric quantification of E2F1
protein level, and are expressed as the percentage of each E2F1 protein (mean + SEM,
n=3), and are expressed as the percentage of a given E2F1 form relative to its abundance
in Low Ca2+ medium, which is set to 100%. The asterisks indicate P<0.05. NES: nuclear
export sequence.
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3.9 Role of E2F1 pseudo-phosphorylation at Ser403 and
Thr433
To further understand the role of E2F1 Ser403 and Thr433, three E2F1 mutants with
serine and/or threonine substituted for aspartic acid at sites 403 and/or 433 (S403D,
T433D, and ST/D) were generated and expressed in keratinocytes. The E2F1 S403D,
T433D, and ST/D proteins are phospho-mimetic mutants, where the aspartic acid adds a
negative charge, which mimics phosphorylation of a protein. First, their subcellular
localization was assessed in the absence or presence of Ca2+. As shown in Figure 3.15,
WT-E2F1 shows nuclear localization in 90% of undifferentiated keratinocytes and Ca2+
treatments leads to a change in E2F1 localization to the cytoplasm in 40% of cells. The
S403D, T433D, and STD E2F1 mutants also showed 50-55% of cells with cytoplasmic
localization in differentiated keratinocytes compared to only 20% of cells with
cytoplasmic localization in undifferentiated keratinocytes (Figure 3.17). The result
suggests that the presence of Ca2+ contributes to the nuclear export of E2F1 and
phosphorylation at Ser403 and Thr433 is required for this to occur.
To further characterize the contribution of Ser403 and Thr433 to overall E2F1
phosphorylation in keratinocytes, the mobility pattern in lysates from undifferentiated
and differentiated keratinocytes of WT-E2F1, S403A, T433A, ST/A, S403D, T433D, and
ST/D was examined. The results showed at least three species of E2F1 with different
mobility, which collapsed into a single band when treated with λ phosphatase in lysates
from both undifferentiated and differentiated keratinocytes (Figure 3.18). This indicates
that E2F1 is phosphorylated in keratinocytes. The S403A and S403D E2F1 mutants had a
single predominant species that migrated at the same level as the unphosphorylated form

Figure 3.17: Subcellular localization of pseudophosphorylated E2F1 mutant
proteins in keratinocytes.
Undifferentiated keratinocytes were transfected with vectors encoding V5-tagged wild
type (WT) or the indicated E2F1 mutant proteins. Four hours after transfection, the
culture medium was replaced with Low or High Ca2+ medium and

processed for

immunofluorescence microscopy 24 h later, using anti-V5 antibodies. DNA was
visualized with Hoechst 33342. The values in the histograms represent the precentage of
cells (mean + SEM, n=3) that exhibited nuclear (N) or cytoplasmic (C) E2F1 distribution.
The asterisks indicate P<0.05 relative to values in the corresponding subcellular
compartments in Low Ca2+ medium (ANOVA).Bar, 16 μm.
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Figure 3.18: Ser403 and Thr433 are critical contributors to E2F1 phosphorylation.
Undifferentiated keratinocytes were transfected with vectors encoding V5-tagged wild
type (WT) or the indicated E2F1 mutant proteins. Four hours after transfection, the
culture medium was replaced with Low (Top) or High (Bottom) Ca2+ medium. After 24
h, cell lyates were prepared and incubated in the presence or absence of λ phosphatase (4
U/mg lysate protein), resolved by denaturing polyacrylamide gels, and analyzed by
immunoblot, with antibodies against V5 or γ-Tubulin, used as loading control. n=3.
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of E2F1, indicating that Ser403 likely contributes to the overall phosphorylation status of
E2F1. The T433A and T433D E2F1 mutants showed a similar banding pattern as WTE2F1 and treatment with λ phosphatase led to an increase in mobility. This suggests that
other Ser/Thr residues on E2F1 can be phosphorylated when Thr433 is mutated (Figure
3.18). Finally, the ST/A and ST/D E2F1 mutants behaved similarly to S403A and S403D,
and these E2F1 mutants migrated with a mobility that was indistinguishable from that
observed in lysates treated with λ phosphatase (Figure 3.18). This indicates that Ser403
and to a lesser extent Thr433 are critical contributors to E2F1 phosphorylation in
keratinocytes.

3.10 Differentiation-specific role of Ser403 and Thr433 in
E2F1 degradation
To determine whether phosphorylation at Ser403 and Thr433 sites has a role in the
turnover of E2F1 following Ca2+ induction in keratinocytes, the apparent t½ of the
Ser403 and Thr433 phosphorylation site mutants was examined. In undifferentiated
keratinocytes, the apparent t½ of E2F1 was 74±0.4 min (Figure 3.19A) and following
Ca2+ induction, the apparent t½ of E2F1 was 63±3.5 min (Figure 3.19B). In the half-life
experiments, keratinocytes were treated with Ca2+ for 4 h prior to cycloheximide chase
assay, by 4 h the steady-state level of E2F1 protein had decreased by 30% (Figure 3.13).
Therefore, when the cycloheximide chase assay was performed, the change in E2F1
apparent t½ may not have been apparent. Interestingly, the apparent t½ of S403D
(124±27 min) and T433D (104±2.3 min) E2F1 was higher than WT-E2F1 in
undifferentiated keratinocytes (Figure 3.19A), and following Ca2+ induction, the apparent
t½ were similar to WT-E2F1 (Figure 3.19B), but S403D and T433D E2F1 apparent t½

Figure 3.19: Ser403 and Thr433 regulated E2F1 protein half-life in differentiated
keratinocytes.
Undifferentiated keratinocytes were transfected with vectors encoding V5-tagged wild
type (WT) or the indicated E2F1 mutant proteins. Twenty-four hours after transfection,
the culture medium was replaced with A. Low or B. High Ca2+ medium, followed by
addition of cycloheximide (100 µg/ml). Cell lysates were prepared from replicate
samples at the indicated times thereafter, and analyzed by immunoblot using anti-V5
antibodies, to detect E2F1, or γ-Tubulin used as loading control. Representative blots of
each E2F1 protein are shown. The graphs represent the densitometric quantification of
E2F1 protein levels (mean + S.D., n=3) calculated from experiments conducted on three
independent keratinocyte isolates, and are expressed as a percentage of levels measured
at t=0, set to 100%. Decay curves were used to calculate the apparent half-life of each
E2F1 protein (t½), summarized in the chart. The asterisks indicates P<0.05 relative to t½
of a given E2F1 form proteins cultured in Low Ca2+ medium and # indicates P<0.05
relative to t½ of wild type E2F1 (ANOVA).
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decreased by 2- and 1.6-fold, respectively, compared to undifferentiated keratinocytes.
Further, the apparent t½ of ST/D E2F1 was found to be similar to WT-E2F1 in
undifferentiated keratinocytes (76±15 min). In differentiated keratinocytes, the apparent
t½ of ST/D E2F1 decreased by 1.6-fold as compared to WT-E2F1 and by 1.8-fold as
compared to undifferentiated keratinocytes (Figure 3.19). Thus, although the phosphomimetic mutants have a similar t½ as WT-E2F1 in undifferentiated keratinocytes, Ca2+
induction decreased the t½ of phospho-mimetic E2F1 mutants, suggesting that they are
subjected to degradation at a higher rate. In contrast, the t½ of ST/A E2F1 was 59±8.9
min, which was increased by >10-fold in the presence of Ca2+ (Figure 3.19). This
suggests that E2F1 phosphorylation at Ser403 and Thr433 is required for E2F1
degradation in Ca2+-induced keratinocyte differentiation.

3.11 K11- and K48-linkages on E2F1 promotes its
degradation in differentiated keratinocytes
The mechanisms of protein ubiquitylation are complex. They involve sequential catalytic
reactions to transfer ubiquitin onto a substrate protein, and a single ubiquitin monomer
can then be further ubiquitylated to form polyubiquitin chains through any of the sevenlysine residues present in ubiquitin. Different ubiquitin linkages can lead to different
biological outcomes. For example, K48-linked polyubiquitin targets substrates for
degradation, whereas K63-linked polyubiquitylation targets substrates for changes in
subcellular localization or endocytosis. Since ST/A is ubiquitylated (Figure 3.15), the
different types of ubiquitin linkages were examined on WT-E2F1 and E2F1 ST/A mutant
in undifferentiated and differentiated keratinocytes. Keratinocytes were transfected with
vectors encoding V5-tagged WT-E2F1 or ST/A and HA-tagged mutant ubiquitin in
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which all Lys residues were mutated to Arg except for one (K11, K48, or K63) or a
mutant in which all Lys residues were mutated to Arg (K0). In undifferentiated and
differentiated keratinocytes, the presence of WT-E2F1 immunoreactivity was detected in
ubiquitin-K0, -K11, -K48, and -K63 HA-immunoprecipitates (Figure 3.20A, 3.20B).
Similar to WT-E2F1, ST/D-E2F1 is detected in HA-containing immune complexes when
cells were exogenously expressing K11-, K48-, or K63-ubiquitin (Figure 3.20C). Further,
I found robust ubiquitylation of ST/A-E2F1 in undifferentiated keratinocytes when K11or K48- ubiquitin was expressed (Figure 3.20A). This indicates that K11- and K48polyubiquitylation of ST/A-E2F1 can occur in keratinocytes. Strikingly, in differentiated
keratinocytes, E2F1 ST/A ubiquitylation through K11- and K48-linkages was barely
detectable, but K63-associated modifications were readily detected (Figure 3.20B). These
results suggest that phosphorylation at Ser403 and/or Thr433 is required for K11- and
K48-linked ubiquitylation and targeting of E2F1 to the proteasome for degradation when
keratinocytes are induced to differentiate with Ca2+.

3.12 Cdh1 regulates E2F1 degradation in keratinocytes
Three different E3 ubiquitin ligases, Skp2, Cdh1 and Cdc20, are known to ubiquitylate
E2F1 during S phase, late S phase, and mitosis, respectively (Budhavarapu et al., 2012;
Marti et al., 1999; Peart et al., 2010). In a high-throughput microarray analysis of the
keratinocyte transcriptome during differentiation, SKP2 and CDC20 transcripts were
reportedly down regulated, whereas FZR1 transcripts, which encode Cdh1, were up
regulated (Toufighi et al., 2015). This indicates that Skp2 and Cdc20 might not be
involved in regulating E2F1 ubiquitylation and that, potentially, Cdh1 may play a role in

Figure 3.20: Ser403 and Thr433 regulate K11- and K48-linked ubiquitylation of
E2F1 in differentiated keratinocytes.
Keratinocytes cultured in Low Ca2+ medium were transfected with vectors encoding the
indicated V5- tagged and HA-tagged ubiquitin proteins. After 4 h, the cultured medium
was replaced with A. Low or B. C. High Ca2+ medium, and cells were cultured for 18 h,
followed by incubation in the presence of MG132 (10 µM) for 6 h. Cell lysates were
prepared and HA immunecomplexes were isolated and analyzed by immunoblot with
anti-V5 antibodies. The abundance of exogenous E2F1 and HA-ubiquitin-containing
proteins in the lysates was analyzed by immunoblot, using γ-Tubulin as loading control.
n=3.
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E2F1 turnover in differentiating mouse keratinocytes.
To test this hypothesis, I exogenously expressed V5-tagged E2F1 in the presence of
FLAG-tagged -Cdh1 and -Skp2. I then examined E2F1 levels in undifferentiated
keratinocyte extracts and in extracts isolated from keratinocytes induced to differentiate
by incubation in High Ca2+ medium for 24 h. Expression of Skp2 had a negligible effect
on E2F1 protein levels, whereas the presence of exogenous Cdh1 decreased E2F1
abundance in undifferentiated and in differentiated keratinocytes (Figure 3.21). These
data suggest that Cdh1 is likely involved in E2F1 degradation in keratinocytes.
I next conducted experiments to confirm the role of Cdh1 in E2F1 degradation using two
complementary approaches to interfere with Cdh1 function. First, Cdh1 activity was
repressed by exogenously expressing the human early mitotic inhibitor 1 (hEmi1), a
Cdh1 inhibitor (Hsu et al., 2002). To this end, keratinocytes were transfected with vectors
encoding E2F1 in presence of hEmi1 and/or Cdh1. The cells were maintained
undifferentiated or induced to differentiate by culture in High Ca2+ medium for 3 h in the
absence of de novo protein synthesis. This allowed me to assess changes in E2F1 protein
levels specifically associated with degradation during the early stages of Ca2+ induction
of differentiation. Exogenous expression of hEmi1 induced a two-fold increase in the
abundance of E2F1 in undifferentiated keratinocytes (Figure 3.22). Notably, hEmi1
prevented the decrease in E2F1 levels associated with differentiation, and E2F1
abundance in cells cultured in High Ca2+ medium was indistinguishable from that in
undifferentiated keratinocytes (Figure 3.22). Exogenously expressed hEmi1 was also
able to interfere with the reduction in E2F1 levels in both undifferentiated and

Figure 3.21: Cdh1 and not Skp2 reduce the abundance of E2F1 protein in
keratinocytes.
Primary epidermal keratinocytes cultured in Low Ca2 medium were transfected with
vectors encoding the indicated FLAG-tagged ubiquitin ligases in the presence of V5tagged E2F1 at a ratio of 1:5 (E2F1 and each ubiquitin ligase). Four hours after
transfection, the culture medium was replaced with Low (-) or High (+) Ca2+ medium and
continued to culture for 24 h. Cell lysates were prepared and analyzed by immunoblot
with the indicated antibodies. n=3.
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Figure 3.22: Inhibition of Cdh1 activity with hEmi1 increases E2F1 protein levels.
Undifferentiated keratinocytes were transfected with vectors encoding V5-tagged E2F1
in the presence or absence of vectors encoding FLAG-tagged Cdh1 and myc-tagged
hEmi1, as indicated. Twenty-four hours later, the cells were treated with cycloheximide
(100 μg/ml) and the cultured medium was replaced 30 min later with Low (-) or High (+)
Ca2+ medium. Keratinocyte lysates were prepared 3 h later and analyzed by immunoblot
with the indicated antibodies. The histograms represent quantification of E2F1 proteins
(mean + SEM, n=3), relative to E2F1 abundance in Low Ca2+ medium in the absence of
exogenous Cdh1 and hEmi1, which is set at 100%. The asterisks indicate P<0.05 relative
to E2F1 levels in cells cultured in Low Ca2+ without other exogenous proteins except
where otherwise indicated (ANOVA).
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differentiated keratinocytes observed upon overexpression of Cdh1. In a complementary
approach, I silenced Cdh1 using RNA interference. A three-fold increase in E2F1 levels
in undifferentiated keratinocytes treated with Cdh1-targeting siRNA was observed, which
was unaffected by induction of differentiation following Ca2+ treatment (Figure 3.23).
Together, these observations indicate that Cdh1 plays key roles in decreasing E2F1
abundance in differentiating keratinocytes.
The E2F1 ST/A mutant is stable in differentiated keratinocytes, therefore I determined
whether Cdh1 could associate and promote the degradation of ST/A E2F1 in
keratinocytes. FLAG-tagged Cdh1 was co-transfected with V5-tagged WT-E2F1, ST/D,
or ST/A in undifferentiated keratinocytes, or in cells induced to differentiate by 24 h of
culture in medium containing 1.0 mM Ca2+. FLAG-Cdh1 immune complexes were
isolated and analyzed for the presence of E2F1. In these complexes, V5-tagged WTE2F1, STD, or ST/A were readily detected, irrespective of the differentiation status of the
keratinocytes (Figure 3.24A, 3.24B). Unexpectedly, I observed similar decreases in all
three E2F1 forms (WT, ST/D, or ST/A) in the presence of exogenous Cdh1 (Figure
3.24A, 3.24B). These results suggest that phosphorylation of E2F1 at Ser403 and/or
Thr433 is not essential for its interaction with Cdh1, and that a high level of Cdh1 is able
to target the very stable ST/A E2F1 mutant for degradation. The results presented in
section 3.11 show that E2F1 ST/A mutant is not defective in forming K11- and K48linkages in undifferentiated keratinocytes, but following Ca2+-induced differentiation,
little or no detectable K11- and K48-associated modifications were observed. Since Cdh1
could interact with E2F1 ST/A, the lack of K11- and K48-linkages is not likely due to its
inability to interact with the ubiquitin ligase, but other aspects of the degradation process.

Figure 3.23: Cdh1 promotes E2F1 degradation in differentiating keratinocytes.
Undifferentiated keratinocytes were sequentially transfected with control, non-targeting
(NC) or Cdh1-targeting siRNAs, followed by transfection with vectors encoding V5tagged E2F1, as described in Materials and Methods (Chapter 2, Section 2.13). Cells
were treated with cycloheximide (100 μg/ml) and the cultured medium was replaced 30
min later with Low (-) or High (+) Ca2+ medium. Keratinocyte lysates were prepared 3 h
later and analyzed by immunoblot with the indicated antibodies. The histograms
represent normalized densitometry quantification of E2F1 levels (mean + SEM, n=3),
relative to those in cells cultured in Low Ca2+ medium transfected in the presence of NC
siRNA, which is set to 100%. The asterisks indicate P<0.05 relative to cells transfected in
the presence of NC siRNA, except where otherwise indicated (ANOVA).
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Figure 3.24: E2F1 interacts with Cdh1 in keratinocytes.
Primary epidermal keratinocytes cultured in Low Ca2+ medium were transfected with
vectors encoding FLAG-tagged Cdh1 and the indicated V5-tagged E2F1 proteins. Four
hours after transfection, the cells were cultured in Low (-) or High (+) Ca2+ medium for
24 h. Cell lysates were prepared and subjected to immunoprecipitation with anti-FLAG.
The immunecomplexes were analyzed by immunoblot with anti-V5 antibodies, to detect
E2F1. Samples of the lysates were also analyzed by immunoblot with the indicated
antibodies. n=3.
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One likely possibility is that E2F1 ST/A associate with deubiquitylase that actively
remove K11- and K48-linkages. Alternatively, substitution of S403 and T433 with nonphosphorylatable alanine could specifically associate with ubiquitin ligases that favors
K63-linkages and inhibits K11- and K48-modifications.

3.13 E2 conjugating enzyme preferentially interacts with
ST/A-E2F1 in differentiated keratinocytes
Ubiquitin-conjugating enzyme 13 (UBC13) is the only known mammalian E2 ubiquitin
enzyme that catalyzes the formation of K63-linked polyubiquitin chains (Hofmann and
Pickart, 1999; Thorslund et al., 2015). Since K63-polyubiquitylation on E2F1 was
observed, the interaction between UBC13 and all three forms of E2F1 (WT-E2F1, ST/A,
or ST/D) was investigated. In undifferentiated keratinocytes, WT-E2F1, ST/A, and ST/D
were able to efficiently interact with UBC13 (Figure 3.25A, 3.25B). However, following
Ca2+ induction of differentiation, the interaction of WT-E2F1 and ST/D was no longer
detected, whereas that of ST/A was maintained (Figure 3.25A, 3.25B). This indicates that
modification at Ser403 and Thr433 (potentially phosphorylation) may prevent UBC13
from interacting with E2F1 when differentiation pathways are activated in keratinocytes.

Figure 3.25: E2F1 interaction with E2 UBC13 conjugating enzyme is modulated by
Ser403 and Thr433 in differentiated keratinocytes.
Undifferentiated keratinocytes were transfected with vectors encoding FLAG-tagged
UBC13 and the indicated V5-tagged E2F1 proteins. After 4 h, the cells were cultured in
Low (-) or High (+) Ca2+ medium for 24 h. Cell lysates were prepared and subjected to
immunoprecipitation with anti-FLAG antibodies. The immunecomplexes were analysed
by immunoblot with anti-V5 antibodies, to detect E2F1. Samples of lysates were also
analyzed by immunoblot with the indicated antibodies. n=3.
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Chapter 4

4

Discussion

Epidermal keratinocytes provide a barrier function to protect against environmental and
physical damage. Keratinocytes undergo constant self-renewal to repair damaged tissues
and replace old cells that have gone through the normal process of differentiation.
Therefore, it is crucial to understand the regulation of repair mechanisms and the
processes that control keratinocyte differentiation. In this thesis, I explored the function
of E2F1 in these two processes and elucidated some of the mechanisms that regulate
E2F1 stability and turnover following DNA damage or during differentiation. This study
showed that the regulation of E2F1 stability plays a critical role during epidermal DNA
repair and differentiation. First, I identified a novel interaction between E2F1 and
hHR23A, whereby the stability of E2F1 is modulated by hHR23A. More importantly, I
showed that following UV-induced DNA damage, E2F1 recruits hHR23A to damage
sites, which leads to an increase in DNA repair efficiency. Secondly, I demonstrated that
multiple mechanisms are involved in the degradation of E2F1 following Ca2+-induced
keratinocyte differentiation, including nuclear export and ubiquitylation. This study
further shows that Ser403 and Thr433 of E2F1 are likely major phosphorylation sites in
keratinocytes, and appear to be essential for E2F1 turnover through the formation of K11or K48-linked ubiquitin chains in differentiated keratinocytes. Finally, I showed that the
ubiquitin ligase Cdh1 mediates E2F1 degradation in differentiated keratinocytes.
Elucidating the events required for E2F1 turnover in keratinocytes, brings us one step
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closer to understanding various epidermal diseases such as non-melanoma skin
carcinoma.

4.1 E2F1 regulation by hHR23 proteins in keratinocytes
This study has uncovered a complex reciprocal regulation between hHR23 proteins and
E2F1. Specifically, hHR23 proteins can bind E2F1 and protect it from proteasomal
degradation. In turn, E2F1 can recruit hHR23A to the nucleus in the absence of DNA
damage. Upon photodamage, E2F1 is stabilized and is recruited to DNA lesion sites,
bringing hHR23A with it, and increasing the efficiency of DNA repair (Figure 4.1).
hHR23A and the yeast orthologous protein Rad23 function as shuttle proteins that deliver
ubiquitylated cargo to the proteasome for proteolysis (Chen and Madura, 2002).
However, hHR23A can also associate directly with unmodified proteins. For example,
the HIV-1 protein Vpr binds to the UBA2 and XPC domains of hHR23A (Jung et al.,
2014). Similarly, in vitro binding assays with bacterially produced proteins demonstrate
that hHR23A also binds unmodified E2F1. The association of hHR23A and E2F1 in vivo
is likely more complex, due to the presence of ubiquitylated E2F1 pools normally
targeted for proteasomal degradation in mammalian cells. Domain mapping analysis
clearly indicates that the UBA2 domain in hHR23A is neither necessary nor sufficient for
E2F1 interaction. The data presented in this thesis further suggests that the UBA1 and
XPC domains of hHR23A are important regions involved in E2F1 binding in
keratinocytes. Whereas the XPC domain mediates binding to unmodified E2F1 residues,
UBA1 also contacts ubiquitylated E2F1. An important area for future research will be to

Figure 4.1: Proposed model for hHR23A and E2F1 regulation of DNA repair in
undifferentiated keratinocytes
A. In the absence of DNA damage, hHR23A remains mainly localized to the cytoplasm.
E2F1 is known to undergo nucleocytoplasmic shuttling in these cells, with the
equilibrium favouring nuclear concentration of this protein. Under these conditions, E2F1
turnover is promoted by polyubiquitylation and proteasomal degradation. B. DNA
photodamage induces hHR23A nuclear translocation and E2F1 recruitment to sites of
DNA lesions, with potential involvement of factors that serve as a bridge between DNA
and E2F1. E2F1 can form complexes with hHR23A at those sites, promoting DNA
repair. In a coordinate fashion, E2F1 is also protected from degradation through various
mechanisms, likely including association with hHR23 proteins.
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determine which domains in hHR23A and E2F1 bind to each other, independent of
ubiquitin modifications.
The diversity of domains and possible modes of interaction of hHR23A and E2F1 imply
that diverse cellular processes may be activated, depending on cell type, differentiation
status and presence of DNA-related stresses. For example, under normal conditions
hHR23A appears to be largely cytoplasmic in undifferentiated keratinocytes.
Significantly, E2F1 is capable of modulating hHR23A subcellular localization, as its
exogenous expression results in nuclear concentration of hHR23A in the absence of DNA
damage in these cells. Reciprocally, hHR23A is able to reduce E2F1 turnover in
undifferentiated keratinocytes. The ability of E2F1 to modulate hHR23A subcellular
localization is further emphasized by the observation that both E2F1 and hHR23A remain
cytoplasmic as a result of differentiation in keratinocytes. E2F1 is indispensable to
maintain proliferative capacity in undifferentiated keratinocytes and for their activation
during epidermal repair after injury (D'Souza et al., 2002). A potential role of hHR23A in
these cells might be to stabilize E2F1 to ensure maintenance of a proliferative cell
population. Further, it will be important to determine if hHR23A also plays a role in
mediating the increases in E2F1 abundance observed in the regenerating epidermis.
Similar stabilizing roles for hHR23A have been reported vis-à-vis p53 and ataxin-3
(Blount et al., 2014; Glockzin et al., 2003).
Because of their location at the skin surface, epidermal keratinocytes are uniquely
exposed to UV-related damage, and have evolved several protective mechanisms,
including the ability of these cells to repair damaged DNA through NER. The importance
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of these pathways for epidermal homeostasis is underlined by the existence of
dermatological diseases such as xeroderma pigmentosum, which is associated with skin
photosensitivity. Individuals with this disorder exhibit hypersensitivity to solar UV light
and frequent development of skin cancers (Cleaver, 1968). Several genetic abnormalities
that cause XP have been identified, including alterations in XPC. In response to DNA
damage, various signaling proteins are recruited to areas with altered bases. Under these
conditions, hHR23 proteins play key roles facilitating recognition by XPC of DNA lesion
sites, contributing to the repair of transcriptionally silent genome regions or of nontranscribed strands of transcriptionally active genes (Bergink et al., 2012; Dantuma et al.,
2009). Given that E2F1 is most abundant in undifferentiated basal keratinocytes with
proliferation potential (Dagnino et al., 1997), the cells of origin of nonmelanoma skin
carcinoma, it is conceivable that a major role in vivo for the interaction between hHR23
proteins and E2F1 is as a protective mechanism against DNA damage and malignant
transformation of undifferentiated keratinocytes with proliferative potential in the
interfollicular epidermis and hair follicles.
The regulation of E2F1 in response to DNA damage is complex, depends on the
damaging agent, and occurs through various mechanisms. The human ortholog of E2F1 is
phosphorylated by the ATM and ATR kinases on Ser31 (Ser 29 in mouse E2F1) upon
drug-induced DNA damage, promoting its binding to 14-3-3τ, which decreases its
ubiquitylation and proteasomal degradation (Wang et al., 2004). Under these
circumstances, stabilization of E2F1 leads to the transcriptional activation of its proapoptotic targets TAp73 and Apaf1. E2F1 can also be acetylated on several Lys residues
in response to chemicals that cause DNA double-strand breaks, with similar outcomes on
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transcriptional activation of E2F pro-apoptotic targets (Galbiati et al., 2005; Pediconi et
al., 2003). Efficient DNA repair in response to UV-induced DNA damage also requires
E2F1, although different mechanisms appear to be involved. Under those conditions,
E2F1 is also phosphorylated on Ser31 and stabilized (Berton et al., 2005; Pediconi et al.,
2003). Phospho-E2F1 can bind TopBP1, decreasing TAp73 and Apaf1 transcription.
TopBP1 also mediates recruitment of E2F1 to DNA double-strand breaks, where it
colocalizes with BRCA1, and promotes NER through mechanisms that appear to involve
formation of complexes containing TopBP1, E2F1 and GCN5 (Guo et al., 2011). Indeed,
E2F1-deficient cells are deficient in NER through mechanisms that involve impaired
recruitment of DNA repair factors, such as GCN5, to sites of DNA damage. Further, a
mouse E2F1 mutant protein lacking Ser29 is incapable of localizing to UV-induced sites
of DNA damage, and epidermal keratinocytes expressing this protein exhibit increased
susceptibility to UV-induced carcinogenic transformation (Biswas et al., 2014). This
study identifies a novel mechanism that contributes to NER, involving interactions
between hHR23 proteins and E2F1, and the recruitment of hHR23A by E2F1 to sites of
DNA photodamage. Key issues for future research are to determine if E2F1- hHR23
complexes also contain XPC, and to establish the relative importance of the E2F1-hHR23
interaction to the overall capacity of keratinocytes to repair UV-induced DNA. This is a
complex issue to address, given that individual depletion of hHR23 proteins or E2F1
impair cellular repair capacity. The identification of E2F1 mutants incapable of binding
to hHR23A may provide answers to this question.
E2F1 is a well-established promoter of cell proliferation, but its roles in tumour formation
and progression are complex, as it can either induce or suppress tumourigenesis. In the
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context of the epidermis, E2F1 is necessary for normal wound healing (D'Souza et al.,
2002), and its overexpression leads to spontaneous tumour formation, exacerbated by the
loss of p53 (Pierce et al., 1998b). Paradoxically, E2F1 also protects the epidermis from
UV-induced transformation, and cooperates with the retinoblastoma protein, pRb, to
prevent spontaneous carcinogenic transformation of hair follicle keratinocytes through
modulation of β-catenin/Wnt pathways (Biswas et al., 2014; Costa et al., 2013). These
studies now provide new insights on the role of E2F1 in maintenance of genomic
stability, underlining the importance of this transcription factor in maintenance of
epidermal homeostasis.

4.2 E2F1 induction following genotoxic stress in
keratinocytes
This study revealed that the residues involved in the stability of E2F1 following
genotoxic stress differ from the residues required for the degradation of E2F1 following
keratinocyte differentiation. Moreover, residues identified previously to be required for
E2F1 stability in response to DNA damage are similar in primary mouse keratinocytes
and cancer cells. E2F1 response following DNA damage has been extensively studied
over the years. Post-translational modifications on E2F1 lead to protein stability
following genotoxic stress. For the first time, the importance of E2F1 post-translational
modification in primary mouse keratinocytes has been analyzed and shows that a similar
mechanism of E2F1 accumulation in cancer cells exists in primary mouse keratinocytes.
Modifications at Ser31, Lys117, Lys120, and Lys125 are essential for the accumulation
of E2F1 in response to genotoxic stress whereas Arg111, Arg113, and Lys185 are
unmodified following DNA damage, which contributes to E2F1 accumulation. E2F1
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plays a dual role in response to genotoxic insults, either leading to apoptosis or favoring
cell survival (Poppy Roworth et al., 2015). In cancer cells, these modifications on E2F1
promote an increase in apoptotic events leading to cell death (Cho et al., 2012; Kontaki
and Talianidis, 2010; Lin et al., 2001; Pediconi et al., 2003). On the other hand, E2F1
accumulates at DNA damage sites to stimulate NER pathway, which favors cell survival
and resistance to genotoxic stress (Castillo et al., 2015; Guo et al., 2010). The increase in
DNA repair is dependent on E2F1 residue Ser31 to favor recruitment of E2F1 at sites of
DNA damage (Biswas et al., 2014). The Mer11 complex, containing Mer11, Nbs1, and
Rad50, is recruited to sites of DNA DSB during DNA replication. Mer11 is methylated
by PRMT1 and methylation favors the binding of Rad51 to damage sites (Yu et al.,
2012). E2F1 interacts with Mer11 at the replication fork to recruit Rad51 in the presence
of DNA DSB (Maser et al., 2001). E2F1 is also methylated by PRMT1 at residue Arg109
and increases E2F1 protein stability (Zheng et al., 2013). It will be of interest to
determine whether Arg109 and other residues on E2F1 play a role in either accumulating
E2F1 at DNA lesion sites or promoting E2F1-induced apoptosis in primary keratinocytes.

4.3 Regulation of E2F1 turnover in differentiated
keratinocytes
The present study demonstrated multiple mechanisms of E2F1 degradation following
Ca2+-induced keratinocyte differentiation. First, the stability of E2F1 is associated with
E2F1 nuclear export through the CRM1-mediated pathway, as previously shown in our
laboratory (Ivanova and Dagnino, 2007). Second, phosphorylation of E2F1 at Ser403 and
Thr433 prevents the cleavage of K11- and K48- polyubiquitin chains in differentiated
keratinocytes leading to recognition by the proteasome for degradation. Third, E2F1
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protein stability is regulated through E3 ubiquitin ligase, Cdh1, in differentiated
keratinocytes.
The interaction between E2F1 and pRb plays an essential role in E2F1 transcriptional
activity and stability (Helin et al., 1993; Martelli and Livingston, 1999). In my study, I
established that modification at residues previously identified to be involved in the
interaction between pRb and E2F1 do not prevent E2F1 degradation. Therefore, although
pRb dissociation leads to increased transcription of genes through E2F1, this dissociation
may not favour E2F1 degradation in primary mouse keratinocytes as seen in late S phase.
E2F1 nuclear export plays an essential role leading to its degradation following Ca2+induced keratinocyte differentiation. However, this is not the only step necessary for
E2F1 turnover under these circumstances. Modification at Ser403 and Thr433 of E2F1
also appears to contribute significantly to E2F1 degradation. When Ser403 and Thr433
are substituted for an alanine in a mutant also containing an NES to ensure proper
CRM1-mediated nuclear export, this mutant E2F1 protein is cytoplasmic but still
protected from degradation. The use of pseudo-phosphorylation mutants further
confirmed the involvement of Ser403 and Thr433 in keratinocytes. The negative charge
of aspartic acid can mimic phosphorylation of a protein. Notably, when E2F1 Ser403 and
Thr433 are substituted for Asp, the half-life of this protein was significantly reduced in
differentiated keratinocytes. Together, these findings strongly suggest that E2F1 can be
phosphorylated at Ser403 and Thr433 and this post-translational event is required for its
turnover in response to keratinocyte differentiation. The activity of p38β has been shown
to be necessary for E2F1 degradation in keratinocytes, and in vitro kinase assays
demonstrated that E2F1 Ser403 and Thr433 are substrates of p38β-MAPK
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phosphorylation (Ivanova et al., 2009). However, whether E2F1 is phosphorylated by
p38β-MAPK in cultured differentiating keratinocytes is yet to be determined.
The regulation of E2F1 through ubiquitylation has been extensively studied. The APC/C
complex plays a pivotal role in targeting E2F1 for degradation during cell cycle
progression (Budhavarapu et al., 2012; Peart et al., 2010). E2F1 interacts with Cdh1, the
activator of the APC/C complex during early G1 phase to down regulate E2F1 through
K11 linked ubiquitin chain formation (Budhavarapu et al., 2012). My studies for the first
time show phosphorylation-linked ubiquitylation and E2F1 degradation is modulated by
Cdh1. In this thesis, I show that hEmi1-induced inhibition of Cdh1 and loss of Cdh1
interfered with E2F1 down regulation in keratinocytes. Moreover, K11-, K48, and K63polyubiquitylation of E2F1 occur in response to keratinocyte differentiation, and the
modification of E2F1 at Ser403 and Thr433 regulate K11- and K48-polyubiquitin
linkages. These results could explain why the ST/A E2F1 mutant is more stable that wild
type E2F1. Exogenous overexpression of Cdh1 can promote the degradation of ST/A
E2F1 mutant protein as efficiently as wild type E2F1. This suggests that modification at
Ser403 and Thr433 on E2F1 does not interfere with the ability of Cdh1 to target E2F1 for
degradation. Moreover, phosphorylation of E2F1 also does not appear to directly
interfere with the interaction with Cdh1, since all three forms of E2F1, WT, ST/A, and
ST/D can interact with Cdh1 in keratinocytes. The absence of E2F1 post-translational
modifications does not prevent its interaction with Cdh1 (Budhavarapu et al., 2012).
Therefore, it was not surprising to observe the interaction between Cdh1 and all three
forms of E2F1. If overexpressed Cdh1 can still interact with and mediate the degradation
of ST/A E2F1, why does the ST/A mutant show decrease K11- and K48-linked
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polyubiquitylation? One possibility is that under physiological conditions in
differentiated keratinocytes, where Cdh1 is maintained at a normal level, both
phosphorylated E2F1 and substitution of Ser403 and Thr433 with non-phosphorylatable
alanine could interact with Cdh1 and catalyzes K11-linkage ubiquitin chain formation
(Figure 4.2A). The phosphorylated E2F1 is then targeted for 26S proteasomal
degradation. On the other hand, deubiquitylating enzymes (potentially ubiquitin-specific
protease (USP) 37) could specifically interact with ST/A E2F1 and actively remove K11or K48-linked ubiquitin molecules, thus protecting ST/A E2F1 from degradation (Figure
4.2A). Ectopic expression of Cdh1 decreases endogenous USP37 protein levels (Huang et
al., 2011). Therefore, in keeping with the notion that ST/A E2F1 could potentially be a
target of USP37, when USP37 is down regulated, ST/A E2F1 is no longer
deubiquitylated, thus could now be targeted for degradation (Figure 4.2B). Future study
is warranted to identify whether E2F1 is a USP37 substrate.
The increase in the half-life of E2F1-ST/A mutant and exclusive formation of K63-linked
polyubiquitin chains in differentiated keratinocytes prompted me to investigate the
possibility of interactions between E2F1 and the only known mammalian E2 ubiquitin
conjugating enzyme, UBC13, which specifically generates K63-linked polyubiquitin
chains. These studies identified a previously unrecognized interaction between E2F1 and
UBC13. The phosphorylation state of E2F1 does not affect the ability of UBC13 to
interact with E2F1 in undifferentiated keratinocytes. However, following Ca2+-induced
differentiation, UBC13 preferentially interacts with E2F1-ST/A mutant and not with

Figure 4.2: Proposed model of E2F1 phosphorylation-linked ubiquitylation
modulated by ubiquitin ligases and deubiquitylating enzymes.
A. Under normal conditions, Cdh1 and UBC13 interact with phosphorylatable E2F1 at
Ser403 and Thr433 and non-phosphorylatable E2F1 (ST/A E2F1) to form specific K11and K63-linked ubiquitin chains respectively. However, the K11-linkages on ST/A E2F1
could be specifically cleaved by deubiquitylating enzymes (DUB, potentially by USP37)
which lead to its stabilization. The phosphorylatable E2F1 is on the other hand targeted
for degradation. B. The deubiquitylating enzyme, USP37 is targeted for degradation
when Cdh1 is overexpressed. Under this circumstance, the ST/A E2F1 is likely no longer
deubiquitylated by USP37 leading to its degradation via the 26S proteasome just like
wild type E2F1.
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E2F1 ST/D or wild type E2F1. Modifications on residues Ser403 and Thr433 do not
appear to be necessary for UBC13 to interact with E2F1, but differentiation might alter
E2F1 and/or UBC13 structure and thus prevent the physical interaction between
phosphorylated E2F1 and UBC13. Therefore, one possibility of increased stability of the
non-phosphorylated form of E2F1 mutant, ST/A could be due to its interaction with
UBC13, which promotes the formation of K63-linked polyubiquitin chains that are
modifications that likely regulate aspects of E2F1 function different from degradation
(Figure 4.2A).
Polyubiquitylation of protein through K63-linked ubiquitin chains is critical for recruiting
DNA repair proteins upon DNA damage (Doil et al., 2009; Pinato et al., 2011;
Ramachandran et al., 2010). Studies have shown that RNF168, an E3 ubiquitin ligase
together with UBC13 catalyzes K63-linked ubiquitylation on the chromatin that
surrounds DNA lesions. This follows by recruitment of RAP80-ABRA1-BRCA1
complex to the damage sites (Stewart et al., 2009). RNF168 is able to ubiquitylate
various histones and potentially other proteins found at sites of DNA damage to promote
efficient DNA repair. E2F1 is important for recruitment of DNA repair proteins, such as
XPC, XPA and hHR23 to sites of double strand breaks (Biswas et al., 2014; Chen et al.,
2011). Whether Ser403 and Thr433 play a role in favoring the accumulation of DNA
repair proteins to lesion sites is yet to be determined.
E2F1 activity is essential for keratinocyte proliferation and it is regulated through the
pRb/E2F pathway. E2F1 down regulation is a prerequisite for keratinocytes to begin the
differentiation process followed by entry into quiescence. The PKC-MAPK pathway is
implicated in the epidermal differentiation process leading to E2F1 degradation (Ivanova
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et al., 2006). This study has provided a mechanism of E2F1 turnover through
phosphorylation-linked ubiquitylation mediated by ubiquitin ligase Cdh1. Following
extracellular Ca2+ stimulation, the PLCγ enzyme is activated by PIP3, which hydrolyzes
PIP2 to IP3 and DAG (Bikle et al., 2012). This leads to the release of Ca2+ from
intracellular stores, and activation of PKC. The PKCη and PKCδ are specifically
activated by DAG leading to activation of p38β-MAPK through the Ras-MEKK1MEK3/6 pathway (Denning et al., 1995; Efimova et al., 2002; Ivanova et al., 2006). In
response to PKCδ activation, phosphorylated p38δ translocates into the nucleus (Efimova
et al., 2004). Therefore, activation of p38β by phosphorylation could cause its
translocation to the nucleus, where it could phosphorylate E2F1 at Ser403 and Thr433
(Ivanova et al., 2009). Phosphorylation of E2F1 at these sites may prevent its
deubiquitylation (likely occurring through USP37) and interaction with UBC13, which
catalyzes specific K63-linkage ubiquitin chains. Together, the data favour a model where
E2F1 degradation is mediated through its association with Cdh1 (Figure 4.3).
Understanding the signaling events that lead to the degradation of E2F1 is vital as
increased E2F1 expression in the epidermis results in hyperproliferation and hyperplasia
(Pierce et al., 1998a).

4.4 Future studies
This study identified a novel interaction between E2F1 and hHR23A proteins. Together,
these proteins promote DNA repair of UV-damaged keratinocytes. The proximal
promoter region of Rad23A contains a consensus E2F1 binding site but putative binding
sites for any of the other E2F family members were not detected. A future direction of

Figure 4.3: Proposed model of E2F1 regulation and function in differentiated
keratinocytes.
The activation of phospholipase C γ (PLCγ) through binding of extracellular Ca2+ to cell
surface receptor(s) catalyzes the hydrolysis of phosphatidylinositol 4,5-bisphosphate
(PIP2) to inositol 1,4,5-trisphosphate (IP3) and diacylglycerol (DAG). Through DAG,
novel PKC (η/δ) are activated which leads to phosphorylation of p38β through the RasMEKK1-MEK3/6 pathway. Phosphorylated p38β translocate to the nucleus where it
might phosphorylate E2F1 at Ser403 and Thr433. E2F1 phosphorylation at Ser403 and
Thr433 might prevent DUB enzymes (USP37) from cleaving K11- and K48-linkages.
Phosphorylation of E2F1 through Ca2+ induction also prevents its interaction with
UBC13, which catalyzes specifically K63-linked ubiquitin chains. Together, this favors
degradation of E2F1 mediated through its association with Cdh1 in differentiated
keratinocytes.
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this study would be to determine whether E2F1 binds to the promoter of Rad23A in a UV
damage induced-dependent manner by chromatin immunoprecipitation (ChIP)-qPCR
assays.
Following DNA damage, hHR23A associates with XPC, and subsequently recruits XPC
to DNA damage sites. The recruitment of hHR23A to DNA damage sites is transient and
the protein does not accumulate at local DNA damage sites (Bergink et al., 2012). In this
study, I showed that exogenous expression of E2F1 favours hHR23A localization to
DNA damage sites. However, whether the interaction between XPC and hHR23A is
necessary for E2F1 to recruit hHR23A to these DNA lesions has yet to be determined. To
understand the dynamics between the E2F1-hHR23A-XPC complex, future studies
should examine whether a mutant hHR23A, defective in interacting with XPC by
deleting the XPC domain, can be recruited to DNA damage sites in the presence of E2F1
following UV irradiation. Given that E2F1 could maintain its interaction with a hHR23A
mutant lacking the XPC sequences (∆XPC; Figure 3.14C), I would expect that the mutant
hHR23A would be recruited to the damage sites. Moreover, I predict that the interaction
between E2F1 and hHR23A ∆XPC will not promote efficient DNA repair, since XPC is
no longer recruited to the damage sites. Together this would reveal whether E2F1 and
hHR23A are necessary to recruit XPC to DNA damage sites to initiate DNA repair
successfully.
E2F1 post-translational modifications are numerous and have been extensively studied;
however, the specific ubiquitin-modified lysine residues on E2F1 have yet to be
nonequivocally identified. By identifying sites of protein modification, one can better
understand the biological role of such covalent modifications. E2F1 substitution at a.a.
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sites 117, 120, and 125 or 185 were identified as acceptor lysines where ubiquitin
molecules are catalyzed (Galbiati et al., 2005; Kontaki and Talianidis, 2010). However,
in keratinocytes, exogenous expression of E2F1 KTR or K185R did not prevent
ubiquitylation of E2F1 (Appendix 2). Therefore, lysines at position 117, 120, and 125 or
185 may not be the only acceptor sites where ubiquitin molecules attach. E2F1 has 14
lysine residues (16 lysines in murine E2F1) and mutating each residue could be very
challenging. Moreover, this method only indirectly maps ubiquitylation sites (Kaiser and
Wohlschlegel, 2005). Future studies should utilize protein mass spectrometry analysis to
identify the direct location of these modifications. One could also identify the type of
ubiquitin linkages, using proteomic approaches, since E2F1 can be modified to form
K11-, K48-, or K63-linkages.
My study also provided new evidence for the involvement of modifications at Ser403 and
Thr433 in K11- and K48-linked polyubiquitylation of E2F1 and subsequent turnover of
E2F1 in differentiated keratinocytes. In denaturing polyacrylamide gels, the S403A and
S403D E2F1 mutant migrated at the same position as analogous samples treated with λ
phosphatase, indicating that Ser403 is an important contributor to the overall E2F1
phosphorylation state. Whether phosphorylation at Ser403 is necessary for the
phosphorylation of other serine/threonine sites will need to be examined in future
experiments. Phospho-specific antibodies could be used to determine whether
phosphorylation of Thr433 and other serine/threonine residues is dependent on
phosphorylation at Ser403. However, commercially available phospho-specific
antibodies could not detect phosphorylated E2F1 in my hands. The use of
phosphopeptide mapping could potentially help understand the interplay between
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phosphorylation at Ser403 and Thr433 in vivo. The generation of a conditional knock-in
ST/A-E2F1 mouse model could further define the physiological role of the Ser403 and
Thr433 post-translational modification during epidermal development.

4.5 Concluding remarks
The maintenance of genomic integrity is a crucial requirement for cell viability, and its
disruption can result in aneuploidy and diseases such as cancer in mammals. The
mechanisms of differentiation and DNA damage repair play crucial roles in the
homeostasis of a cell. In this thesis, I investigated the regulation of E2F1 stability during
epidermal DNA repair and differentiation. I showed that the interaction between E2F1
and hHR23A prevents E2F1 degradation and that together, E2F1 and hHR23A are
recruited to UV-induced DNA damage sites to promote DNA repair. During keratinocyte
differentiation, I found that E2F1 residues Ser403 and Thr433 are required for ubiquitin
K11- and K48-linkage leading to subsequent turnover of E2F1. Modification of these
same residues prevent E2 ubiquitin conjugating enzyme UBC13 from interacting with
E2F1 and potentially favour the association of Cdh1 in differentiated keratinocytes. Tight
control of E2F1 expression thus plays an essential role to ensure proper DNA repair
following genotoxic stress and differentiation.
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Appendix 1: Primary epidermal keratinocytes irradiated with UV.
Keratinocytes isolated from 3-day-old mice were plated at 70% confluence. Twenty-four
hours later, keratinocytes were subjected to various dose of A. UVB or B. UVC
irradiation through no filters or through 3-µm polycarbonate isopore filters, and cultured
for 30 min. DNA was denatured with 2 N HCl and processed for immunofluorescence
microscopy using anti-CPD antibodies. DNA was visualized with Hoechst 33342. Bar, 16
μm.

210

211

Appendix 2: Ubiquitylation of E2F1 proteins in keratinocytes.
Undifferentiated keratinocytes were transfected with vectors encoding HA-tagged
ubiquitin and the indicated V5-tagged E2F1 proteins, cultured in Low (-) or High (+)
Ca2+ medium, treated with MG132 (10 µM) for 6 h, and harvested to prepare whole-cell
lysates. HA or unrelated IgG immunoprecipitates were isolated from the lysates and
analyzed by immunoblot with anti-V5 antibodies. The abundance of exogenous E2F1
proteins in the lysates was analyzed by immunoblot, using γ-Tubulin as loading control.
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